Studies of common variations in two candidate genes of dyslipidemia and coronary artery disease by HE XUELIAN
STUDIES OF COMMON VARIATIONS IN TWO 
CANDIDATE GENES OF DYSLIPIDEMIA AND 



































STUDIES OF COMMON VARIATIONS IN TWO 
CANDIDATE GENES OF DYSLIPIDEMIA AND 










HE XUELIAN  












A THESIS SUBMITTED  
FOR THE DEGREE OF DOCTOR OF PHILOSOPHY 
DEPARTMENT OF PAEDIATRICS 






LIST OF ORI GANAL PUBLICATIONS…………………………………...………iii 
TABLE OF CONTENTS……………………………………………………………..iv 
SUMMARY………………………………………………………………………..….v 
LIST OF ABBREVIATIONS……………………………………………………...….x 
LIST OF TABLES…………………………………………………………..……….xii 









This study was carried out at the Department of Paediatrics, Yong Loo Lin School of 
Medicine at the National University of Singapore during the years 2002 to 2004. I 
wish to express my greatest gratitude to my supervisor, Dr Heng Chew Kiat. His 
profound knowledge in lipid metabolism and in candidate gene study and in statistics 
has given me great help in this project. I am indebted to him for sharing his 
constructive criticism of the publications related this project and for his support 
throughout my whole graduate study. 
 
I would like to express my appreciation to Dr Yang Hongyuan from Department of 
Biochemistry, National University of Singapore, for providing excellent research 
facilities and reagents for the functional study of ACAT2 gene.  
 
I thank also Lu Yongjian for his guidance and sharing his experience in SNP 
discovery work and genotyping. 
 
I thank my friends and colleagues for their generous help when I was in need.  
 
I am extremely indebted to family members, especially parents, the best parents. I was 
always provided with delicious food after work during the period that they stayed 
with me. They have always supported me and their love has been endless and 
invaluable through my whole life. 
 
Finally, I thank my dear husband and my two lovely sons, and their love and support 
have been most important to me. 
 iii
LIST OF ORI GANAL PUBLICATIONS 
 
Posters in conferences 
1. Xuelian He, Yongjian Lu, Chew Kiat Heng, Robert Hongyuan Yang, 
Identification of Novel Polymorphisms in the Acyl-CoA: Cholesterol 
Acyltransferase-2  Gene and Their Impact on Plasma Lipid Levels, The 1st 
Bilateral Symposium on Advances in Molecular Biotechnology and 
Biomedicine between the National University of Singapore and University of 
Sydney, 23-24 may, 2002 
2. Xuelian He, Yongjian Lu, Nilmani Saha, Hongyuan Yang, Chew-Kiat Heng, 
Identification of Novel Polymorphisms in the Human Acyl-CoA: Cholesterol 
Acyltransferase-2 Gene and Association Study with Lipids and Coronary 
Artery Disease, 54th Annual Meeting of The American Society of Human 
Genetics.  26-31 October, 2004 
 
Articles  
1. Xuelian He, Yongjian Lu, Hongyuan Yang, Chew-Kiat Heng, Acyl-CoA: 
Cholesterol Acyltransferase-2 Gene Polymorphisms and Their Association 
with Plasma Lipids and Coronary Artery Disease Risks, Hum Genet. 2005 
Dec;118(3-4):393-403.  
2. Xuelian He, Hongyuan Yong, Chew-Kiat Heng, Functional analysis of 
ACAT2 polymorphisms, submitted. 
3. Chew-Kiat, Heng Xuelian He, Hongyuan Yong, Association of three 
lipoprotein lipase polymorphisms with Coronary artery disease in Chinese and 























TABLE OF CONTENTS 
 
1. INTRODUCTION AND BACKGROUND………………………………………….. 
1.1. Introduction……………………………………………………………………… 
1.2. Background ……………………………………………………………………... 
1.3. Objectives of this study……………………………………………………………
1.3.1. Study on ACAT2 gene………………………………………………………. 
1.3.2. Study on LPL gene………………………………………………………….. 
1.4. Significance and limitation of this study………………………………………… 
 
2.  LITERATURE REVIEW……………………………………………………………. 
2.1. Coronary artery disease (CAD)………………………………………………….. 
2.1.1. Definition of CAD………………………………………………………….. 
2.1.2. Prevalence of CAD…………………………………………………………. 
2.1.3. Pathophysiology and pathogenesis of CAD………………………………….
2.1.4. Genetics of CAD……………………………………………………………. 
 
2.2. Genetic epidemiological study of complex disease……………………………….
2.2.1. Genetic variations…………………………………………………………... 
2.2.2. The discovery of genetic variants…………………………………………… 
2.2.2.1. Single-strand confirmation polymorphism (SSCP)……………………. 
2.2.2.2. Cleavage fragment length polymorphism (CFLP)……………………... 
2.2.2.3. Denaturing gradient gel electrophoresis (DGGE)…………………….. 
2.2.2.4. Denaturing high performance liquid chromatography (DHPLC)……... 
2.2.3. Complex diseases…………………………………………………………….
2.2.4. Approaches for genetic study of complex diseases………………………… 
2.2.4.1. Family-based genome-wide linkage studies…………………………… 
2.2.4.2. Association studies…………………………………………………….. 
2.2.4.2.1. Candidate-gene association studies……………………………...... 
2.2.4.2.2. Genome-wide association studies………………………………… 
2.2.4.2.3. Association tests…………………………………………………... 
2.5.4.2.4.Data analyis of association studies………………………………… 
 
2.3. Dyslipidemia…………………………………………………………………….. 
2.3.1. Lipids and lipoproteins……………………………………………………... 
2.3.2. Definition of dyslipidemia ………………………………………………... 
2.3.3. Dyslipidemia and CAD……………………………………………………. 
2.3.4. Genetics of dyslipidemia…………………………………………………... 
. 
2.4. Acyl-coenzyme A: cholesterol acyltransferase (ACAT)………………………… 
2.4.1. Identification of ACAT2……………………………………………………..
2.4.2. Distribution and function of ACAT2………………………………………. 
2.4.3. ACAT2 and atherosclerosis…………………………………………………  
2.4.4. ACAT2 protein structure …………………………………………………... 
2.4.5. ACAT2 genomic organization and the regulation of ACAT expression …… 
2.4.6. Genetic analysis of ACAT2…………………………………………………..
 
2.5. Lipoprotein lipase (LPL)………………………………………………………… 
2.5.1. Function and localization of LPL…………………………………………... 


















































2.5.2.1. The anti-atherogenic effects of LPL…………………………………… 
2.5.2.2. The pro-atherogenic actions of LPL…………………………………… 
2.5.3. The organization of LPL protein and gene ………………………………… 
2.5.4. Genetic analysis of LPL…………………………………………………….. 
 
 
3. MATERIALS AND MTHODS………………………………………………………. 
3.1. Subjects……………………………………………………………………………
3.2. DNA analysis …………………………………………………………………… 
3.2.1. DNA Extraction……………………………………………………………. 
3.2.2. Primer design for polymorphism screening of ACAT2 gene………………. 
3.2.3. PCR amplification…………………………………………………………..  
3.3. Survey of genetic variant in ACAT2 gene from public resources…………………
3.4. DHPLC analysis…………………………………………………………………..
3.5. Sequencing……………………………………………………………………….. 
3.6. Predicting biological impact of ACAT2 polymorphisms …………………………
3.7. Genotyping of ACAT2 gene Polymorphisms……………………………………. 
3.8. Genotyping of three LPL gene polymorphisms…………………………………. 
3.9. Estimation of plasma lipid levels………………………………………………... 
3.10. Statistical analysis………………………………………………………………. 
3.11. Cell line, vector and reagents…………………………………………………... 
3.12. Cell culture……………………………………………………………………... 
3.13. Expression of various ACAT2 proteins………………………………………… 
3.13.1. Construction of various ACAT2 gene expression plasmids ……………… 
3.13.2. Transfection of AC-29 with various pcDNA3.1/His/ACAT2…………….. 
3.13.3. Selection of stable transformants………………………………………… 
3.13.3. Selection of positive stable transformants………………………………... 
3.14. Ex vivo ACAT activity assay…………………………………………………… 
3.15. Quantitative reverse transcription PCR………………………………………… 
3.16. Western blot……………………………………………………………………. 
 
4. STUDY OF ACAT2 GENE…………………………………………………………… 
4.1. Introduction……………………………………………………………………… 
4.2 Results……………………………………………………………………………. 
4.2.1. Polymorphism screening…………………………………………………... 
4.2.1.1. Survey of known genetic variants in ACAT2 gene…………………... 
4.2.1.2. Polymorphism screening ……………………………………………... 
4.2.1.3. Improved efficiency of mutation screening using modified primer …. 
4.2.1.4. Factors affecting DHPLC elution profiles……………………………. 
4.2.1.5. Prediction of functional implications of ACAT polymorphisms……… 
4.2.2. Association studies of ACAT2 gene ………………………………………. 
4.2.2.1. Genotyping of three polymorphisms ………………………………… 
4.2.2.2. Population Demographics…………………………………………….. 
4.2.2.3. Genotype and allele frequencies………………………………………  
4.2.2.4. Linkage disequilibrium among the three polymorphisms …………… 
4.2.2.5. Multi-loci case-control analysis………………………………………. 
4.2.2.6. Association of single-locus genotype with lipid traits in CAD 
subjects…………………………………………………………………………………... 





















































4.2.2.6.3. c. 41A>G……………………………………………………………. 
4.2.2.7. Association of diplotypes with lipid traits ……………………………. 
4.2.3. Functional analysis of two nsSNPs of ACAT2 gene……………………….. 
4.2.3.1. Expression of ACAT2 in AC-29 cell…………………………………. 
4.2.3.2. ACAT2 activity assay…………………………………………………..
4.3. Discussion…………………………………………………………………………
 




5.2.1. Demographic characteristics of subjects…………………………………… 
5.2.2. Genotyping of three LPL polymorphisms………………………………….. 
5.2.3. Distribution of three LPL polymorphisms…………………………………. 
5.2.4. Hapolotype distribution ……………………………………………………. 
5.2.5. Association with plasma lipid levels……………………………………….. 
5.3. Discussion………………………………………………………………………... 
 








































Coronary artery disease is a disorder with multiple genetic and environmental factors 
and dyslipidemia is one of most prominent risk factors. The major purpose of this 
study is to determine the influence of some of the genetic factors on CAD 
susceptibility and on plasma lipid traits. 
 
Acyl-CoA: cholesterol Acyltransferase-2 (ACAT2) catalyzes the formation of 
cholesteryl esters using cholesterol and long-chain fatty acids as substrates. As such 
ACAT2 is a very important enzyme in the intestinal cholesterol absorption and in the 
production of apoB-containing lipoproteins in the liver. ACAT2 has been 
demonstrated to be a potential target for treating coronary artery atherosclerosis in 
hypercholesterolemic animal model.  
 
In order to explore the effects of genetic variations in the ACAT2 gene, we screened 
for variants on its entire coding regions, intron-exon boundaries, and putative 
promoter region, using denaturing high performance liquid chromatography. A total 
of 14 polymorphisms were identified. These included three missense mutations, 
namely c. 41A>G (Gly>Glu) in exon1; c.734C>T (Thr>Ile) in exon7; and c.1291G>T 
(Ala>Ser) or G>A (Ala>Thr) in exon13; two base changes in putative promoter 
region (-331C>T and -440G>T), two synonymous exonic base changes (c.609G>T 
and  c. 610C>T in exon6), seven intronic sequence variations, comprising six single 
base substitutions (IVS1-8C->G; IVS4+172T/G, IVS5-137A/T, IVS9-178G/C, 
IVS9+37A->T and IVS9+51G->T) and one 48bp insertion.  Among these, 3 
polymorphisms, 41A>G (Glu14Gly), 734C>T (Thr254Ile), and IVS4-57_58ins48bp, 
were analyzed for their association with CAD and plasma lipid levels. A total of 2113 
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subjects, comprising 1228 Chinese, 367 Malays, 518 Indians, were included in this 
case-control association study. We found these three ACAT2 polymorphisms showed 
significant ethnic variations in allele frequencies as well as significantly different 
effects on plasma lipid levels and CAD risk, though some significances were not 
observed after Bonferroni correction.  In addition, in vitro experiments were carried 
out to determine the expression levels of ACAT2 wild type and mutant proteins and 
their enzymatic activities in the ACAT-deficient AC-29 cells. The results showed that 
the enzymatic activity of mutant Glu14Gly was about two times higher compared to 
that of the wildtype ACAT2, and this increase was mostly due to the higher 
expression and/or stability of the mutant ACAT2 protein. Our observations suggest 
that the Glu14Gly polymorphism might be very important to ACAT2 protein 
expression and/or stability.  
 
 ix
Another important enzyme, lipoprotein lipase (LPL), the rate-limiting enzyme in 
hydrolysis of triglycerides in chylomicron and very-low-density lipoprotein particles, 
was analyzed in this study. LPL has a paradoxical role in the development of 
atherosclerosis as it can be considered both anti-atherogenic and pro-atherogenic. 
There is no uniform consensus regarding the association of genetic variations in LPL 
with CAD susceptibility and lipid levels. In addition, it is interesting to evaluate the 
impact of the combination of IVS6+1594C>T, IVS8+483T>G, and c.1342C>G 
polymorphisms in Asian populations. Our study showed that the most prevalent CTC 
haplotype of three LPL polymorphisms was consistently associated with increased 
CAD susceptibility in male Chineses and Indians living in Singapore. In addition, the 
rare alleles of three individual polymorphisms were also found to lower CAD risk in 
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1. INTRODUCTION AND BACKGROUND 
 
1.1. Introduction 
Coronary artery disease (CAD) is a complicated disease with multiple genetic and 
environmental contributions, such as dyslipidemia, hypertension, diabetes mellitus, 
obesity, cigarette smoking, high-fat and high-cholesterol diet, and physical inactivity.  
Among these risk factors, dyslipidemia is the most important contributor to CAD 
susceptibility.  Dyslipidemia can be caused by monogenic disorders, such as familial 
hypercholesterolemia (Brown and Goldstein, 2001), and familial defective 
apolipoproetin (apo) B (Fisher et al., 1999).   Studies on these monogenic disorders 
have helped to unravel the pathways of cholesterol metabolism regulation and 
contributed importantly to the understanding of lipid metabolism and atherosclerosis.  
However, most cases of dyslipidemia are attributed to a combination of many 
common genetic variations and environmental factors and our understanding of these 
aspects remains incomplete.  Study on such genetic variants of candidate genes in 
lipid metabolism would contribute towards elucidating the genetic mechanisms of 
CAD and dyslipidemia. 
 
1.2.  Background  
Given the prominent role of dyslipidemia in atherosclerosis, genetic studies on 
enzymes which are important to lipid and lipoprotein metabolism have captivated 
generations of researchers.  
 
A relatively novel protein, acyl CoA: cholesterol acyltransferase (ACAT)2, an 
enzyme which converts cholesterol into cholesterol esters (CEs) (Chang et al., 1997), 
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has been shown to be associated with hypercholesterolemia and atherosclerosis using 
ACAT2-/- mice model (Buhman et al., 2000). Furthermore, the deletion of ACAT2 has 
been demonstrated to be consistently athero-protective (Willner et al., 2003; Lee et al., 
2004). Thus, selective inhibition of ACAT2 would be an important strategy for 
treatment and prevention of atherosclerosis (Rudel et al., 2005). The ACAT2, also 
called Soat2, should not be confused with acetyl-Coenzyme acetyltransferase 2, which 
is also denoted as ACAT2.   
 
Another important protein, lipoprotein lipase (LPL), is the rate-limiting enzyme 
responsible for the hydrolysis of triglycerides (TGs) in chylomicrons and very low 
density lipoproteins (VLDL). This hydrolysis functions to clear TGs from the 
circulation and also provides phospholipids and apolipoproteins to high-density 
lipoprotein (HDL) cholesterol, therefore, driving the plasma lipids in anti-atherogenic 
direction.  The familial deficiency of LPL may lead to type I hyperlipidemia, 
characterized by severe hypertriglyceridemia and extremely low HDL levels (Brunzell, 
1995). Even heterozygous LPL mutations may result in reduced or loss of LPL 
activity and increased risk of familial combined hyperlipidemia (Babirak et al., 1992). 
On the other hand, LPL also has a non-enzymatic molecular bridging function and has 
been shown to act as a ligand to mediate cellular uptake of lipoproteins and CEs 
(Stein and Stein, 2003). Furthermore, LPL has been shown to stimulate the 
proliferation of vascular smooth muscle cells (VSMC) (Mamputu et al., 2000). Hence, 
LPL may also have pro-atherogenic effects. Whether LPL acts to be anti-atherogenic 
or pro-atherogenic depends on the tissues specifically expressing LPL (Mead and 
Ramji, 2002).  
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Because of their crucial roles in lipid metabolism and atherogenesis, the ACAT2 and 
LPL are considered as important candidate genes in studies to determine whether they 
contribute to predisposition for dyslipidemia and atherosclerosis.  
Singapore is a small immigrant nation in Southeast Asia comprising different ethnic 
groups: Chinese (77.4%), Malays (14.2%), Indians (7.2%) and European Caucasians 
(0.2%). The ancestors of the Chinese were mostly migrants from the coastal regions of 
southern China. The Malays came from neighboring Malaysia and Indonesia. Most 
Indian Singaporeans are second, third or even fourth generation descendants of migrants 
from the southern Indian subcontinent. 
Over the past few decades, Singapore has witnessed a high degree of social and 
political stability and a rapid-growth economy since it obtained independence in 1965.  
Since 1980, Singapore has been considered a fully urbanized and developed city-state.  
With the rapid socioeconomic development, some “modern diseases”, such as 
cardiovascular diseases and cancer, have become the major causes of morbidity and 
mortality in this population.  Among them, CAD is the leading cause of death in this 
population.   
Each of the ethnic groups residing in Singapore has contrasting mortalities due to 
CAD (Hughes et al., 1990a; Hughes et al., 1990b; Heng et al., 1999), though they 
reside in the same physical environment and environmental factors are relative 
constant except their habitual diets, and culturally determined lifestyles. Thus, 





1.3. Objectives of this study 
1.3.1. Study on ACAT2 gene 
Although ACAT2 has been shown to be associated with hypercholesterolemia and 
atherosclerosis in animal models (Buhman et al., 2000), studies on the effects of 
genetic variants of this gene on CAD susceptibility have not been performed in the 
general population.  There was only one other genetic study which explored the 
association of two ACAT2 polymorphisms, Glu14Gly and Thr254Ile, with 
dyslipidemia in Japanese when this study was initiated in the Singaporean population 
(Katsuren et al., 2001). In 2003, a similar study on another polymorphic site, 
IVS1-8G>C, was reported by the same group (Katsuren et al., 2003).  Their studies did 
not reveal any positive association except with plasma apoIII level, which was found to 
be higher in Thr254Ile heterozygotes (Katsuren et al., 2001).  However, no further 
functional study on the genetic variant was carried out. 
Based on the significant effects of ACAT2 on atherosclerosis in ACAT2-/- mice 
(Buhman et al., 2000), it was hypothesized that genetic variants of ACAT2 gene could 
exert an important influence on susceptibility to CAD and dyslipidemia in the general 
population. The Singaporean population is made up of multiple ethnic groups, namely, 
Chinese, Malays, and Indians.  It is also therefore worthwhile to determine if the effect 
of ACAT2 variants is ethnic-specific.  
The following steps were taken to verify these hypotheses: 
1. To identify novel polymorphisms of the ACAT2 gene using denaturing high 
performance liquid chromatography (DHPLC) and to predict their possible 
biological function using computational approaches 
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2. To determine the impact of the ACAT2 gene polymorphisms on CAD susceptibility 
and plasma lipid levels in three major ethnic groups in Singapore using 
population-based case-control association study 
i. To determine the allele frequencies of ACAT2 polymorphisms between 
CAD patients and healthy control, as well as between the normolipidemic 
and dyslipidemic subgroups 
ii. To determine the allele frequencies of the ACAT2 polymorphisms in the 
three  ethnic groups, and  
iii. To evaluate the effect of these polymorphisms on plasma lipid profiles in 
different population subgroups, 
3. To conduct an in vitro functional study of two potential functional polymorphisms in 
mammalian cells. 
1.3.2. Study on LPL gene 
Three common genetic variants, IVS6+1595C>T, IVS8+484T>G, and c.1342C>G of 
the LPL gene, have been reported to be associated with abnormal lipid concentrations 
and atherosclerosis. Though these three polymorphisms have been extensively studied, 
there is no uniform consensus on their effects on CAD susceptibility and plasma lipid 
concentrations. Furthermore, most studies were conducted in Caucasian populations, 
with only a few that had examined the Asian populations (Shimo-Nakanishi et al., 
2001; McGladdery et al., 2001; Hall et al., 2000; Lee et al., 2004; Liu et al., 2004).  
In addition, to our knowledge, the combined effect of these three polymorphisms on 
CAD risk has not been determined in an Asian population.  In this study, it was 
evaluated whether these polymorphisms are associated with CAD risk and with 
abnormal lipid traits. The combined effect of these three polymorphisms on CAD risk 
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was also explored in two Asian ethnic groups with contrasting CAD risk, namely, the 
Indians and Chinese.  In addition, the different distribution of allele frequencies 
between different ethnic groups was compared. 
 
1.4. Significance and limitation of the study 
CAD is the most common cause of death in developed countries and its prevalence is 
rapidly increasing in developing countries owing to the burgeoning epidemic of 
obesity and the aging population.  For the treatment of CAD, other than modifying 
lifestyle risk factors, pharmacological intervention is an important strategy. The 
determination of specific susceptibility genes and these disease-associated genetic 
variants will contribute to the development of new drugs. In addition, the 
identification of high-risk individuals would be important for the efficient prevention 
of CAD and dyslipidemia. However, although many candidate genes and genetic 
variants related to CAD and dyslipidemia have been reported, the available data are 
either inconclusive or inconsistent. 
 
In our study, fourteen polymorphisms were identified in ACAT2 gene by screening 
cord blood samples using DHPLC. Our association study showed that a 
nonsynonymous SNP (nsSNP) in exon 7, 734C>T, was associated with decreased 
CAD risk while another nsSNP in exon 1, 41A>G, had decreased dyslipidemia in 
Chinese subjects, after correction for multiple comparisons. It was observed that these 
two nsSNPs and IVS4-57_58ins48bp (D/I), a 48bp insertin in intron 4, were in strong 
linkage disequilibrium (LD). The frequency of the most common AC haplotype of 
these two nsSNPs was significantly increased in dyslipidemic subjects when 
compared with normolipidemic ones in the Chinese.  The CAD+ group had almost 
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2-fold higher GC haplotype frequency than the CAD- controls in the three ethnic 
groups, but statistical significance was only attained in the Chinese. However, the 
normolipidemic subjects had about 3-fold higher GC haplotype frequency than 
dyslipidemic ones in the Chinese and Malay groups, although the latter did not reach 
a significant level.  The preliminary results from the functional study of these two 
nsSNPs suggested the 41A>G probably increased ACAT2 enzymatic activity by 
altering protein expression and/or stability.  
 
The identification of novel polymorphisms in ACAT gene would contribute to the 
SNP database, which is very useful for genetic association studies. Secondly, our 
association study would provide important information about the impact of ACAT2 
and LPL polymorphisms with CAD and dyslipidemia. Furthermore, our preliminary 
results from in vitro study would be helpful for the understanding of the relationship 
between the structure and function of ACAT2 protein.  
 
The study is not without its limitations, such as the age disparity between case and 
control subjects and the relatively small sample size, especially after stratification by 
gender, ethnic groups and lipid profiles.  Hence, further study using a larger sample 
size with well-matched case-control may be needed to confirm our current findings 
related to association with CAD, dyslipidemia susceptibility and altered plasma lipid 
profiles.   In addition, although the functional study of nsSNPs of ACAT2 gene in 
mammalian cell line have shown that the 41A>G (Glu14Gly) variant had significant 
effects on ACAT2 enzymatic activity, only one colony for each ACAT2 polymorphic 
type was examined.  To verify the results obtained from functional study, at least 
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three colonies for each ACAT2 polymorphic types should be included in future 
studies.  
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2.  LITERATURE REVIEW 
 
2.1. Coronary artery disease 
CAD is the leading cause of death and disability in the developed world, with an 
increasing prevalence (Bonow et al., 2002).  In the last 30 years, dyslipidemia has 
been identified as a major modifiable risk factor for CAD (Willerson and Ridker, 
2004).  In the following sections, the clinical, etiological, and epidemiological 
aspects of the most prominent risk factor, dyslipidemia, will be reviewed. 
 
2.1.1. Definition of CAD 
CAD, also called coronary heart disease (CHD) or ischemic heart disease (IHD), is 
characterized by a “narrowing” of coronary arteries resulting in inadequate blood flow 
to the heart muscle and leading to angina pectoris, with exertion or at rest, or 
myocardial infarction (MI), and even sudden death, depending on the severity of 
obstruction. The narrowing is usually caused by atherosclerosis.   
 
2.1.2. Prevalence of CAD 
CAD is a major cause of morbidity and is a leading contribution to mortality 
worldwide, especially in developed countries (Murray and Lopez, 1997).  According 
to the Heart Disease and Stroke Statistics update 2005 from American Heart 
Association (AHA), CAD caused 1 of every 5 deaths each year and every minute 
someone will die from CAD in the United States. CAD is responsible for about 
US$142.1 billion in 2005 in direct and indirect economic costs in the United States 
(Heart Disease and Stroke Statistics – AHA 2005 Update).  With the rapid economic 
development and urbanization in Singapore, CAD has been the most common cause 
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of death (Lee et al; 2001).  Even in developing countries, both CAD associated 
mortality and the prevalence of CAD risk factors continue to rise rapidly (Okrainec et 
al; 2004).  With the aging of population, westernization of the lifestyle in developing 
countries and the increasing survival rate during acute phases of ischemic disease, 
which transform acute patients into chronic patients (Viles-Gonzalez et al; 2004), 
CAD will be the single largest cause of disease burden globally by the year 2020. By 
that year, it is estimated that nearly 40% of all deaths worldwide will be due to 
cardiovascular disease (CVD), more than twice the percentage of deaths from cancer 
(Heart Disease and Stroke Statistics – AHA 2005 Update). 
 
2.1.3. Pathophysiology and pathogenesis of CAD 
Atherosclerosis in the artery wall is the major feature of CAD and is an organized, 
active, lifelong process. Our views of the pathophysiology of the progressive disease 
have evolved substantively over the past decades. Before the 1970s, the lipid 
hypothesis which is based on strong experimental and clinical relationships between 
hypercholesterolemia and atherosclerosis dominated our thinking. During the 1970s 
and 1980s, growth factors and the proliferation of smooth muscle cells have been 
considered to play a prominent role in atherosclerosis.  However, at the end of the 
last century, an increasing number of researchers have considered atherosclerosis an 
inflammatory disorder (Libby, 2002; Reiss and Glass, 2006).  
 
The accumulation of lipids has a role in inducing and promoting inflammation and 
atherogenesis. In experimental models, such as atherosclerosis-susceptible apoE-/- or 
VLDL-/- mice, the accumulation of lipoprotein particles and their aggregates are 
initially observed in the subendothelial space (Zhang et al., 1992; Ishibashi et al., 
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1993).  These retained lipoproteins, particularly those modified LDL, elicit a series 
of biological responses that lead to endothelial dysfunction, which is a critical step in 
the development of inflammation and atherosclerosis (Gonzalez and Selwyn, 2003).  
Endothelial dysfunction is caused not only by elevated and modified LDL, but also by 
other factors, such as elevated plasma homocysteine concentrations, hypertension, 
infectious micro-organisms, and free radicals.  These factors increase the 
adhesiveness of the endothelium with respect to monocytes, macrophages, and 
lymphocytes, as well as its permeability to lipoproteins and other constituents. In 
addition, the injured endothelia also increase the expression of adhesion molecules, 
such as vascular cell adhesion molecule-1 (VCAM-1), P- and E-selectin (Cybulsky et 
al., 2001; Libby, 2002; Collins and Cybulsky, 2001).  All these responses induce the 
migration of monocytes, macrophages and T lymphocytes from the blood into the 
intima of artery wall (Ross, 1999).  These monocytes and monocyte-drived 
macrophages then scavenge the subendothelial lipoproteins and become lipid-laden 
foam cells, which are the earliest lesions of atherosclerosis. These lesions are not 
clinically significant, but they may evolve to form fibrous plaques by accumulating 
lipids, smooth muscle cells and extracellular matrix.  These plaques can become 
increasingly complex and grow large by vascularization, haemorrhage, rupture, 
ulceration and calcification.  The most serious clinical complication is MI or sudden 
death caused by an acute occlusion due to the thrombus formation.  
 
All these insights suggest that lipids play a crucial role in the development and 
progression of atherosclerosis and that abnormal level of lipid accumulation is the 
triggering event in the pathogenesis of atherosclerosis.  
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2.1.4. Genetics of CAD 
A few forms of Mendelian diseases that involve premature CAD or atherosclerosis 
have been identified (Table 2-1). Most of these disorders affect the levels of LDL and 
HDL cholesterols.  Monogenic CAD due to monogenic defects without dyslipidemia 
syndrome is not common. A few genes with mutation have been identified to be 
associated with premature CAD. For example, myocyte enhancing factor-2, which 
encodes a transcription factor, has been shown to be involved in CAD in a single large 
family with dominant inheritance of CAD and MI (Lusis et al., 2004).  
 
Except for a few cases of CAD of monogenic origin, most have been proposed to be 
caused by common genetic variants with small-to-moderate effects in candidate genes. 
The magnitude of the effects of genetic factors for CAD has been studied.  A cohort 
study over 36 years in 20,966 Swedish twins has shown that the heritability of death 
from CAD due to genetic effect was 0.57 amongst male twins, and 0.38 amongst 
female twins (Zdravkovic et al., 2002). Furthermore, genetic factors are in operation 
throughout the entire life span, though genetic effects appeared to be greater at 
younger ages. This phenomenon possibly is owing to the increasing variance in 
environmental factors with age (Watkins and Farrall, 2006). A family history of 
premature coronary, cerebrovascular or peripheral vascular disease has been 
well-established risk factor for CAD by the Framingham Heart Study, PROCAM 
study, and the INTERHEART study, with the odds ratio (OR) ranging from 1.45-2.4 
(Lloyd-Jones et al., 2004; Assmann et al., 2002; Yusuf et al., 2004; Watkins and 
Farrall, 2006).  
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Although it has been well-accepted that the genetic factors have contributed to CAD 
susceptibility, the magnitude of their effect and number of contributing effects could 
not be determined until all CAD-susceptibility genes are identified.  Due to the long 
list of known risk factors and many traits having their own genetic basis, the number 
of candidate genes could be large. Successful identification of these susceptibility 
genes for CAD could be dependent on a combination of classical candidate-gene 
studies and genome-wide positional cloning. Similarly, combined genetic and 
genomic approaches have the potential to reveal new realms of quantitative heritable 




Table 2-1. Mendelian diseases relevant to premature CAD 




hypercholesterolemia LDLR 1/500 
Decrease in LDL 
uptake by the live 
due to the defective 





ApoB ApoB 1/3250 
Reduced binding of 
ApoB to LDLR 
Fisher et al., 
1999 
Sitosterolemia ABCG5, ABCG8 rare 
Increased absorption 
of plant sterols by 
the intestine 
Heimerl  et al., 
2002 
Autosomal recessive 





Garcia et al., 
2001 
Tangier disease ABCA1 rare 
Impaired cholesterol 
and phospholipids 
efflux, resulting in 
very low level of 
HDL 
Rust et al., 1999 
 ApoA1 rare 
Delection or 
loss-of-function 
mutation results in 
the virtual absence 
of HDL 
Matsunaga  et 
al., 1991 
Ad CAD1 MEF2A Rare  
A mutation in 
MEF2A results in 
dominant vascular 
disease 
Wang et al., 
2003 








Kluijtmans et al., 
1999 
ABCG, ATP-binding cassette, subfamily G; ARH, autosomal recessive hypercholeterolaemia; 
MEF2A, myocyte enhancing factor-2; CBS, cystathionine β-synthase 
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2.2 Genetic epidemiological study of complex disease 
2.2.1. Genetic variations 
Genetic variations refer to the changes in DNA sequence and a variation with an allele 
frequency of at least 1% in the population is considered as a polymorphism.  There 
are several types of polymorphisms in the genome: single nucleotide polymorphisms 
(SNPs), tandem repeat polymorphisms, and insertions or deletions, which range from a 
single base pair to thousands of base pairs in size.   SNP refers to a single nucleotide 
in a locus having two, or sometimes three, forms in the population. There are two 
classes of SNPs: transition, changing from pyrimidine to pyrimidine or from purine to 
purine, and transversion, changing from pyrimidine to purine or from purine to 
pyrimidine.  The transition is the most common single base substitution.  A tandem 
repeat polymorphism consists of variable lengths of sequence motifs that are repeated 
in tandem in a variable copy number. Tandem repeat polymorphisms are subdivided 
into two subgroups based on the size of the tandem repeat units: micro-satellites (short 
tandem repeats, STR) and mini-satellites (variable number of tandem repeats, VNTRs).  
The STR repeat unit consists of only 1-6 base pairs (bp) while the VNTR repeat unit 
ranges from 10-50bp.  The most common microsatellites are dinucleotide, 
trinucleotide, and tetranucleotide, and they occur once in every 10kb in eukaryotic 
genomes.  Human microsatellites are informative in linkage studies as there are many 
alleles present at a microsatellite locus.  
 
SNP is the simplest and most common type of genetic variation with one 
approximately every 180 bp, making up 90% of natural variation in the human genome 
(Crawford et al., 2005).  In the latest release of SNP database (dbSNP) in the National 
Centre for Biotechnology Information, there are more than 27 million of SNPs 
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recorded with more than 4 million of SNPs lying within genes (build 125) (Serre and 
Hudson, 2006).  It is believed that these SNPs within genes, especially those within 
promoter regulatory regions, encoding regions, or splicing sites, are more likely to be 
deleterious or beneficial to humans than those within intergenic spaces.  
 
For these SNPs within encoding region, they are called non-synonymous SNP (nsSNPs) 
if they alter the encoded amino acid or synonymous SNPs if they do not change any 
amino acid. NsSNPs may be the cause of most known inherited monogenic disorders 
and may be routinely analyzed for diagnostic purposes.  However, most SNPs are 
located in non-coding regions and may have no direct known impact on an individual 
but are shown to be associated with certain traits.  These SNPs have been found to be 
useful markers in population genetic association studies of complex diseases. 
 
SNPs most often result from a non-repaired error that occurs during DNA replication.  
The frequency of the error is relatively low (10-8 substitution per base per generation), 
thus, the vast majority of SNPs are inherited rather than de novo mutations.  If 
individuals share the same allele at one position, they are most likely from same 
ancestor rather than two independent mutations occurring on them (Serre and Hudson, 
2006).   
 
A few public SNP database have been established, such as dbSNP 
(http://www.ncbi.nlm.nih.gov/projects/SNP), the SNP consortium (TSC) 
(http://snp.cshl.org), a database of Japanese SNPs (JSNP database) 
(http://snp.ims.u-tokyo.ac.jp) and Human Genome Variation database (HGVbase) 
(http://hgvbase.cgb.ki.se/).  The dbSNP aims to catalog variations throughout the 
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genome, regardless of their functional consequences and was established by the NCBI 
in collaboration with the National Human Genome Research Institute (NHGRI) 
(Sherry et al., 2001).  TSC was established in 1999 as a collaboration of several 
companies and institutions. Its initial goal was to discover 300,000 SNPs within two 
years, but to date nearly 1.8 million SNPs had been characterized. JSNP is a database 
for SNP in Japanese population with emphasis on the identification of SNPs located in 
genes or in adjacent regions that might influence the coding sequence of genes 
(Hirakawa et al., 2002). 
 
2.2.2. The discovery of genetic variations 
Direct DNA sequencing is the “gold standard” in the identification of genetic variation. 
It is an expensive methodology.  As such, the cost of identifying sequence variants in a 
gene can be substantially reduced by prescreening methods, especially when the gene 
contains multiple exons.  The prescreening methods are able to distinguish SNP alleles 
without identifying the exact position of the SNP and the affected base pair.  Each 
novel SNP would subsequently require sequencing for its confirmation and 
characterization.  Here, several classical pre-screening methods will be reviewed and 
their principles, advantages and disadvantages, will be briefly discussed. 
 
2.2.2.1. Single-strand confirmation polymorphism (SSCP) 
SSCP is based on the principle that a single base change in the DNA sequence can cause 
single-strand DNA to migrate differently under non-denaturing electrophoresis 
conditions. SSCP analysis involves the denaturation of the double-strand PCR product, 
immediate cooling of the denatured DNA, followed by gel electrophoresis under 
non-denaturing conditions.  With the exception of traditional incorporation of 
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radioisotope labeling and sliver staining, recent advances in SSCP have made the 
technique more convenient, safe, and have improved efficiency of detection through the 
application of fluorescent dye-labeled PCR primers, and more recently, capillary-based 
electrophoresis (Suh and Vijg, 2005).  SSCP is a simple technique; however, its 
sensitivity depends on the fragment size and sequence and the detected fragment should 
be shorter than 250bp.  
 
2.2.2.2. Cleavage fragment length polymorphism (CFLP) 
CFLP is a prescreening method based on the reproducible hairpin duplexes during the 
self-annealing of single-stranded DNA, the hairpins are cleaved by endonuclease 
cleavage I at the 5’ side of the junctions between the single strand and duplex region 
(Lyamichev et al., 1993).  Compared with SSCP, CFLP is more rapid and accurate and 
permits the analysis of larger fragment.  However, the assay time and temperature need 
to be optimized for each type of DNA fragment to generate reproducible hairpin 
duplexes (Suh and Vijg, 2005).  
 
2.2.2.3. Denaturing gradient gel electrophoresis (DGGE) 
DGGE has been used to separate DNA fragments based on the principle that the 
mobility of a partially melted double-stranded DNA in polyacrylamine gels increases 
compared with its complete helical form.  DNA fragments with different sequences 
may have different melting behaviors and will therefore stop migrating at different 
positions when they are subjected to a gradient of increasingly denaturing conditions.  
Although DGGE appears to be a relatively popular technique with high sensitivity, 
some disadvantages greatly hinder its rapid application, such as the designing of 
primers for optimal PCR amplification, optimal melting behavior of the amplicons 
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DHPLC is a relatively recent method that has rapidly gained popularity.  Its major 
advantage is in being an automated alternative to gel-based techniques, requiring no 
post-PCR sample processing (Suh and Vijg 2005; Xiao and Oefner, 2001; Rudolph et 
al., 2002). 
The basic principle of DHPLC for screening sequence variations is that the DNA helical 
structure tends to be unstable at or close to its melting temperature, at which 50% of the 
DNA strand is single-stranded and 50% is double-stranded.  The heteroduplexes 
display different melting properties from their corresponding homoduplexes due to the 
presence of mismatch base pairs in the former (Figure 2-1 A).  The heteroduplexes 
were formed upon mixing, denaturing, and re-annealing of two or more chromosomes 
which differ in sequence in a single base pair or the presentation of a short insertion in 
single copy.   As a result, when being analyzed on a reverse-phase column using 
DHPLC under partially denaturing temperatures, the heteroduplexes elute from the 
column earlier than the homoduplexes because of their reduced melting temperature 
(Xiao and Oefner, 2001).  As the fragments elute, they are detected by an UV detector 
and analyzed as chromatograms. Analysis can be performed on individual samples to 
determine heterozygosity, or on mixed samples to identify sequence variation between 





Figure 2-1. The principle of the DHPLC. A: Heteroduplex formation through hybridization 
after heating and cooling the PCR products. B: the typical DHPLC profile of a heteroduplex  
 
Separation of the two forms of duplex DNAs by DHPLC is based on ionic forces 
between the negatively charged DNA and the hydrophobic stationary phase, which 
consists of C (18) chains on non-porous polystyrene-divinylbenzene (PSDVB)  
particles (2.1± 0.12酸) .  The PSDV B  par ticl es are coated with positively charged 
ion-pairing agent triethylammonium acetate (TEAA), acting as a “bridge” molecule 
between negatively charged DNA fragments and the electrically neutral and 
hydrophobic stationary phase.  The elution of the adsorbed DNA is achieved by an 
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B 
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(Rudolph et al., 2002). The linear gradient of acetonitrile allows separation of DNA 
fragments based on size and/or presence of heteroduplexes.  
Other than the concentration of acetonitrile, temperature is another factor which affects 
the retention of DNA fragments (Xiao and Oefner, 2001).  Temperature determines 
the sensitivity of DHPLC, and the optimum can be determined either empirically or 
predicted using DNA melting analysis software provided with the Transgenomic 
WAVE DHPLC system. 
Compared to the rest of the methodologies for mutation prescreening, DHPLC offers 
the advantage of being the automated, hand-free alternative to gel-based techniques, 
requiring no post-PCR ample processing (Suh and Vij, 2005). However, there are some 
limitations of DHPLC.  One major one is the failure to detect homozygous mutants, 
which could hardly be differentiated from homozygous wildtypes.  This limitation can 
be overcome by mixing wildtypes and homozygous mutants at ratio of 1 to 1 to 
generate the heteroduplexes during denaturing and re-annealing post-PCR processing.  
In addition, the primers should be designed to generate a single partially denaturing 
domain.  The optimal temperature could be empirically determined by running the 
samples at temperatures ranging from 2oC above and below the temperature predicted 
by the WAVE System utility software. 
 
2.2.3. Complex diseases 
Unlike monogenic diseases which result from mutations in a single gene, complex 
diseases are influenced by multiple factors, such as environmental influences, 
gene-environment interactions, and interactions among genetic variants at different 
loci.  Complex diseases, such as CAD, cancer, diabetes, asthma, hypertension, 
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obesity, and schizophrenia are very common.  In addition, complex diseases vary in 
severity of symptoms, age of onset, and even in their etiological mechanisms.  Finally, 
an important feature of complex diseases is that the contribution of each candidate gene 
and their genetic variants is small (Tabor et al., 2002). 
 
2.2.4. Approaches for genetic study of complex diseases 
Generally, two approaches are used to map the genes and to identify genetic variations 
that underlie common diseases and disease-related quantitative traits: linkage studies 
and association studies.   
 
2.2.4.1. Family-based genome-wide linkage studies 
For the last two decades, linkage studies have been the most popular approach for 
associating genes and genetic variants with human diseases.  The genome-wide 
linkage analysis is used to examine the genotypes of related individuals using numerous 
evenly distributed polymorphic markers throughout the genome to map the 
chromosomal regions that are associated with diseases or traits.  
  
Linkage analysis has been successful for mapping genes underlying monogenic 
diseases (Hirschhorn and Daly, 2005).  Genome-wide linkage analyses have also been 
carried out for many common diseases, such as inflammatory bowel disease (Hugot, et 
al., 2001; Ogura et al., 2001; Rioux et al., 2001; Stoll et al., 2004), schizophrenia 
(Stefansson et al., 2003) and type 1 diabetes (Nistico et al., 1996) and quantitative 
traits, leading to the discovery of variants that contribute to their susceptibility.  
However, any individual genetic factor generally have small to moderate effect on 
disease susceptibility.  Therefore, only linkage studies with dense marker sites, large 
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sample sizes, and large pedigrees could yield meaningful results.   For example, a 
linkage study which was able to detect the association of the Pro12Ala variant in the 
peroxisome proliferative activated receptor-γ gene (PPARG) with type 2 diabetes, 
required a genome scan of over one million affected sib pairs (Altshuler et al., 2000).  
As such, it is clear that most of these well-established disease-susceptibility alleles 
could never be detected by linkage study.  Hence, association studies with increased 
statistical power should be carried out as a strategic complement to linkage analysis.  
 
2.2.4.2. Association studies 
A genetic association study is designed to determine whether genetic variants are 
associated with the frequency or severity of particular traits.   Association studies 
provide a direct way to unravel the genetic contribution to the etiology of complex 
disease and help to predict susceptibility of an individual to certain diseases, as well 
as his or her response to environmental factors including response to drug treatment 
and adverse drug effects.   
 
Here, two approaches of association studies, namely the candidate gene and the 
genome-wide approaches, will be reviewed.  
 
2.2.4.2.1. Candidate gene association studies 
Candidate gene studies focus on genes that are related to a complex disease based on 
hypothesis about their etiological role in the pathophysiology.  Candidate gene studies 
are usually conducted with a population-based case-control design.  In the 
candidate-gene approach, the genetic influences on a complex trait are usually studied 
by carrying out the following: generate hypotheses, identify candidate genes, identify 
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variants in or near those functional genes or those that are in LD with functional 
changes, genotype variants in a population, and finally analyze the genotyping data 
statistically to determine whether there is a correlation between those variants and 
phenotypes (Tabor et al., 2002; Hirschhorn and Daly, 2005).   The two general 
strategies for analyzing genotyping data are comparing the allelic and genotype 
frequencies between the samples and allelic association.  By means of association 
studies, variations in candidate gene sequences can be interpreted as providing a 
protective or a disease-causing effect.  
Candidate genes are selected on the basis of different types of information, including 
available linkage results and results from mouse models of the phenotype.  When 
examining the association of genetic variants in a particular candidate gene with the 
disease of interest, it is important to select carefully a limited number of SNPs to 
genotype. In theory, it is desirable to study only those polymorphisms that affect the 
function or expression of the protein (Tabor et al., 2002).  However, in most situations, 
the information on the effects of these genetic variants is not available. Therefore, the 
information about the location and the type of genetic variants can be used for the 
selection of polymorphisms.  Generally, nsSNPs and nonsense changes that result in 
premature stop codon are most likely to affect disease susceptibility, and therefore they 
should be given the highest priority for genotyping in candidate-gene studies 
(Hirschhron and Daly, 2005; Tabor et al., 2002).  In addition, the correlation with 
potential causal variants (LD) and technological considerations including the 
availability of high-throughput, lower cost pre-selected SNP sets are also the criteria of 
polymorphism selection (Newton-Cheh and Hirschhorn, 2005). 
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Although candidate gene association study takes advantage of both great statistical 
power and biological understanding of the disease, it has been subjected to criticisms.  
The most common problem is the lack of reproducibility; many candidate gene 
association studies have not been replicated in subsequent independent studies.  The 
possible reasons for the discrepant findings are listed as follows: 1) Studies might differ 
in the selected population and true association in one population may not be true in 
another due to heterogeneity in genetic and environmental background; 2) The 
definition of phenotype might be different, which leads to the different 
inclusion/exclusion criteria of subject; 3) Type I error could arise from statistical 
fluctuation and the widespread, inappropriate use of P-value below 0.05 as a criterion 
for declaring association; 4) Inconsistent results could be due to technical errors in 
genotyping; 5) False association could arise from performing data analysis of 
quantitative traits if appropriate transformation to achieve normality of non-Gaussian 
traits and removal of outliers are not carried out. In addition, population stratification, 
confounder publication bias, and disease misclassification are all potential problems of 
association study. 
 
2.2.4.2.2. Genome-wide association studies 
Although candidate gene association studies have been proposed as a powerful means 
of identifying the common variants that underlie complex disease, it relies on the 
biological hypotheses generated or the fundamental location of the candidate genes 
within a previously determined region of linkage.  When these information and the 
fundamental physiological defects of a disease are unknown, the candidate-gene 
approach will be unable to fully explain the genetic basis of the disease.  In the 
absence of convincing evidence regarding the function or location of the causal genes, 
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the unbiased and comprehensive genome-wide association approach is a preferred 
option.  Genome-wide association studies involve genotyping a sufficiently 
comprehensive set of variants in a large patient sample and surveying most of the 
genome for causal genetic variants without having to guess the identity of the causal 
genes (Collins et al., 1997).  Due to the expense and labor involved, genome-wide 
studies have not been applied widely and only a few reports are available (Ozaki and 
Tanaka, 2006; Duerr et al., 2006; Donfack et al., 2006; Fung et al., 2006).  However, 
with the development of high-throughput genotyping technologies and the 
determination of LD patterns on a genome-wide scale through the HapMap project 
(Need and Goldstein, 2006; de Bakker et al., 2006; Conrad et al., 2006; The 
International HapMap Consortium, 2003), more genome-wide association studies will 
be carried out and should greatly advance our understanding of the genetic basis of 
common diseases and complex traits. 
 
2.2.4.2.3. Association tests 
To observe the association of genotypes with disease status, the most common analysis 
of SNP genotypes and case-control status at a single locus is to test the null hypothesis 
of no association between rows and columns of the 2x3 matrix that contains the counts 
of the three genotypes among cases and controls (Balding, 2006).  In terms of 
association of allele with disease, the 2x2 contingency table is used to test the null 
hypothesis of no association.  Considering the effect of confounding factors, linear and 
logistic regression methods would be advantageous as they are able to adjust these 
confounding variables (Clayton and McKeigue, 2001). 
For the association with quantitative traits, analysis of variance (ANOVA) is a 
statistical method that is generally used.  Linear regression is an alternative tool to 
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ANOVA by achieving a reduction in degrees of freedom from 2 to 1 by assuming a 
linear relationship between mean value of the trait and genotype (Balding, 2006).  In 
either case, the traits have to be normally distributed and with an equal variance.  
Haplotype is a popular strategy in association studies with multiple loci involved.  In 
regions of little recombination, haplotype can capture the correlation structure of SNPs. 
More importantly, haplotype can capture the combined effects of tightly linked variants 
(Balding 2006).  We can interpret haplotye as complete data and genotype as 
incomplete data from the statistical viewpoint, as we can extract all genotype data from 
haplotype, while the revere is not the case.  Therefore, it is generally more useful to 
consider the association based on haplotype or diplotype rather than genotype (Ito et 
al., 2004).  However, haplotype poses the problem of not being observed directly 
without involvement of family members.  They must be inferred and some uncertainty 
could arise in phase inference and the uncertainty may cause some loss of information.  
However, the information loss is usually small when LD between markers is strong 
(Balding, 2006). 
 
2.2.4.2.4. Data analysis of association studies 
Other than a well-designed study, appropriate statistical methods are very crucial to 
minimize the chance of false positives. First of all, data quality is of paramount 
importance.  Testing for Hardy-Weinberg equilibrium (HWE) using a Pearson 
goodness-of-fit test should be done before processing the analysis of association 
(Balding, 2006).  Rather than genotyping error, deviation from HWE can be due to 
population stratification, inbreeding, selection, and gene drift (Balding, 2006).  
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If multiple loci have been genotyped for association studies, haplotypes should be 
more informative than genotypes.  The haplotype frequencies can be inferred using 
softwares, such as SNPHAP (Adkins, 2004), PHASE (Stephen et al., 2001), and 
SNPAlyze from Dynacom (Kanagawa, Japan).   
Whether these polymorphisms of interest are in LD should be examined when multiple 
loci are analyzed. LD, simply defined, is the nonrandom association of alleles at linked 
loci (Jorde, 2000) and it describes the tendency of alleles to be inherited together more 
often than would be expected under random segregation.  The measure of LD, D 
quantifies disequilibrium as the difference between the observed frequency of a 
two-locus haplotype and the expected frequency if the alleles were segregating at 
random (Ardlie et al., 2002). D, one of the simplest measures of LD is equal to PAB-PA 
X PB, ,where PAB is the observed frequency of the haplotype of alleles A and B, and PA is 
the frequency of allele A at the  first locus and PB is the frequency of allele B at the 
second locus.  The most common measures are the absolute values of D’ (Lewontin, 
1964), and r2 (also denoted by ∆2) (Hill and Robertson, 1968).  The absolute value of 
D’ is determined by dividing D by its maximum possible value, given allele frequencies 
at two loci, while r2 is formed by dividing D2 by the product of the four allele 
frequencies at the two loci. The case of D’ = 1 or r2 = 1 is known as complete LD.  
However, D’ values that are near to 1 provide a useful indication of minimal historical 
recombination, but intermediate values should not be used for comparisons of the 
extent of LD. When r2 is used as a pairwise measure of LD for association studies, 
values above 1/3 might indicate sufficiently strong LD is present between two loci 





2.3.1. Lipids and lipoproteins 
The major plasma lipids are cholesterol and TGs.  Cholesterol is an essential structural 
component of cell membranes and is the precursor of steroid hormones and vitamin D 
while TGs are energy sources.  These lipids are transported as components of the 
lipoprotein particles in the plasma, from sites of synthesis and absorption to sites of 
uptake.   These lipoprotein particles contain a hydrophobic core of CEs and TGs, with 
a hydrophilic surface coat consisting of phospholipids, free cholesterol, and 
apolipoproteins, which provide plasma lipoproteins with structural stability and 
solubility.  According to their densities, lipoproteins can be classified into four major 
subtypes: chylomicron (<0.95g/ml), VLDL (0.95-1.006g/ml), LDL (1.019-1.063g/ml) 
and HDL (1.063-1.210g/ml).  Chylomicrons are produced for the purpose of 
transporting dietary TGs and cholesterol absorbed by intestinal epithelia, while VLDLs 
are formed to transport endogenously derived TGs to extra-hepatic tissues. In addition 
to TGs, VLDLs contain some cholesterol and CEs and the apoproteins, apoB-100, 
apoC-I, apoC-II, apoC-III and apoE.  IDLs are derived from TG depletion of VLDLs. 
IDLs can be taken up by the liver for reprocessing or upon further TG depletion, be 
converted to LDLs.  LDLs are the primary plasma carriers of cholesterol for delivery 
to all tissues from the liver and apoB-100 is the exclusive apolipoprotein of LDLs.  
HDL facilitates the reverse cholesterol transport from peripheral cells to the liver. 
 
2.3.2. Definition of dyslipidemia  
Dyslipidemia describes a range of disorders that include both abnormally high and 
low lipid and lipoprotein levels, as well as disorders in the composition of these 
particles. The National Cholesterol Education Programme (NCEP) Adult Treatment 
 30
Panel (ATP) III defines dyslipidemia as an elevation of serum TGs, presence of small 
LDL particles and low HDL-cholesterol level.  No standard and non-expensive 
methodologies are available for the measurement of small LDL particle and 
approximately 70% of total plasma cholesterol is partitioned into LDL, thus, the 
measurement of total plasma cholesterol concentration is a surrogate of LDL level.  
In practice, dyslipidemia is defined as total plasma cholesterol (TC) ≥ 240mg/dl 
(6.15mmol/L) or TG ≥200mg/dl (2.25mmol/L).   
 
Dyslipidemia is a heterogeneous group of disorders which can be classified in several 
ways.  According to etiology, dyslipidemia can be classified into primary and 
secondary dyslipidemia.  Based on the biochemical phenotype, dyslipidemia can be 
classified into (1) mainly hypercholesterolemia, (2) a combined increase in cholesterol 
and TGs and (3) mainly hypertriglyceridemia.   
 
2.3.3. Dyslipidemia and CAD 
Dyslipidemia is a prominently important risk factor for CAD. In this thesis, two main 
types of dyslipidemia, namely, hypercholesterolemia and hypertriglyceridemia are 
reviewed. 
 
The casual relationship between cholesterol and atherosclerosis has been extensively 
surveyed from three aspects, epidemiological studies, clinical trials, and pathological 
studies, by Steinberg (2002; 2004; 2005a, 2005b, and 2006).  In population studies, 
the Framingham Heart Study (Kannel et al; 1961), the Seven Countries Study (Keys, 
1970 and 1980), and a cohort study in three large cohorts (Stamler et al., 2000) have 
provided the evidences linking hypercholesterolemia to CAD. Numerous clinical 
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trials with larger number of subjects have conclusively shown that 
cholesterol-lowering treatment reduces both coronary events and total mortality 
(Libby et al., 2000;  NCEP, ATPIII, 2002; Yokoi, et al., 2005; Ballantyne, 2005; 
Huse et al., 2006).  Moreover, the pooled results of many clinical trials using 
different cholesterol-lowering regimens indicated that for every 10% reduction in 
plasma cholesterol level, CAD mortality will be reduced by 15% (Gould et al., 1998); 
patients who received statin treatment demonstrated a 20% to 30% reduction in death 
and major cardiovascular events compared with patients who received placebo (Ross 
et al., 1999).  Other than these epidemiological studies and clinical trials, 
pathological studies also showed that the early lesion of atherosclerosis consists of 
subendothelial accumulation of foam cells.  It was nearly 100 years ago that 
cholesterol had been found to cause arterial lesions by the Russian investigators, 
Antisckkow and Chaltow (Anitschkow anf Chalatow, 1913).  The trigger event for 
atherosclerosis is the accumulation of oxidized LDL, which stimulates the underlying 
endothelial cells to produce a number of pro-inflammatory molecules (Ross, 1999), 
which then lead to foam cell formation and atherosclerosis development.   
 
In summary, the causal relationship between blood cholesterol and coronary artery 
atherosclerosis is generally accepted.  Cholesterol is not only a component of 
atherosclerotic plaques but also is an initiator of atherosclerosis (Steinberg, 2002).  
Therefore, cholesterol-lowering treatment is one of the most promising therapeutic 
targets in the prevention of coronary atherosclerosis, especially those with 
hypercholesterolemia.   
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The impact of hypertriglyceridemia on CAD risk has long been a matter of intense 
debate. However, during the last decade, a considerable number of evidences have 
been gathered to support hypertriglyceridemia as an independent risk for CAD 
(Hokanson and Austin, 1996; Assmann et al., 1996; Yarnell et al., 2001). Clinical 
trials also demonstrated the benefits of triglyceride lowering alone on clinical or 
cardiovascular outcomes (Fruchart et al., 2004). In addition, a meta-analysis of 
prospective studies conducted in the Asia-Pacific region also suggested that serum 
TGs are an important and independent predictor of CAD and stroke risk in this region 
(Patel et al., 2004) 
 
2.3.4. Genetics of dyslipidemia 
Dyslipidemia can be monogenic disorders or a part of a complex genetic disease.  
Some monogenic dyslipidemia, such as familial hypercholesterolemia and 
sitosterolemia, are found to be associated with atherosclerosis. Studies on these 
monogenic disorders have provided important insights into the fundamental biology 
of cholesterol metabolism.  For example, studies of familial hypercholesterolemia 
led to the discovery of LDLR and the elucidation of the feedback control of 
cholesterol synthesis (Brown and Goldstein, 2001).  In addition, the study of 
monogenic diseases can lead to successful drug therapies for atherosclerosis.  For 
instance, the discovery of LDLR led to development of statin drugs, which 
significantly reduce cholesterol and CAD mortality.  Statins are used as routine 
medication not only for the treatment of CAD by tens of millions of CAD patients but 
also for the prevention of CAD by the healthy.   Last but not least, monogenic 
diseases also provide a logical basis for candidate gene study for the more common 
forms of dyslipidemia (Lusis et al., 2004).  However, monogenic dyslipidemia can 
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only account for a small percentage of atherosclerosis and most dyslipidemia are 
regarded as complex diseases involving common variations in candidate genes.  
 
Over the years, many genes encoding apolipoproteins, lipoprotein receptors, and 
enzymes involved in plasma lipid metabolism have been evaluated to examine the 
possible associations with levels of plasma lipids and lipoproteins.  Some of those 
associations observed are convincing and have been replicated.  For example, three 
common apoE alleles exhibit marked effects on plasma cholesterol level in Western 
populations, accounting for 4% or more in total plasma cholesterol variation and 
increased atherosclerosis risk (Lusis et al., 2004)  Furthermore, the apoE genetic 
variation is also associated with type III hypercholesterolemia and >95% of type III 
hyperlipoproteinemia individuals have the E2/2 phenotype.  However, only 1/50th of 
E2/2 individuals manifest the overt disease (Mahley and Rall, 1995; Breslow, 2000). 
These studies also implied that lipid disorders are complex diseases and can be 
influenced not only by genetic but also by environmental factors.  Identification of 
these genetic factors and quantifying their effects are an area of great interest and the 
objective of much current research.   
 
2.4. Acyl-coenzyme A: cholesterol acyltransferase (ACAT) 
ACAT (EC2.3.1.26) catalyzes the formation of CEs by using cholesterol and 
long-chain fatty acids as substrates, and ATP and coenzyme A (CoA) as co-factors.  
The esterification of cholesterol serves several important functions in cholesterol 
metabolism: 1) Addition of long-chain fatty acids to cholesterol reduces its solubility 
in the cell membrane phospholipid bilayer and promotes CEs to be stored as lipid 
droplets within the cytoplasm (Rudel and Shelness, 2000).  This process prevents 
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toxic accumulation of free cholesterol in various cell membrane fractions.  2) The 
cholesterol esterification is required for the intestinal cholesterol absorption, since 
75-80% of cholesterol absorbed undergoes esterification before incorporation in 
chylomicrons (Klein and Rudel, 1983).  3) CEs are also required for the synthesis 
and secretion of apoB-containing lipoproteins (e.g., VLDL) by the liver (Buhman et 
al., 2000).  4) ACAT has a role in the accumulation of CEs in macrophages and 
vascular tissue, an event that is central to foam cell formation and atherosclerosis.  
 
There are two forms of ACAT, ACAT1 and ACAT2, which catalyze the formation of 
CEs using cholesterol and fatty acids. However, their distribution, physical structures 
and physiological functions in cholesterol metabolism are distinct from one another.  
Another enzyme catalyzing the formation of CEs, lecithin cholesterol acyltransferase 
(LCAT), is noteworthy. LCAT transfers an acyl chain from phosphatidylcholine 
(lecithin) to cholesterol. Furthermore, the CEs provided by LCAT are responsible for 
the maturation of HDL particles (Chang et al., 1997) and have anti-atherosclerotic 
potential (Lee et al., 2004). Before reviewing these characteristics, the identification 
of ACAT2 is described below.  
 
2.4.1. Identification of ACAT2 
The first evidence suggesting that at least two forms of ACAT exist was obtained by 
Kinnunene and his colleagues in early 1988.  They found that ACAT activity in 
pancreas was inhibited by 94% while hepatic ACAT activity was only inhibited by 
6% (Kinnunen et al., 1988) by chemically modifying an active-site histidine residue. 
In 1996, two ACAT-related sterol-esterifying enzymes (Are1p and Are2p) were 
simultaneously but independently identified in yeast (Yang et al., 1996; Yu et al., 
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1996). However, convincing evidence that at least two mammalian intracellular 
cholesterol esterifying enzymes must exist came from ACAT1-/- mice, as the 
esterification activity was absent in the adrenal glands, but not significantly reduced in 
the liver and small intestine (Meiner et al., 1996).  In 1998, the immunodepletion 
using anti-human ACAT1 monoclonal antibody further supported this hypothesis.  
After immunodepletion, ACAT activity was inhibited by 80% in adult human liver, 
adrenal glands, macrophages and kidneys, while ACAT activity was only inhibited 
20% in human intestine (Lee et al., 1998).  All these studies led to the identification 
of a second mammalian ACAT isoform, designated ACAT2, in monkeys, mice, and 
humans (Anderson et al., 1998; Cases et al., 1998; Oelkers et al., 1998).   
 
2.4.2. Distribution and function of ACAT2 
Whereas ACAT1 is ubiquitously present in a variety of tissues and cell types in 
mammals, ACAT2 is only expressed in the small intestine and liver (Lee et al., 1998; 
Oelkers et al., 1998; Chang et al., 2000; Sakashita et al., 2000).  Even in same tissue, 
the cell types of their expressions are also different. In the liver and intestine, ACAT2 
is confined to hepatocytes and enterocytes, which secrete apolipoprotein B-containing 
lipoproteins, while ACAT1 is present in numerous other cell types, such as Kupffer 
cells and macrophages (Lee et al., 2000; Parini et al., 2004).  It is clear that the 
intestine and liver are the only tissues to express ACAT2 under normal conditions and 
enterocytes and hepatocytes are the only cell types to abundantly express ACAT2 but 
do not express detectable amounts of ACAT1 (Rudel et al., 2005).   
 
The different distribution of these two ACATs determines their different 
physiological roles.  ACAT2 facilitates cholesterol absorption in the intestine and the 
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incorporation of atherogenic CEs into apoB-containing lipoproteins (Buhman et al., 
2000), while ACAT1 mainly contributes to the foam cell formation in the early stage 
of atherosclerosis development (Meiner et al., 1996; Chang et al., 1997).  The 
distinct functions of these two ACAT enzymes in cholesterol metabolism determine 
their different contributions to atherosclerosis development and render them 
tissue-specific targets for drug development.   
 
2.4.3. ACAT2 and atherosclerosis  
Due to the specific distribution of ACAT2 and its role in cholesterol absorption in the 
intestine, and in secretion and assembly of apoB-containing lipoproteins in the liver, 
the relationship between ACAT2 and atherosclerosis has attracted great interest 
among researchers.  In 2000, a study in ACAT2-/- mice indicated that the deficiency 
of ACAT2 results in a reduction in CE synthesis in the small intestine and liver, which 
in turn limits intestinal cholesterol absorption, cholesterol gallstone formation, and the 
accumulation of CEs in the plasma apoB-containing lipoproteins (Buhman et al., 
2000).  In order to examine the contribution of ACAT2 to atherosclerosis, ACAT2-/- 
mice were crossed with apoE-/- mice to generate double-knockout mice (Willner et 
al., 2003).  The results from this study suggested that it is the amount of 
ACAT2-derived CEs present in the core of these lipoproteins and not the number of 
apoB-containing lipoproteins that plays a critical role in the development of 
atherosclerotic lesions (Willner et al., 2003).  Further evidence for the atherogenic 
role of ACAT2 was obtained from studies in LDLR-/- mice with deletion of ACAT2, 
LCAT, or both enzymes together (Lee et al., 2004).  This study demonstrated that 
only LCAT and ACAT2 are responsible for synthesis of plasma CEs and the CEs 
provided by LCAT and ACAT2 have opposite atherosclerotic potential (Lee et al., 
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2004).  These data further supported the importance of ACAT2 in the development 
of atherosclerosis since this enzyme facilitates intestinal cholesterol absorption and 
incorporation of atherogenic CEs into apoB-containing plasma lipoproteins, which 
then appear to accumulate in the aortic intima and promoting atherosclerotic lesion 
development.   
 
Although ACAT1 is the enzyme responsible for the formation of CEs in macrophages 
(Meiner et al., 1996), ACAT1 deficiency did not prevent the development of 
atherosclerotic lesions in either apoE-/- or LDLR-/- mice (Accad et al., 2000; Yagyu 
et al., 2000).  Instead, severe side effects, such as extensive cutaneous xanthomatosis, 
were observed (Accad et al., 2000; Yagyu et al., 2000). Furthermore, macrophage 
ACAT1 deficiency even promotes lesion formation (Fazio et al., 2001).   Together, 
these studies suggested that complete ACAT1 deficiency has been varyingly 
problematic.   
 
All information available about ACAT1 and ACAT2 suggests that it would be 
beneficial to selectively inhibit ACAT2 to decrease atherogenicity of plasma 
lipoproteins without causing severe side effects and affecting normal membrane 
function to the body with the availability of adequate ACAT1 function (Rudel et al., 
2005).   
 
2.4.4. ACAT2 protein structure  
Human ACAT2 protein contains 522 amino acid residues and exhibits 48% sequence 
identity with ACAT1 at their carboxyl termini.  The molecular weight of ACAT2 is 
46 kDa, which is bigger than the predicted molecular size (Chang et al., 2000).   
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Some studies have been performed to unravel the relationship between the structure 
and function of ACAT and its related protein, especially regarding the activity and 
substrate-binding site.  Joyce et al. (2000) used mutagenesis methods to demonstrate 
that the conserved serine in the 245th residue of ACAT2 may be essential for ACAT 
activity.  Guo et al. (2001) also suggested the importance of the conserved serine for 
enzyme activity and stability in the ACAT1 and Are2p, an ACAT-related-enzyme in 
yeast.  Furthermore, Guo et al. (2001) also found that the mutation of a tyrosine or 
the tryptophan in the conserved FYxDWWN motif either decreased or nullified 
enzyme activity.  Because the motif containing the conserved serine is absent from 
DGAT, a member in the acyltransferase family, they speculated that the conserved 
serine of (H/Y)SF may play a role in sterol binding and the FYxDWWN domain may 
mediate the binding of acyl-CoA.  However, Lin et al. (2003) confirmed that the 
conserved serine is important for ACAT protein stability but not essential for ACAT 
catalytic activity, as they found that the mutagenesis of ACAT protein from serine to 
leucine or to alanine caused the mutant protein to be expressed at a much lower level.  
Instead, they found that a conserved histidine (His434) may be essential for ACAT2 
catalysis.  In addition, Guo et al. (2001) reported that the 31 amino acid residues at 
the amino-terminal region in Are2p, the ACAT-related-enzyme (Are)2, may mediate 
the enzyme activity in a negative fashion using the truncation approach, and suggested 
that it may be true for ACATs in general.  However, whether the amino terminal 
amino acid residues have important biological function is unclear. 
 
2.4.5. ACAT2 genomic organization and its regulation of ACAT expression 
 39
The ACAT2 gene (NT_029419) maps to chromosome 12 (12q13.13) and spans 
slightly over 18 kb. It is much smaller than the ACAT1 genomic DNA, which is about 
200kb in length (Li et al., 1999).  ACAT2 comprises 15 coding regions and exon 1 
contains 5’-untranslated region (5’-UTR) (AF332857, AF332858).  
 
Most genes involved in the cholesterol metabolism pathway, such as LDLR and 
HMG-CoA reductase genes, are regulated by the sterol response element binding 
protein (SREBP) (Brown and Goldstein, 1986 and 1997).  These gene promoters 
contain a 10-base-pair sterol-regulatory element and SREBP binds this element to 
mediate these gene expressions.  However, the sterol-regulatory element could not 
be identified within the ACAT1 and ACAT2 promoters (Li et al., 1999; Song et al., 
2001).  These findings indicated that both ACATs are not regulated by the SREBP 
mode.   
 
The 5’-flanking region ACAT2 gene contains many potential cis-acting elements for 
multiple potential transcriptional regulatory factors, such as Cdx-2, HNF-3b, Sp1 and 
CEBP, but lack TATA and CCAAT boxes (Song et al., 2001).  There are studies to 
show that Cdx-2, HNF-1 alpha and beta play important regulatory roles in ACAT2 
gene expression (Song et al., 2003; Pramfalk et al., 2005).  In addition, analysis of 
the promoter activity of serially deleted 5’-flanking regions of ACAT2 suggested that 
there might be positive regulatory elements between -1299 to -768 (the transcription 





2.4.6. Genetic analysis of ACAT2  
Although the ACAT2 gene certainly qualifies as a candidate gene for 
hypercholesterolemia and atherosclerosis, genetic association study of this gene has 
only been carried out in Japanese population (Katsuren et al., 2001 and 2003).  They 
used single-strand conformation polymorphisms (SSCP) to identify 4 polymorphisms 
and found the association of the heterozygotes of Thr254Ile with plasma apoCIII 
concentrations in 91 dyslipidemic subjects (Katsuren et al., 2001). Whether there is 
any association of ACAT2 polymorphisms with CAD susceptibility is still unknown.  
Furthermore, the association of the ACAT2 polymorphisms with dyslipidemia and 
plasma lipid parameters is worth investigating in other non-Japanese populations.   
Genetic studies on this gene may offer the opportunity to identify the determinants of 
hypercholesterolemia and atherosclerosis and help to unravel certain structural and 
functional features. 
 
2.5. Lipoprotein lipase (LPL) 
LPL (EC 3.1.1.34) is a member of the lipase super-family that includes hepatic lipase, 
pancreatic lipase and LPL itself (Hide et al., 1992). Research carried out over the past 
two decades has not only established the central role of LPL in the overall lipid 
metabolism and transport but also identified novel, non-catalytic functions of the 
enzyme. Abnormal LPL expression has also been found to be associated with 
atherosclerosis, dyslipidemia and diabetes. 
 
2.5.1. Function and localization of LPL 
LPL is a crucial enzyme in the removal of plasma TG-rich lipoproteins, such as 
chylomicrons and VLDL from the circulation, and provides non-esterified fatty acids 
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and 2-monoacylglycerol for tissue utilization.  After the hydrolysis process, the 
chylomicrons in the intestine are converted to smaller remnants and transported into 
the liver. In the case of VLDL, the lipoprotein particles become smaller IDLs and 
LDLs after the hydrolysis of its TG component by LPL.  This process also results in 
the generation of surface remnants, phospholipids and apolipoproteins, which give 
rise to HDLs.  Therefore, LPL is critical for the formation of HDL particle (Lewis 
and Rader, 2005).  
 
Other than its role in the hydrolysis of the TG component in chylomicrons and VLDL, 
LPL also fulfills other important functions. For example, LPL can function as a 
non-catalytic bridge to facilitate the uptake and cellulization of plasma lipoproteins 
and CEs through specific receptors, such as LDL receptor, and VLDL receptor 
(Pentik鄜nen et al., 2002; Merkel et al., 2002b; Stein and Stein, 2003; Loeffler et al., 
2006).  In addition, LPL has been shown to stimulate the proliferation of VSMCs 
(Mamputu et al., 2000).  Thirdly, LPL has been reported to have differential effects 
on several inflammatory pathways, such as tumor necrosis factor-alpha and 
interferon-gamma -mediated inflammatory cytokine signal transduction pathways in 
human aortic endothelial cells (HAECs) (Kota et al., 2005).  These inflammatory 
pathways are known to be important in atherosclerosis.  Finally, LPL reduces the 
secretion of apoE from macrophages, which could significantly influence apoE 
accumulation in arterial vessel wall lesions (Mead et al., 2002). 
 
Adipose and muscle cells are the major sources of LPL synthesis.  LPL is 
synthesized and secreted in catalytically active form by adipocytes and myocytes and 
then transported to the luminal surface of the capillary endothelium. The 
 42
physiological function in capillary endothelium is to hydrolyze the TG component of 
chylomicrons and VLDL and IDL particles on the luminal side.  The LPL in 
capillary endothelium drives the lipoprotein profiles in a non-atherogenic direction 
with increase in HDL levels.  The vast majority of the total LPL in the body is 
located in capillary endothelium.  However, LPL is also found in the arterial 
endothelium and most of the arterial LPL is derived from monocyte-derived 
macrophages and macrophage-derived foam cells and smooth muscle cells (Wang et 
al., 2006).  The LPL on the arterial intima can lead to the retention of LDL in these 
structures by acting as a molecular bridge.  Therefore, the arterial LPL has been 
suggested to have a role in atherogenesis.   Taken together, the localization of LPL 
is curicial to determine whether its role in the development of atherosclerosis is 
predominantly pro-atherogenic or anti-atherogenic. 
 
2.5.2. LPL and atherosclerosis 
2.5.2.1. The anti-atherogenic effects of LPL 
LPL expressed in adipose tissue and muscle is believed to be anti-atherogenic because 
it aids the clearance of circulating lipoprotein particles and the formation of HDL.  
The anti-atherogenic effect of LPL has been backed by clinical and experimental 
evidences. Firstly, LPL-deficient patients were reported to develop premature 
atherosclerosis (Benlian et al., 1996).  Furthermore, individuals with heterozygous 
LPL mutations which lead to decreased enzyme activity (e.g. Asn291Ser, Gly188Glu, 
and Asp9Asn) or reduced expression (e.g. -93T>G in the promoter) have been 
reported to be predisposed to hyperlipidemia and premature atherosclerosis (Reymer 
et al., 1995; Gilbert et al., 2001; Wittrup et al., 2006; Goldberg and Merkel 2001; 
Frikke-Schmidt et al., 2006).  The Ser447Ter, a naturally occurring mutation, has 
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been proven to increase LPL catalytic activity (Ross et al., 2005).  Most studies have 
suggested that this beneficial mutation was associated with decreased plasma TG 
levels, higher HDL and reduced risk of CAD (Rip et al., 2006).  Finally, 
administration of the compound NO-1886, a LPL activator, may contribute to 
improving atherosclerosis by increasing HDL cholesterol or influence the expression 
of inflammatory cytokines (Nakamura et al., 2006; Cai et al., 2006).  
 
2.5.2.2. The pro-atherogenic action of LPL 
In contrast to LPL expressed in adipose tissue and muscle, the enzyme expressed in 
cells of the arterial wall, particularly macrophages and smooth muscle cells, is 
proposed to be pro-atherogenic (Babaev et al., 1999 and 2000).  Zilversmit was the 
first to propose that chylomicron and VLDL remnants produced by LPL would 
contribute to the development of atherosclerosis (Zilversmit, 1973). LPL induces the 
formation of atherogenic lipoprotein remnants by the following mechanisms. Firstly, 
LPL converts TG-rich lipoproteins to small and dense particles with enrichment in 
their CE contents and such remnants are taken up readily by macrophages (Zilversmit, 
1995; Lindqvist et al., 1983).  In addition, LPL has been shown to act synergistically 
with sphingomyelinase in the lesion to enhance the association of LDL and the highly 
atherogenic lipoprotein(a) [Lp(a)] to the vascular wall (Tabas et al., 1993; Mead et al., 
1999).  Finally, additional functions of LPL, including stimulation of smooth muscle 
cell proliferation, adhesion of monocytes to endothelial cells and regulation of gene 
expression, may trigger other pro-atherogenic events (Mamputu et al., 1997; 
Mamputu et al., 2000; Renier et al., 1994).  It has been shown that the suppression 
of LPL expression attenuated pro-inflammatory cytokine secretion in THP-1 
macrophages (Qiu et al., 2006). 
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2.5.3. The organization of LPL protein and gene  
Mature LPL protein contains 448 amino acid residues.  LPL consists of two 
structurally distinct regions, a larger amino-terminal domain (residues 1-312) and a 
smaller carboxyl-terminal end (residues 313-448).  The C-terminus appears to be 
implicated in the uptake of lipoproteins by cell surface receptors whereas the 
N-terminus is important for the catalytic activity (Mead et al., 2002).  
 
The LPL gene is located on chromosome 8p22, spanning about 35 kb, and contains 10 
exons separated by 9 introns.  Exon 1 encodes the 5’–UTR while exon 10, notably 
longer than the others, encodes the entire 3’-UTR (Enerback and Gimble, 1993; 
Raisonnier et al., 1995). LPL gene expression is regulated by transcriptional and 
post-transcriptional control (Mead et al., 2002). 
 
2.5.4. Genetic analysis of LPL 
Because of the physiological importance of LPL in the catabolism of TG-rich 
lipoprotein particles and its possible role in lipid-related pathologies, LPL is an 
important candidate gene for association studies on atherosclerosis risk in the general 
population.  About 100 natural-occurring polymorphisms have been identified in the 
LPL gene, of which 80% occur in coding regions and the others in non-coding regions 
(Murthy et al., 1996).  There are 61 missense mutations, most of which are located 
on exons 5 and 6; 12 nonsense mutations, 10 frameshift mutations or small 
insertions/deletions, 3 gross mutations, 8 splicing mutations, and 4 promoter variants 
(Merkel et al., 2002a).  Some functional mutations can influence LPL function in 
different ways, such as affecting catalytic activity, dimerization, secretion, and 
heparin binding (Razzaghi et al., 2000), leading to altered lipid profiles.  Some of 
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them have been associated with familial LPL deficiency (FLLD) and 
chylomicronemia.  For instance, Gly188Glu has been identified in almost 50% 
FLLD in European and Indian ancestry (Mailly, et al., 1997) and two families with 
type I hyperlipidemia (Paulweber et al., 1991).  Pro207Leu is the most common 
cause of familial chylomicronemia in French Canadians (Ma et al., 1992).  However, 
most of these functional LPL mutations are rare, either restricted to families with LPL 
deficiency or isolated geographic regions.  For example, Gly188Glu, Asn291Ser, 
and Asp9Asn are common in some Western populations, such as the French Canadian 
population, but not in the Asian general population (Yoshida et al., 2000; Yamana et 
al., 1998: Yang et al., 2003).  In this review, only three most common genetic 
variants with modest effects on lipids profiles are surveyed.  
 
The c.1342C>G, a C to G transversion, results in a premature stop codon truncating 
the LPL protein by two amino acids and it is usually defined as Ser447Ter or S447X.  
The c.1342C>G  is a very common variant, occurring at a frequency approximately 
20% in general population and has been reported to be the only variant with increased 
LPL activity (Merkel et al., 2002a).  Results from association studies suggested that 
the 1342G carriers had a beneficial lipid profile (Kuivenhoven et al., 1997; Razzaghi 
et al., 2000; Groenemeijer et al., 1997; Arai et al., 2005; Souverein et al., 2005; 
Brousseau et al., 2004; Morabia et al., 2003; Chen et al., 2001; Humphries et al., 
1998) and a reduced risk of atherosclerosis (Humphries et al., 1998; Clee et al., 2001; 
Arca et al., 2000; Shimo-Nakanishi et al., 2001).  However, inconsistent results have 
been reported (Morrison et al., 2002; Jemaa et al., 1995; Fidani et al., 2005).  
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Two variations, IVS6+1595C>T and IVS8+484T>G, in intronic regions, have been 
most extensively studied.  The IVS6+1595C>T polymorphism, a C>T transition, can 
be identified by the cleavage of restriction enzyme PvuII (Chamberlain et al., 1991; 
Nicklas et al., 2000), hence, it is usually defined as PvuII polymorphism.  The 
IVS8+484T>G polymorphism is a T>G transversion and can be identified by 
restriction enzyme HindIII (Heizmann et al., 1991), so it is also known as HindIII 
polymorphism. The rare G allele of the IVS8+484T>G polymorphism has 
consistently been shown to be associated with lower TGs and/or elevated 
HDL-cholesterol, and the impact may be modulated by other environmental factors, 
such as smoking and physical activity (Senti et al., 2001; Corella et al., 2002; Whiting 
et al., 2005; Reilly et al., 2005).  In addition, the IVS8+484T>G polymorphism has 
been shown to influence CAD susceptibility and the progression of atherosclerosis in 
several studies (Jemaa et al., 1995; Taylor et al., 2004; Socquard et al., 2006). The 
results on the association of the IVS6+1595C>T polymorphism with plasma lipids 
have been inconsistent; increased TGs in T allele carriers were reported in some 
studies (Chamberlain et al., 1989; Galton et al., 1994; Duman et al., 2006) but not in 
others (Peacock et al., 1994; Jemaa et al., 1995).  Although the IVS6+1595C>T 
polymorphism has been reported to be associated with the severity of CAD in 
Australian whites (Wang et al., 1996), no association was found with CAD in most 
studies in other populations (Galton et al., 1994; Taylor et al., 2004; Duman et al., 
2006).  
 
The three polymorphisms,  c.1342C>G , IVS8+484T>G, IVS6+1595C>T, have been 
found to be in LD in most populations (Chamberlain et al., 1989; Hallman et al., 1999; 
Razzaghi et al., 2000). Furthermore, most IVS8+484T>G-associated effects could be 
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explained by the LD between the IVS8+484T>G and c.1342C>G (Humphries et al., 
1998; Talmud and Humphries, 2001).  
 
As mentioned above, although there have been many studies to examine the effects of 
LPL genetic variants, these results are inconsistent.  Furthermore, most studies were 
carried out in Caucasian populations and only a few studies have examined the impact 
of these polymorphisms in Asian populations (Shimo-Nakanishi et al., 2001; 
McGladdery et al., 2001; Hall et al., 2000; Radha et al., 2006) and in Singaporeans 
(Lee et al., 2004; Liu, et al., 2004).  To our knowledge, there are no large-scale 
studies to explore their combined effects of these three polymorphisms on CAD risk 
and lipid profiles in an Asian population. Therefore, other than individual effects of 






3. MATERIALS AND METHODS 
 
3.1. Subjects 
For polymorphism screening of the ACAT2 gene, umbilical cord blood was collected 
from 336 consecutive newborns at the National University Hospital, Singapore.  
Informed consent was obtained from mothers of the neonates.   
 
For the association studies, the CAD+ subjects were selected from patients who had 
been admitted to Singapore National Heart Center for coronary artery bypass graft 
surgery.  All the patients had more than 50% stenosis in at least one of the major 
coronary arteries as revealed by angiography.  The controls were recruited from 
workers sent by their employers to attend routine health screening.  This screening 
included blood hemoglobin estimation, urine analysis for albumin and sugar, chest 
X-ray and resting electro-cardiogram.   Subjects with any abnormal test results or 
who had a history of heart illnesses, stroke, diabetes or hypertension were excluded.   
All subjects gave informed consent.  
 
A total of 809 CAD patients (CAD+) were included in the ACAT2 gene association 
study.   These comprised 526 Chinese, 137 Malays and 146 Asian Indians.  A total 
of 1304 controls (CAD-) comprising 702 Chinese, 230 Malays and 372 Indians were 
studied. 
 
However, only male Chinese and male Indians were studied in our LPL gene 
association study.  Since the LPL gene has been extensively studied in many 
populations, we are interested to examine the genetic effect in male Chinese and 
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Indians, which have contrasting mortalities from CAD and Malays have intermediate 
mortality from CAD (Hughes et al., 1990a and 1990b). The CAD+ patient samples 
comprised only 899 Chinese males and 302 Indian males and the CAD- controls 
comprised 538 Chinese and 305 Indians.  
 
This study was approved by the Research and Ethics Committee, National University 
Hospital, which is the predecessor of the Institutional Review Board . 
 
3.2. DNA analysis  
3.2.1. DNA Extraction 
After blood was collected, the white blood cells and plasma were separated by 
centrifugation at 1500g for 15 min.   The white blood cells were used for DNA 
extraction and the plasma was freezed at -20oC for the measurement of lipids.  
Afterwards, genomic DNA was isolated from white blood cells using Parzer’s method 
(Parzer and Mannhalter, 1991).  Five ml of blood sample was lyzed using 10ml of 
lysis buffer (0.32 M sucrose, 5mM MgCl2, 0.01M Tris-HCl, 1% Triton X-100, pH 8.0) 
and then centrifuged for 10 min at 3000g.  The supernatant was discarded and the 
pellet was re-suspended in 14ml of NaCl/EDTA solution (10mM NaCl, 10mM EDTA, 
pH8.0) and centrifuged as before. Then the pellet was incubated with 210痞 of  20% 
sodium sarcosyl, 150痞 o f  7 . 5M a mmo ni um a cet ate,  2 . 1ml  o f  6M guani di um 
hydrochloride and 60痞 of  10mg / ml  pr ot ei nase K at  60 oC for 2-5min until the solution 
was clear.  This digested mixture was cooled to 0oC on ice and DNA was 
precipitated using 10ml of cold absolute ethanol. The precipitated DNA was dried at 
room temperature and then dissolved with 100痞 of  TE (10mM Tr i s -HCl, 1M EDTA, 
pH 8.0) and stored at 4oC.  
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3.2.2. Primer design for polymorphism screening of ACAT2 gene 
The DNA sequence of the ACAT2 gene was obtained from a public database 
(http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=16163027; accession no. 
NT_030118).  For the polymorphism detection, the regions of interest, such as the 
coding regions, the intron-exon boundaries, 5’-UTR, and the putative promoter region, 
were screened.  Primers to amplify these regions in separate amplification reactions 
were designed using the program at http://seq.yeastgenome.org/cgi-bin/web-primer.  
The primer sequences and their related information are shown in Table 3-1.  For the 
region, exon 9 and its flanking intronic boundary, an additional upstream primer with 
20bp of GC content (CGCCCGCCGCCGCCCGCCGC) at the 5’ end was used to 
increase the resolution (Marsh et al., 2001; Narayanaswami and Taylor, 2001).  All 




Table 3-1. PCR primers and DHPLC conditions  
 

































5’-CTTCTCTCCATAGCGCATCTC-3’         
323 62-56 
60-66% B 
 3 min 
61-63 
Exon 2 5’-GTCTGCAGAACCCCAATTCC-3’ 





Exon 3 5’-CTGGTGAATGAAAGGATGGCTG-3’  

















Exon 6 5’-CAGACTGAAGAGGAAGGGGAC-3’ 
5’-CCCCTCTGCTGAGATGGC-3’ 
399 63-56 55-64%B 
5 min 
61-64 


















Exon 10 5’-TGCTGGGCCAGAGGTCAATG-3’ 





Exon 11 5’-GCCTCTTGTCCCCAACCAC-3’  





Exon 12 5’-GAACCCAGATGCTTGCTTACCTC-3’ 






















*: buffer B percentage (start gradient - stop gradient). 
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3.2.3. PCR amplification 
All amplification reactions were carried out in a 40µl of mixture containing 100ng of 
genomic DNA, reaction buffer, 0.2 mM each dNTP, 10% dimethyl sulfoxide, 40 pmol of 
each primer and 0.4U of DynaZyme II (Finnzymes, Espoo, Finland).  The reaction 
mixture was denatured at 94oC for 2 min, followed by an initial 14 cycles of denaturing 
at 94oC for 30s and annealing from a range of temperatures as given in Table 3-1 at 
ramping rate of 0.5oC per cycle.  The subsequent 20 cycles were run at annealing 
temperature BoC (Table 3-1). The final extension step is at 72oC for 10 min. The 
reactions were carried out in the T-GRADIENT Thermocycler (Biometra, Goettingen, 
Germany).  
 
3.3. Survey of genetic variant in ACAT2 gene from public resources 
Before screening the regions of interest, known SNPs have been identified using the 
program at http://www.ncbi.nlm.nih.gov/projects/SNP/snp_blastByOrg.cgi. Other SNP 
resources, such as TSC at http://snp.cshl.org, JSNP at http://snp.ims.u-tokyo.ac.jp, and 
HGVbase at http://hgvbase.cgb.ki.se/, were also explored.  We aimed to identify 
novel polymorphisms when we screened these regions using DHPLC. 
 
3.4. DHPLC analysis 
DHPLC was carried out using the Transgenomic WA V E® DNA  Fragment A nalysis 
system (Transgenomic, Omaha, USA). The amplified DNA fragments of interest were 
injected (3-10µl) automatically from the 96-well autosampler onto the DNAsep 
cartridge.  They were then eluted at a constant flow rate of 0.9ml/min with a linear 
acetonitrile gradient that has been determined by the WAVEMaker software 
(Transgenomic) based on their size and GC. The gradient was achieved by combining 
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buffer A (0.1M triethylammonium acetate, pH 7.0) and buffer B (0.1M TEAA and 25% 
acetonitrile in water, pH 7.0). The DNA fragment elution was monitored with a UV 
detector at 260nm and displayed as chromatography using the Transgenomic WAVE 
MAKERTM software, and the chromatograms were compared and analyzed. 
 
The processing time for each sample was about 7 min, comprising a 2.2-min lag for the 
detector, a 0.5-min sample loading with a 5% decrease in Buffer B, a 3-min linear 
gradient step with a slope of 5% decrease in Buffer B per minute, a 0.5-minute cleaning 
stage using 75% acetonitrile, and a 0.9-min equilibration before next injection.  Homo- 
and hetero-duplex peaks were detected between the initial injection peak, which is 
produced by residual nucleotides and primers in the sample mixture, and the washing 
peak. The washing peak is produced by the acetonitrile wash at the end of each analysis. 
 
PCR products were initially analyzed under non-denaturing conditions (50oC) to assess 
the quality of the PCR products. A single sharp peak was taken as indication for pure 
PCR products that could be used for subsequent polymorphism screening at partial 
denaturation temperatures.  The WAVE System utility software predicted the range of 
partial denaturation temperatures based on the DNA fragment sequence.  The sample 
was run at 2oC above and below the predicted temperature.  Given that heteroduplexes 
are less stable, they denatured earlier than the homoduplexes and will be eluted first.  
 
A minimum of 48 samples for each of three ethnic groups (Chinese, Malay and Indian) 
were screened by DHPLC.  In order to increase the chance of heteroduplex formation, 
eight individual samples were pooled together by mixing same amount of PCR products 
from each individual sample.  The mixture and all the individual samples were 
denatured at 95oC for 4 min, and then gradually re-annealed by decreasing the 
temperature to 25 蚓 over  a per i od of  45 mi n in a thermal cycler.  The pooled samples 
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were screened first and if a heteroduplex peak was detected in the DHPLC profile, the 
corresponding 8 individual samples were then screened to find the mutant samples.  
The DHPLC gradient and the range of partial denaturation temperature are displayed in 
Table 3-1.  
 
3.5. Sequencing 
Samples that generated abnormal DHPLC heteroduplex patterns were further 
sequenced using ABI3100 to confirm the presence of the altered sequence.  For this 
purpose, the genomic DNA from the samples with atypical DHPLC profiles were 
amplified using PCR and purified via Qiaquick gel extraction kit (Qiagen, Tokyo, 
Japan ) following agarose gel electrophoresis (if more than one band was observed by 
UV) or Qiaquick PCR purification kit (Qiagen, Tokyo, Japan). The purified PCR 
products were used as templates for sequencing with the ABI Prism BigDye 
Terminator cycle sequencing kit (Applied Biosystems, USA).  For cycle sequencing, 
each 20µl sequencing reaction comprises 20ng of template, 3.2 pmol of primer, 2µl of 
Terminator Ready Reaction mix and 3µl of 5x sequence buffer.  The reaction mixture 
was denatured at 94蚓 for  5 mi n and then 25 cycl es of  denatur i ng at  96蚓 f or 10 s, 
annealing at 50蚓 f or  5 s,  and ext ensi on at 60蚓 f or  4 mi n.   Af ter  25 cycl es,  the 
reaction was rapidly chilled to 4蚓.   The react ion pr oduct s we re pr eci pi tat ed by the 
ethanol/sodium acetate method.  Firstly, 20µl of a mixture of 3.0µl of 3M sodium 
acetate (pH 4.6), 14.5μl of deionized water and 62.5μl of non-denatured 95% ethanol 
was added to each sequencing sample.  After a minimum 15 min of incubation at 
room temperature, the products were the centrifuged for 20 min at 14,000 rpm.  After 
removing the supernatant, the pellet was washed in 250μl of 70% ethanol and then 
re-centrifuged for 10 min at 14,000 rpm.  The samples were finally air dried for 5 
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min.  After the clean-up step, 15µl of HiDi-formamide (ABI) was added to each 
sample and then samples were loaded into 96 well optical microplate and ran on the 
A BI PRISM ® 3100 Genetic A nalyzer. The sequencing data was analyzed using the 
ABI Genetic Analyzer Data Collection Software. 
 
In case the polymorphic sites were located at the extreme end of the fragment of 
interest,   each fragment was sequenced bi-directionally using forward and reverse 
primers in two separated reactions. 
 
3.6. Prediction of biological impact of polymorphisms 
Among the polymorphisms that were found in this study, two SNPs were located in 
the putative promoter region. However, it is unlikely that these two SNPs affect 
ACAT2 gene regulation, as the deletion of the fragment containing these two SNPs 
did not significantly change the promoter activity (Song et al., 2001). Thus, further 
functional predictions of these two polymorphisms using computational methods were 
not needed.  Hence, only these polymorphisms within encoding region were 
examined using these approaches as follows.   
 
I. Two substitution matrix scores, GRANTHAM (Grantham, 1974) and 
BLOSUM62 (Henikoff and Henikoff, 1992), were used to identify any amino 
acid changes and to assess their potential to be deleterious to the protein. 
Variations involving two amino acids are given the same weight irrespective 
of their positions in the protein.  As such, these substitution scores are merely 
based on physicochemical change but are not position-specific.  Amino acid 
changes with GRANTHAM scores of more than 100 are considered radical 
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changes and increasingly associated with disease (Balasubramanian et al., 
2005).  The BLOSUM62 matrix defines amino acid substitution as 
conservative and non-conservative changes.  Conservative changes are those 
having a positive or neutral value on the matrix, whereas non-conservative 
changes are those having a negative score. Non-conservative changes are more 
likely to be disease-causing mutations (Henikoff and Henikoff, 1992).  
 
II. Multiple sequence alignment was used to identify conserved amino acid 
positions. It is known that an amino acid substitution occurring at a conserved 
position is likely to affect the function of protein. Five mammalian ACAT2 
protein sequences from human (NP 003569), monkey (O 77759), mouse (NP 
666176), rat (NP 714950) and dog (XP 543637)  were aligned using 
CLUSTAL W version 1.82 software program.  All orthologs were at least 
65% identical to human ACAT2 protein sequence.  In addition, the 
sequences of six acyltransferase (ACAT1 NP 003092, ACAT2 NP 003569, 
DGAT1 NP_036211, DGAT2 NP_115953, Are1P NP_009978 and Are2p 
NP_014416) were compared to investigate whether these polymorphic loci are 
conserved in the family.  
 
III. Polymorphism Phenotyping (PolyPhen) (http://genetics.bwh.harvard.edu/pph/), 
a position-specific phylogenetic approach, was employed to evaluate the 
evolutionary conservation of these polymorphic sites.  PolyPhen is based on 
the analysis of profile scores and various structural parameters to discriminate 
between disease-causing mutation and neutral substitution.  An amino acid 
variant is predicted to affect function or structure of the protein if the 
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substitution is at a functional site, or is not compatible with the context of 
amino acid substitution at the position in the family of homologous proteins, 
or changes hydrophobicity and electrostatic charge, or affects solubility, or 
involves a proline residue in the α-helix, or affects protein-ligand interactions 
(Sunyaev et al., 2001).  The profile score, known as 
position-specific-independent count (PSIC), is a logarithmic ratio of the 
likelihood that a given amino acid occurring at a particular site, to the 
likelihood of this amino acid occurring at  any site.  A large PSIC difference 
indicates that the substitution is rarely or never observed in the protein family 
and probably affects protein functions (Sunyaev et al., 2001). A variant is 
predicted to be possibly damaging if PSIC is more than 1.5 (Ramensky et al., 
2002). 
 
3.7. Genotyping of ACAT2 gene Polymorphisms 
Three polymorphisms, 734C>T, 41A>G, and D/I, were genotyped.  The genotyping 
method for 734C>T was carried out as described previously (Katsuren et al., 2001).  
In brief, the presence of the point mutation (ATC to ACC) was verified by digesting 
the PCR amplicons generated with primers 5’-CAG ATC TTA CAC TCT GCC TGC 
CTC T-3’ and 5’-TGC ACC TGC TGG CTT CAT TCA GTC A-3’ with the BamHI 
restriction enzyme.  
     
The 41A>G genotype was determined using mutagenic primers and restriction 
enzyme via restriction fragment length polymorphism (RFLP).   A pair of primers 
was designed to introduce a BsrI restriction site (ACTGGN/) by changing a base from 
A to T: forward primer: 5’-GCC CGT CTG CGT CTG CAG AGG ACT G-3’ and 
reverse primer: 5’-AGG CCA CAG CTC TGA CAT AGC-3’.  The amplified 269-bp 
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PCR product was digested with BsrI enzyme followed by gel electrophoresis. The 
PCR amplicon of the rare G allele (GAA to GGA) is cleaved into 243-bp and 26-bp 
fragments. 
 
The D/I was first found and genotyped in this study.  The D/I polymorphism had an 
amplicon size difference of 48bp between the I allele with the 48bp insertion and the 
D allele without the insertion and as such, can be directly genotyped by visualization 
on a 2% agarose gel after PCR amplification with a pair of primers: 5’-GCT GGA 
AGT TCT GGA TCG CTA-3’ and 5’-TAA CCA AAG GGG GAA CCT GT-3’.  
 
3.8. Genotyping of three LPL gene polymorphisms 
The methods used in genotyping of IVS8+484T>G and IVS6+1595C>T 
polymorphisms have been previously described (Ahn et al., 1993).  The genotyping 
of c.1342C>G was carried out according to Kuivenhoven et al. (1997).  The 
corresponding primers and annealing temperatures for PCR are shown in Table 3-2.  
The PCR products were digested using appropriate restriction enzymes (Table 3-2). 
The digestion reactions were incubated at 37oC overnight.  After digesting the 
amplified fragments, the resultant products were analyzed using 2% agarose gel.  
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3.9. Estimation of plasma lipid levels 
This assay was done by the technician in our laboratory.  Venous blood was drawn 
from subjects after an overnight fast of at least 10 hours.  Plasma was separated from 
blood cells by centrifugation and stored at -20oC until lipid analysis.  
TC and TGs were analyzed by colorimetric enzymatic methods on a COBAS Mira 
autoanalyzer (Roche, Basel Switzerland) using the manufacturer’s reagent kits 
(cholesterol kit 2016630, TG kit 2016647, Roche Diagnostics, Mannheim, Germany).  
Cholesterol was determined using a commercial cholesterol oxidase method by a series 
of enzymatic reactions (Allain et al., 1974).  The principle of the reaction is as follows. 
CEs are hydrolyzed to free cholesterol by cholesterol esterase.  Free cholesterol is then 
oxidized by cholesterol oxidase producing hydrogen peroxide which forms a red 
chromophore when combined with 4-aminophenazone and phenol. The chromophore 
formed is measured at photometrically 520 nm at 37oC and is directly proportional to 
the cholesterol concentration of the sample.  
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TGs were measured using a colorimetric enzymatic assay kit. In this method 
(McGowan et al., 1983), the TGs are hydrolyzed by lipase to produce free glycerol.  
The liberated glycerol is then reacted with glycerol kinase followed by oxidization to 
dihydroxyacetone phosphate and hydrogen peroxide.  The free glycerol is determined 
by enzymatic, colorimetric reaction of peroxide and 4-aminophenazone to form a 
colored product, the concentration of which is directly proportional to the amount of 
TGs present in the sample. 
HDL-cholesterol quantification was performed by using the above-described 
cholesterol method after precipitation of non-HDL cholesterol (LDL and VLDL) with 
polyanions and magnesium chloride.  
 LDL-C was calculated by the Friedewald formula (Friedewald et al. 1972):  
LDL-C = TC- HDL-C – TG/2.2 (all measured in mmol/L) when TG<4.49mmol/L. 
When TG is over 4.49mmol/L, the estimation of LDL-C by this method is not 
accurate.  
ApoA1 and apoB were estimated by an immunoturbidometric assay on the same 
machine using the Tina quant apoA Unisys (no. 03032612122) and Tina quant apoB 
Unisys from Roche Diagnostics (Mannheim, Germany). 
Lipoprotein (a) [Lp(a)] was estimated by enzyme-linked immunosorbent assay 
(ELISA) using commercially available kits [TintElize Lp(a), cat. no. 610220, Biopool, 
Umeå, Sweden].  
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3.10. Statistical analysis 
Allele frequencies were estimated by the gene-counting method.  Before performing 
other data analysis, Pearson’s chi-square test was used to test HWE for each locus. 
Haplotypes were constructed using the Phase Standard analysis software version 2.0.2 
available at http://archimedes.well.ox.ac.uk/pise/.  Haplotype frequencies of each 
group were estimated by the Expectation-Maximization algorithm using the 
SNPAlyze software version 4.0 from Dynacom (Kanagawa, Japan).  Diplotypes 
were obtained by combining genotype information from different polymorphic sites.  
The Z-test was used to determine significant differences in allele frequencies between 
the cases and controls and between the different ethnic groups.  Odds ratios (OR) are 
presented with 95% confidence intervals (CI) when significant associations were 
observed.  LD between polymorphic sites was assessed by Δ (Hill and Robertson, 
1968).  The lipid profiles were significantly different between different ethnic groups 
and gender.  As such we further stratified the subjects by ethnicity and gender.  In 
order to accurately evaluate the influences of ACAT2 gene variants on plasma lipid 
profiles, CAD-subjects within each ethnicity were further stratified into 
normolipidemic (TC<6.15mM and TG<2.25mM) and dyslipidemic (TC>=6.15mM or 
TG>=2.25mM) group according to the NECP ATP III criteria (NCEP ATPIII, 2002).   
Allele, haplotype and diplotype frequencies between cases and controls as well as 
between normolipidemic and dyslipidemic subjects and between ethnic groups were 
compared.  
 
The association of plasma lipids with genotypes and diplotypes was investigated only 
in the CAD- subjects, as the lipid levels of the cases (CAD+) would have been 
affected by treatment with lipid-lowering drugs.  The lipids were presented as means 
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± SD unless otherwise stated. Due to the skewed distribution of TG and L p(a) in all 
populations, their values were transformed by natural logarithm prior to using 
parametric tests.  
 
Three different models were used in this association study: 1) dominant (wildtypes vs. 
heterozygotes and mutant homozygotes), 2) additive (wildtypes vs. heterozygotes vs. 
mutant homozygotes), and 3) recessive (wildtypes and heterozygote vs. mutant 
homozygotes).  Confounding factors such as age, smoking and body mass index 
(BMI) were included as covariates in the analysis of covariance (ANCOVA) model.  
The lipid levels between diplotypes were compared by carrying out post hoc multiple 
comparisons using Tukey’s honestly significant difference (HSD) test.   
 
Most analysis was carried out using the SPSS software version 11.  Statistical 
significance was defined by P value of 0.05 or less.  Bonferroni correction was used 
to adjust the p value according to the number of tests performed. 
 
3.11. Cell line, vector and reagents 
The AC-29 cell line, an ACAT-deficient Chinese hamster ovary cell mutant (Cadigan 
et al. 1988), was kindly provided by TY Chang’s lab (Department of Biochemistry, 
Dartmouth Medical School, US).  The vector pRS426GP and pCR3.1/ACAT2 
(Oelkers et al., 1998; Liang et al., 2004) were obtained from Dr Yang (Department of 
Biochemistry, National University of Singapore).  The pcDNA3.1/His expression 
vector containing Xpress epitope (Asp-Leu-Tyr-Asp-Asp-Asp-Lys) and the 
monoclonal antibody against Xpress were from Invitrogen (California, US).  Antipain, 
chymostatin, leupeptin, fetal bovine serum, and Nile red, were purchased from Sigma 
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(St. Louis, US).  Geneticin (G-418 sulfate), Ham’s F-12 and DMEM/F-12 medium, 
and anti-Xpress were from Invitrogen (California, US). [9,10(n)-3H]oleic acid and 
anti-mouse Ig were from Amersham Biosciences (Hilleroed, Denmark). 
 
3.12. Cell culture 
The AC-29 cells were grown as monolayers in Ham’s F-12 medium supplemented with 
10% fetal bovine serum, 2mM L-glutamine, 1% Eagle’s vitamins and 100 units/ml of 
Penicillin and 100 μg/ml of Streptomcyin in 5% CO2 incubator at 37oC.  
 
3.13. Expression of various ACAT2 proteins 
3.13.1. Construction of various ACAT2 gene expression plasmids  
The expression vector pcDNA3.1/His was digested using restriction enzymes, EcoRI 
and NotI, at 37oC overnight.  The digested product was then purified using the gel 
purification kit from Qiagen (Tokyo, Japan).  
 
The ACAT2 cDNA insert was excised from recombinant pRS426GP/ACAT2, which 
was constructed from vector pRS426GP and pCR3.1/ACAT2, using EcoRI and NotI 
restriction enzymes.  As the pcDNA3.1/His expression vector contained an ATG start 
codon, the ACAT2 gene’s start codon and the upstream sequence between the start 
codon and the EcoRI cutting site were deleted using site-directed mutagenesis 
(Stratagene, California, USA).  The mutagenic primers were designed using 
Stratagene’s recommended program at http://labtools.stratagene.com/QC.  The two 
complimentary oligonucleotides which contained the desired mutations were 
synthesized using pRS426GP/ACAT2 as the template and 5'-TTT GAA AAT TCA 
AGG AAT TCG AGC CAG GCG GGG C-3' and 5'-GCC CCG CCT GGC TCG AAT 
TCC TTG AAT TTT CAA A-3' as sense and anti-sense primers, respectively.  The 
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synthesis reaction was carried out in thermal cycler (T-GRADIENT, Biometra, 
Goettingen, Germany) with a denaturing step at 95oC for 30 s followed by 18 cycles of 
denaturing at 95oC for 30 s, annealing at 55oC for 1 minute and extension at 68oC for 
10 min.  After the mutant strand synthesis, the parental DNA template was digested 
by specific DpnI endonuclease at 37oC for 1 hour.  The selected mutation-containing 
synthesized DNA was then transformed into XL1-Blue super-competent cells 
(Stratagene, California, USA). The generated plasmids were purified using the 
miniprep kit (Qiagen, Tokyo, Japan) and the deletion of the ATG start codon and 
upstream sequence was confirmed by DNA sequencing.  The resultant ACAT2 insert 
was ligated with the expression vector pcDNA3.1/His between the EcoRI and NotI 
sites.  The generated construct pcDNA3.1/His/ACAT2 was confirmed using PCR 
amplification and DNA sequencing. 
 
 
In this study, two nsSNPs, Glu14Gly and Thr245Ile, were explored for their effects on 
the ACAT2 enzyme activity as well as on gene and protein expression.  For this 
purpose, the wildtype and three mutant ACAT2s, consisting of two variants carrying 
one mutant, Gly14 or Ile245, and one variant carrying both mutants, Gly14Ile245, 
were constructed.  The recombinant pcDNA3.1/His/ACAT2, which contained the wild 
type ACAT2, designated as wild type pcDNA3.1/His/ACAT2 (WT), was used as the 
template to generate various mutant ACAT2s using Stratagene’s QuickChange 
site-directed mutagenesis kit. The construction procedure is briefly described here: 1) 
The ACAT2 Gly14 was generated using the wild type pcDNA3.1/His/ACAT2 and 
oligonucleotides 5'-GCA GAG GAC AGG AGG GCT GGG AGG-3' and 5'-CCT CCC 
AGC CCT CCT GTC CTC TGC-3' as sense and anti-sense primers, respectively.  
The resultant ACAT2 was designated ACAT2 Gly14.  2) The ACAT2 Ile254 was 
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produced using the wild type pcDNA3.1/His/ACAT2 as the template and 
oligonucleotides 5’-GCT GTG CCT GGG ATC CTT CGT GCC AGA C-3’ and 
5’-GTC TGG CAC GAA GGA TCC CAG GCA CAG C-3’ as sense and anti-sense 
primers, respectively.  The resultant ACAT2 was designated as ACAT2 Ile254.  3) 
The recombinant pcDNA3.1HisACAT2 with mutant amino acid residues at position 14 
and 254 was produced using pcDNA3.1/His/ACAT2 Gly14Thr254 as the template and 
5’-GCT GTG CCT GGG ATC CTT CGT GCC AGA C-3’ and 5’-GTC TGG CAC 
GAA GGA TCC CAG GCA CAG C-3’ as sense and anti-sense primers, respectively.  
The resultant was designated as pcDNA3.1/His//ACAT2 Gly14Ile254.  The sequences 




3.13.2. Transfection of AC-29 with various pcDNA3.1/His/ACAT2 
The AC-29 cells were transfected with various pcDNA3.1/His/ACAT2 using the 
calcium phosphate transfection kit (Invitrogen, California, US).  The unmodified 
pcDNA3.1/His vector was also used to transfect the AC-29 cells to serve as a negative 
control.  The procedure used is briefly described below.  The day before 
transfection, the AC-29 cells were plated at the density of 1.5x106 cells in 10ml of 
Ham’s F-12 medium in a 100mm-diameter Petri dish.  This would produce cells that 
would be 50-60% confluent on the day of transfection.  On the day of transfection, 
the medium was changed 3-4 hours prior to transfection and the cells were further 
incubated at 37oC.  Twenty 痢 of  DNA  wa s mi xed with 36痞 of  2M Ca Cl 2 in a final 
volume of 300痞, and the mi xt ur e wa s added sl owl y to 300痞 of  2x HBS  ( HEP ES 
Buffered Saline) in 1-2 min and incubated at room temperature for 30 min in order to 
form a fine DNA CaPO4 coprecipitate.  The precipitate was added dropwise to the 
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medium containing the AC-29 cells, which were then incubated in the 37oC CO2 
incubator overnight.  The medium was then removed and the cells were washed 
twice with 1xPBS.  Three ml of 10% DMSO in 1xPBS was added into the Petri dish 
and incubated at room temperature for exactly 2.5 min.  After the DMSO shock 
treatment, fresh medium was added and the cultures were incubated at 37oC in the 5% 
CO2 incubator for another 48 hours.  
 
3.13.3. Selection of stable transformants 
After the cells were maintained in non-selective media for 2 days post-transfection, 
they were scraped off using a scraper and transferred to be grown in selective medium 
containing 500痢/ ml  of  G -418 for 2 weeks.  Discreet G-418 resistant colonies were 
seen after 2 weeks.  Single colonies were picked up and transferred into a 6-well 
plate for subsequent propagation.  
 
 
3.13.3. Selection of positive stable transformants 
After the G-418 resistant cells were grown for 2 weeks, they were examined for their 
cytoplasmic CEs under an inverted phase-contrast microscope (ULWCD 0.30, 
Olympus, Tokyo, Japan).  The cytoplasmic lipid droplets were further examined 
using a differential interference contrast microscope (BX60; Olympus, Tokyo, Japan) 
after staining with 100 痢/ ml  Ni le red .  Nile red is a highly fluorescent compound 
which preferentially partitions into hydrophobic environments such as intracellular 
neutral (Greenspan and Fowler, 1985a and 1985b) lipid droplets. In positive 
transformants containing pcDNA3.1/His/ACAT2, the CEs would be synthesized 
leading to a large accumulation of intracellular CEs.  In contrast, in the negative cells, 
in which the G-418 resistant gene might be expressed but the target ACAT2 gene was 
not expressed, no obvious Nile red-staining lipid drops were observed. 
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The procedure of Nile red staining was described as below.  The monolayers were 
washed twice with 1xPBS and incubated with 1ml non-enzymatic dissociation 
solution (Sigma, St. Louis, US) per well at 37oC for 10 min. The cells were then 
transferred into a sterile tube and then stained using Nile red (100-150ng/ml).  After 
Nile red staining, cytoplasmic CE lipid droplet content was examined using 
differential interference contrast microscope.  Only colonies containing abundant 
cytoplasmic lipid droplets were re-cultured in 6-well plate containing selective 
medium. 
 
3.14. Ex vivo ACAT activity assay 
This activity assay was described by Chang et al. previously (1986).  The cells were 
plated in 25cm2 flask and grown to 80% confluence. Two hours before pulse, medium 
was changed and the cells were incubated in a 37oC water bath capping the flask 
tightly. The cells were pulsed with 3H-oleate BSA and the flask was incubated in 37oC 
water for 30 min.  The medium was then removed and the cells were rinsed five times, 
each with 5 ml of cold 1xPBS.  The cells were lyzed using 0.2 M NaOH at room 
temperature 40 min and then neutralized by adding 3M HCL and KH2PO4.   The 
cellular lipids were extracted with chloroform-methanol (2:1) after adding cholesteryl 
oleate as carrier and [14C] cholesterol as internal standard.  The various lipids were 
then separated using thin layer chromatography and the different lipid bands identified 
using iodine vapor.   The bands of cholesterol ester and cholesterol were excised from 
the sheet and dissolved in scintillation cocktail.  The ACAT enzyme activity was 
determined by calculating the incorporation of labeled oleate into CEs and normalized 
with the concentration of the internal standard, [14C] cholesterol, and total proteins.  
The enzymatic activities were expressed as means ± standard deviations (SDs) of 
triplicate assays over at least three separate experiments. 
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3.15. Quantitative reverse transcription (RT) PCR 
Total RNA was prepared using Trizol ® (Invitrogen, California, US) following the 
manufacturer’s instructions.  Cells were grown in a 25cm2-flask to 70-80% 
confluence and then lyzed with the addition of  2.5ml of Trizol and incubation for 5 
min at room temperature. The cell lysates were put into 10ml tubes and 0.5ml of 
chloroform was added.  The tubes were capped tightly and shaken vigorously by 
hand for 15s and incubated at room temperature for 3 min.  The tubes were then 
centrifuged at 12,000 x g for 15 min at 4oC, and the supernatant was transferred to 
fresh tubes containing 1.25ml of isopropyl alcohol and incubated at room temperature 
for 10 min.  The mixture was centrifuged at 12000 x g for 10 min at 4oC to get the 
RNA pellet.  This RNA pellet was washed again with 3 ml of 75% ethanol, vortexed 
and centrifuged for 5 min at 7500 x g at 4oC.  The pellet was briefly dried and 50痞 
of RNase-free water was added for re-constitution. 
The total RNA extracted from cells grown to 70-80% confluence was used as template 
to run real-time RT-PCR to determine whether the expression of wild type and various 
mutant ACAT2 mRNA were different.  Before doing quantitative the real-time 
RT-PCR, RT-PCR was carried out first using the OneStep RT-PCR kit (Qiagen, Tokyo, 
Japan) to confirm the expression of ACAT2 mRNA in the AC-29 cells.  The 
oligonucleotides, 5’-CCC AGT TTC TCC AGC TAC CT-3’and 5’-AAG ACA GGA 
ACA CAG AGG CG-3’, were used as ACAT2 gene-specific primers in the OneStep 
RT-PCR and the follow-up real-time RT-PCR amplification.   
The real-time RT-PCR amplification was performed to determine the mRNA 
expression of the various ACAT2s using LightCycle RNA Master SYBR Green I 
(Roche Diagnostics, Mannheim, Germany).  Each of 20痞 react ion cont ai ned 3. 25mM 
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Mn(OAc2), 6痞 SYB R Gr een I, 0. 3然 e ach pri mer ,  and 450ng RNA t empl ate.  The  
real-time RT-PCR was started with an initial reverse transcription at 61oC for 20 min, 
followed by a denaturation step of  95oC for 30 s and 40 cycles of amplification (95oC 
for 1s, 57oC for 4s followed by 72oC 13s).  After completion of the amplification 
samples were subjected to a melting curve analysis to test the product specificity.  The 
reaction was carried out in LightCycler capillary tubes.  The LightCycler apparatus 
measured the fluorescence of each sample in every cycle at the end of the annealing 
step.  The Second Derivative Maximum Method was used for the determination of the 
crossing point (Cp) automatically for the individual samples.  A housekeeping gene, 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was included as a reference 
gene.  A pair of primers, 5’-TTC TGG CAA AGT GGA AGT TGT TG-3’ and 5’- 
ATG GTG ATG GCC TTC CCG TT-3’, was used to amplify GAPDH gene.  The 
relative quantification, of the wild type and various mutants, was normalized by 
GAPDH gene.  To ensure that the correct product was amplified in the quantification 
reaction, all samples were visualized on 2% agarose gel electrophoresis.  The 
quantitative reverse transcription was done in triplicate over three experiments.  The 
t-test was employed to test the statistical significance of fold changes in gene 
expression of mutant ACAT2 relative to wildtype. 
3.16. Western blot 
When cells reached 70%-80% confluence in the 75cm2 flask, they were lyzed with 
0.5-1ml of a cocktail consisting of 1x Phosphate Buffered Saline (PBS) containing 
2% SDS and proteinase, and then centrifuged at 14,000rpm at 4oC for 20 min.  The 
supernatant was kept as the total soluble protein.  Protein concentration was 
determined using the method by Bradford (1976). The total soluble protein (15ug) 
was incubated with 5x loading buffer at 37oC for 15 min and subjected to 
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SDS-polyacrylamide gel electropherosis (SDS-PAGE)  using a 12% Tris-glycine gel.  
The separated proteins were electrotransferred to a nitrocellulose membrane. The 
membrane was incubated in 15ml of 5% non-fat milk at 4oC overnight. After blocking, 
the blot was incubated with primary antibody, Anti-Xpress (Invitrogen, California, 
US), at 1:5000 dilutions in Tris Buffered Saline (TBS) at room temperature for 1 hour.  
After washing with TBST (TBS with 0.5% Tween-20) three times and TBS once, the 
blot was then subjected to blotting with  as secondary antibody, anti-mouse Ig, at 
1:10,000 dilutions in TBS, with 2.5% non-fat milk, at room temperature for 1 hour.  
After the second round of washing, the membrane was subjected to the enhanced 
chemiluminescent detection kit (ECL, Amersham Biosciences).  Densitometric 
analysis of western blot signals was conducted to compare the different expression 





4. STUDY OF ACAT2 GENE 
 
4.1. Introduction 
In this study, the putative promoter, 5’-UTR, encoding regions, and intron-exon 
boundaries of ACAT2 gene were screened for genetic polymorphisms with DHPLC. 
After identifying polymorphisms in this gene, the possible biological significances of 
three nsSNPs, 41A>G (Gly>Glu) in exon1, 734C>T (Thr>Ile) in exon7, and 
c.1291G>T (Ala to Ser) or G>A (Ala to Thr) in exon 13, were predicted using 
computational approaches.  The association of three polymorphisms, 41A>G, 
734C>T, and one 48bp insertion (D/I), with CAD and dyslipidemia was examined in 
the three ethnic groups (Chinese, Malay and Indian) in Singapore.  The nsSNP, 
c.1291G>T or G>A, is very rare and only one heterozygote was found among 348 
samples.  It was therefore not included in the association study.  The effects of two 
nsSNPs, 41A>G and 734C>T, on ACAT2 function were further investigated by in 
vitro functional study  using the AC-29 cell line, a mutant Chinese hamster ovary 
(CHO) cell line deficient in ACAT activity (Cadigan et al., 1988).   
 
4.2. Results 
4.2.1. Polymorphism screening 
4.2.1.1. Survey of known genetic variants in ACAT2 gene 
Before screening for novel ACAT2 gene polymorphisms, known SNPs were first 
identified using public SNP resources.  By searching these public SNP databases, 
such as NCBI SNPdatabase, TSC, JSNP, and HGVbase, a total of 10 SNPs were 
identified among these regions of interest (Table 4-1).  
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4.2.1.2. Polymorphism screening  
After the systematic screening of these regions of interest in ACAT2 gene with 
DHPLC using cord blood DNA samples from 336 neonates, distinct elution profiles 
were detected for some DNA fragments of interest (shown in Figure 4-1).  The 
corresponding samples were amplified by PCR and sequenced to verify these variants. 
The sequencing results are shown in Figure 4-2.  A total of 14 polymorphisms were 
detected, 9 of them were novel and are indicated by their corresponding SubSNP (ss) 
numbers in the NCBI SNPdatabase (Table 4-1).  These included three missense 
mutations [c.41A>G (Gly>Glu) in exon1, c.734C>T (Thr>Ile) in exon7, and 
c.1291G>T ss5607249 (Ala to Ser) or G>A (Ala to Thr) ss6313900 in exon13], two 
single-base changes in the putative promoter region (-331C>T ss9807253 and 
-440G>T ss9807252), two silent mutations (c.609G>T ss4480613 and  c. 610C>T 
ss4480614 in exon6), seven single-base changes in intronic regions, comprising six 
single-base substitutions (IVS1-8C>G; IVS4+172T/G ss4329267, IVS5-137A/T 
ss4329269, IVS9-178G/C ss5606370, IVS9+37A>T and IVS9+51G>T), and one 





The DHPLC profile for most polymorphisms showed two different, homozygous and 
heterozygous, patterns (Figure 4-1), while the D/I polymorphism presented three 
distinct profiles: wild type homozygotes (DD), heterozygotes (DI), and mutant 
homozygotes (II) (Figure 4-3).  The wildtype and mutant homozygotes of D/I 
polymorphism each gave one sharp peak in their profiles, except that the retention 
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time of the wildtype was longer than that of the mutant homozygotes.  The 
heterozygotes of D/I however showed an elution profiles quite different from those of 
the two homozygotes.  
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Table 4-1. ACAT2 gene polymorphisms found in the regions of interest in this study 
 
 
a and b: Variations reported by Katsuren et al. (2001) and Haga et al. (2002), respectively.  




Polymorphisms Position Type 
RefSNP 
(rs#) 
Found in this 
study  
Novel variant 
41A>Ga exon Glu>Gly 9658625 yes  








3219200 yes novel 
c. 1291G>T or A exon 
Ala>Ser (or 
Thr) 
4244355 yes novel 
-331C>T promoter SNP 2280698 yes novel 
-440G>T promoter SNP 6413499 yes novel 
IVS1-8C>G intron SNP 17551115 yes  
IVS9+37A>Tb intron SNP 2280696 yes  
IVS9+51G>Tb intron SNP 711315 yes  
IVS4+172T/G  intron SNP 3093945 yes novel 
IVS5-137A/T intron SNP 3093947 yes novel 
IVS9-178G/C intron SNP 4151119 yes novel 
IVS4-57_58INS48bp  intron insertion 3093946 yes novel 
-74A>G 5’-UTR SNP 2280698 no  
-1297G>A promoter SNP 6413499 no  
-1283G>A promoter SNP 1053167 no  
-1327A>C promoter SNP 1053153 no  
-1382A>C promoter SNP 1053149 no  
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41A>G 609 G>T and 610C>T 734C>T c. 1291G>T 
                        
         
1291G>A IVS5-137A>T IVS4+172T>G IVS9+178G>C 
   
    
IVS9+37A>T IVS9+51G>T -331C>T -440G>T 
 
   
 
   
IVS1-8G>C    
Figure 4-1. DHPLC profiles of ACAT2 polymorphisms.  For each polymorphism, 











   
   
   























    
   
Figure 4-2. DNA sequencing results of ACAT2 polymorphisms detected in this study.  
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Figure 4-3. DHPLC profile of ACAT2 D/I polymorphism.  The upper one that gives 
one sharp peak and emerges earlier is wildtype homozygote and the lowest one 
emerging later is mutant homozygote and the middle one giving three peaks is 








Figure 4-4. Sequencing result of ACAT2 D/I.  A: wild type DD; B: mutant 
homozygotes II; Arrow in A indicates the site where the 48bp inserts. 
C B 5 4 0 9
C B 5 4 0 8
C B 5 4 1 0
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4.2.1.3. Improved efficiency of mutation screening using modified primers  
 
Two polymorphisms, IVS9+37A>T and IVS9+51G>T, in the flanking region of exon 
9, were reported in the NCBIs dbSNP.  However, in the study, none of them  was 
detected when normal primers were used to amplify the fragment of interest, as the 
corresponding DHPLC profile generated a broad unresolved peak (Figure 4-5 A).  
The melting profiles of the fragment predicted using WAVEMAKER software is 
shown in Figure 4-6 A.  The two polymorphisms are located in the high melting 
domain, which is predicted to partially denature at 62oC.  The temperature range 
from 60oC to 63oC was chosen to detect the sequence variants.  However, the peaks 
became broad and the variants were poorly discernible when running at 62oC (Figure 
4-5A).  As a result, the polymorphism IVS9+37A>T was not detected when running 
at predicted temperatures.  
 
In order to change the melting property of the DNA fragment and to improve the 
resolution of hetero- and homoduplex peaks in the elution profile, a modified primer 
with a 20bp GC-clamp was used. After the modification, the IVS9+37A>T was able 
to be detected and the resolution of IVS9+51G>T was significantly improved (Figure 
4-6B.  Therefore, it was proved that application of GC-clamp modified primers can 
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Figure 4-5. DHPLC profiles of IVS9+51G>T (lowest) and IVS9+37A>T (middle) 





Figure 4-6. Predicted melting profile of the fragment containing exon 9.  The upper 
panel shows the fragment amplified with the non-GC-clamp primers and the lower 
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4.2.1.4. Factors affecting DHPLC elution profiles 
 
The DHPLC profiles of some fragments of interest showed artefact peaks or shoulders 
in front of the elution peak.  In order to find out the possible reasons causing the 
artefact peak or shoulder, two factors were examined: the methods of extracting DNA 
(Parzer’s method or phenol: chloroform method), and the amount of template used. 
The salts used for DNA extraction in Parzer’ method may not be removed completely 
and thus it may affect the DNA quality and PCR amplification reaction.  However, 
the results showed that the artefact peaks or shoulders could be decreased by using 
less amount of template for PCR amplification (Figure 4-7), while DNA extraction 
methods had no significant effect on the DHPLC profile.  
 













Figure 4-7. DHPLC profile of the fragment containing ACAT2 gene exon 8.  The 
upper profile is the elution profile of the amplicon using 0.6μl template (about 100ng) 
in 20μl reaction and the lower profile for the amplicon using 0.3μl template (about 






4.2.1.5. Prediction of functional implications of ACAT polymorphisms 
Among the 14 identified polymorphisms, only three polymorphisms, 41A>G 
(Glu14Gly) in exon1, 734C>T (Thr254Ile) in exon7, and c.1291G>T (Ala431Ser) or 
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G>A (Ala431Thr) in exon13, are nsSNPs.  The possible biological significances of 
the three nsSNPs were predicted with different approaches. 
 
When evaluating whether there is any difference in the physiochemical properties 
between wildtype and mutant amino acids, two substitution scoring matrices, 
GRANTHAM and BLOSUM62, were applied. The results showed that the 
GRANTHAM D values obtained for Glu14Gly, Thr254Ile, and Ala431Ser (or Thr), 
were 98, 89, and 99 (58), respectively. Variations with values >100 were more likely 
to affect disease susceptibility. However, the distinction between disease-causing 
mutations and neutral mutations is not clear.  The BLOSUM62 scores of these 
substitutions were -2, -1, and 1 (-1), respectively.  The amino acid change with a 
value less than -1 was probably a disease-causing mutation. Taken together, these 
evaluations suggested that the Glu14Gly may have greater biological significance 
than Thr254Ile and Ala431Ser (or Thr). 
 
Other than the influence on the physiochemical properties, the evolutionary 
conservation was also examined by using an interspecies alignment. The protein 
sequences of the ACAT2 protein from human, monkey, mouse, rat, and dog, were 
compared.  The comparison indicated that the Gly14 and Ala431 are identical in the 
five species while the Thr254 was not conserved (Figure 4-8).  The Thr254 was 
present in human, monkey and dog while the Ile254 occurred in mouse and rat.  It 
suggested that the Thr254 was less likely to affect protein function while the other 
two amino acid residues were evolutionarily conserved, at least in the five species, 
and thus, probably had some biological significance.  
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                           Glu14Gly 
Human        -MEPGGARLRLQRTEGLGGERERQPCG-DGNTETHRAPDLVQWTRHMEAVKAQLLEQAQG 58 
Monkey       -MEPGGARLRLQRTEGPGGEREHQPCR-DGNTETHRAPDLVKWTRHMEAVKAQLLEQAQG 58 
Mouse        EMQPKVPQLR--RREGLGEEQEKGARGGEGNARTHGTPDLVQWTRHMEAVKTQFLEQAQR 58 
Rat          -MEPKAPQLR--RRERQGEEQENGACG-EGNTRTHRAPDLVQWTRHMEAVKTQCLEQAQR 56 
Dog          -MEPKATRLR--RGEGPRGEQEDRPSG-EGEPPSGGA----ESWEVLEVVKTQLLEHAQG 52 
              *:*  .:**  * *    *:*  .   :*:. :  :    :  . :*.**:* **:***  
 
                                 Thr254Ile 
 
Human       EQVRFLMKSYSFLREAVPGTLRARRGEGIQAPSFSSYLYFLFCPTLIYRETYPRTPYVRW 294 
Monkey      EQVRFLMKSYSFLREAVPGTLRARRGEGIQAPSFSSYLYFLFCPTLIYRETYPRTPYIRW 298 
Mouse       EQVRLLMKSYSFLRETVPGIFCVRGGKGISPPSFSSYLYFLFCPTLIYRETYPRTPSIRW 298 
Rat         EQVRFLMKSYSFLRETVPGIFCVRGGKGICTPSFSSYLYFLFCPTLIYRETYPRTPSIRW 296 
Dog         EQVRLLMKSYSFLREALPGTLCARVGEGMQAPSFSSYLYFLFCPTLIYRKTYPRTPNVRW 292 
            ****:**********::** : .* *:*: .******************:****** :** 
            
 
                              Ala431Ser 
 
Human       GARARGVAMLGVFLVSAVAHEYIFCFVLGFFYPVMLILFLVIGGMLNFMMHDQRTGPAWN 474 
Monkey      GAQARGVAMLGVFLVSAVAHEYIFCFVLGFFYPVMLILFLVIGGMLNFMMHDQHTGPAWN 478 
Mouse       GRRARGVAMLGVFLVSAVVHEYIFCFVLGFFYPVMLMLFLVFGGLLNFTMNDRHTGPAWN 478 
Rat         GRQGRGAAMLGVFLVSALVHEYIFCFVLGFFYPVMLILFLVVGGLLNFTMNDRHTGPAWN 476 
Dog         GGRARGAAMLAVFLVSAVVHEYIFCFVLGFFYPVMLILFLVIGGLMNFMMHDRHTGPAWN 472 
            * :.**.***.******:.*****************:****.**::** *:*::****** 
 
Figure 4-8. Multiple alignments of ACAT2 protein orthologs from Homo sapiens 
(NP_003569), Africa green monkey (O77759), Mus musculus (NP_666176 ), Rattus 
norvegicus (NP_714950), and Canis familiaris (XP 543637) using CLUSTAL W 
ver.1.82. Highlights are nsSNPs found in current study. “*”: identical residues; “:”: 
conserved residues; “.”: semi-conserved. 
 
 
In addition, multiple sequence alignments were conducted in the acyltransferase 
family and 6 family members (ACAT1, ACAT2, Are1p, Are2p, DGAT1, and DGAT2) 
were chosen. This comparison showed that only the 14th residue is semi-conserved 
and the other two amino acid residues (254th and 431th) are not. The 254th residue is 
most variable, and four different amino acids occurred among these members with 
isoleucine occurring in DGAT1. The 431A>S or T is less variable, with alanine to be 
found in ACAT, DGAT, and Are1p and serine in Are2p.  At the 14th amino acid 
residue, glutamic acid was found in ACAT2 and DGAT2, glutamine in Are2p and 
arginine in ACAT1, Are1p and DGAT1. Although glutamic acid is not completely 
conserved at the 14th residue, no glycine was found at this site in the homologous 
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family.  Therefore, it is likely that the substitution of glutamine to glycine affects 
ACAT2 function or structure. 
 
Whether these nsSNPs affect protein structure and function was also predicted by 
PolyPhen.  Analysis of the Glu14Gly variant with PolyPhen yielded a PSIC of 1.575, 
suggesting that it is possibly damaging while the other two variants were predicted to 
be neutral changes.  
                             Glu14Gly 
ACAT2:     M---EPGGARLRLQRTEGLGGERERQ---------------------PCGDG-NTETHRA 
ACAT1:     MVGEEKMSLRNRLSKSRENPEEDEDQRN-------------------PAKESLETPSNGR 
Are1p:     MTETKDLLQDEEFLKIRRLNSAEANKRHSVTYDNVIL----------PQESMEVSPRSST 
Are2p:     MDKKKDLLENEQFLRIQKLNAADAGKRQSITVDDEGELYGLDTSGNSPANEHTATTITQN      
DGAT1      M-------GDRGSSRRRRTGSRPSSHGG----------------GGPAAAEEEVRDAAAG 
DGAT2      M--KTLIAAYSGVLRGERQAEADRSQRSH---------------GGPALSREGSGRWGTG 
           *             : .        :                     .             
 
                               Thr245Ile 
 
ACAT2:     MKSYSF---------LREAVPGTLRA--RRGEGIQAP----------------------- 
ACAT1:     MKAHSF---------VRENVPRVLNSAKEKSSTVPIP----------------------- 
Are1p:     MKSHSFAFYNGYLWDIKQELEYSSKQLQKYKESLS-PETREILQKSCDFCLFELNYQT-- 
Are2p:     MKMHSFAFYNGYLWGIKEELQFSKSALAKYKDSINDPKVIGALEKSCEFCSFELSSQSLS 
DGAT1      LKLFSYRDVNSWCRRARAK----AASAGKKASSAAAP----------------------- 
DGAT2      MGLGAFCNFSTEATEVSKKFPGIRPYLATLAGNFRMP----------------------- 
           :   ::                              *                        
 
                                           Ala431Ser 
 
ACAT2:     DWLYSYVYQDGLRLLGARARGVAMLGVFLVSAVAHEYIFCFVLGFF--YPVMLILFLVIG 
ACAT1:     DWLYYYAYKDFLWFFSKRFKSAAMLAVFAVSAVVHEYALAVCLSFF--YPVLFVLFMFFG 
Are1p:     KFLLRHVYHSSMGALHLS-KSQATLFTFFLSAVFHEMAMFAIFRRVRGYLFMFQLSQFVW 
Are2p:     KFLLRHVYHSSMSSFKLN-KSQATLMTFFLSSVVHELAMYVIFKKLRFYLFFFQMLQMPL 
DGAT1      KWCIRHFYKPMLR--RGSSKWMARTGVFLASAFFHEYLVSVPLRMFRLWAFTGMMAQIPL 
DGAT2      SKPITTVVGEPITIPKLEHPTQQDIDLY------HTMYMEALVKLFDKHKTKFGLPETEV 
         .          :               :      *   .   .  .        :      
 
Figure 4-9.  Multiple alignments of acyltransferase family members: ACAT1 
(NP_003092), ACAT2 (NP_003569), Are1P (NP_009978), Are2p (NP_014416), 
DGAT1 (NP_036211), and DGAT2 (NP_115953).. Highlights are nsSNPs found in 
current study. “*”: identical residues; “:”: conserved residues; “.”: semi-conserved. 
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4.2.2. Association studies of ACAT2 gene  
4.2.2.1. Genotyping of three polymorphisms 
The individual genotype for three polymorphisms, 41A>G, 734C>T, and D/I, were determined based 

















Figure 4-10. Genotyping results of three ACAT2 gene polymorphisms. A: 41A>G; B: 
734C>T; C: D/I 
 
 
4.2.2.2. Population Demographics  
           The characteristics of the study population are summarized in Table 4-2.  Healthy 
controls were selected from workers who underwent pre-employment medical 
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groups (P<0.0005). The controls had significant lower BMI than the CAD+ subjects 
in Chinese males (P<0.001) and females (P<0.0005) as well as Malay females 
(P<0.001) but not in the Indians.  However, this significance did not exist after 
adjusting for age. Cigarette smoking was more prevalent among males than females in 
three ethnic groups.  The percentage of smokers was significantly higher in the 
CAD+ than the CAD- in the Chinese and male Indians but not in the Malays.  Three 
parameters, age, BMI, and smoking, are known to influence CAD susceptibility and 
plasma lipid profiles, so all of them were included as confounders in the association 
tests. Significantly higher levels of HDL-C, apoA1 and lower levels of Lp(a) were 
seen in the CAD+ subjects as compared to the CAD- subjects.  Smoking is known to 
decrease HDL-C level, thus, its effect was adjusted when the HDL-C level was 
compared between the CAD+ and CAD- subjects. Lower levels of TC, LDL-C, TG 
and apoB were observed in male CAD+ in all ethnicities compared with the male 
CAD- subjects (P<0.05 or less).  The same trend was also seen in the females. These 
observations are most likely due to the effects of lipid-lowering drugs and adoption of 
healthy lifestyle in the CAD+ subjects.  In view of such confounding effects on the 
lipid levels, the CAD+ patients were not included when carrying out ANOVA to see 
whether the genotypes and diplotypes were associated with lipid levels.   
 
.
Table 4-2. Demographics of the Singaporean subjects.  A ge, BM I and plasma lipid profiles are presented in mean ± SD. 
 
Males 
  Chinese   Malays   Indians  
Variables CAD- CAD+ P CAD- CAD+ P CAD- CAD+ P 
 n = 389 n = 402  n = 188 n = 106  n =215 n = 119  
Age (years) 39±14 59±9 <0.0005 39±9 57±10 <0.0005 43±14 59±11 <0.0005 
BMI (kg/m2) 23.41±3.62 24.30±3.59 0.306 25.32±4.15 25.63±3.35 0.265 24.43±3.89 24.75±3.48 0.898 
Smokers* (%) 30.23 59.95 <0.0005 60.96 57.58 0.619 19.16 52.68 <0.0005 
TC (mM) 5.69±1.32 4.53±1.11 <0.0005 5.89±1.25 4.63±1.10 <0.0005 5.86±1.18 4.41±1.16 <0.0005 
HDL-C (mM) 1.26±0.33 0.96±0.27 <0.0005** 1.16±0.26 0.89±0.26 <0.0005** 1.02±0.27 0.91±0.23 <0.001** 
LDL-C (mM) 3.92±1.34 2.92±0.85 0.016 4.26±1.22 3.56±0.85 0.003 4.26±1.20 3.51±1.16 <0.0005 
TG (mM) 2.03±1.98 1.79±1.00 0.035 2.16±1.42 1.92±0.94 0.582 2.24±1.58 1.63±0.76 <0.0005 
ApoA1 (mg/dl) 140.64±24.01 117.49±20.81 <0.0005 128.43±17.70 114.25±19.82 <0.0005 132.08±23.83 112.33±22.27 <0.0005 
ApoB (mg/dl) 108.65±30.68 101.57±29.53 <0.001 122.85±28.75 102.29±28.20 <0.0005 129.70±32.17 101.05±29.16 <0.0005 
Lp(a) (mg/dl) 12.95±15.90 21.73±20.77 <0.0005 11.82±11.18 22.37±18.14 <0.0005 18.30±19.17 29.39±25.04 <0.0005 
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Table 4-2(Continued) Demographics of the Singaporean subjects. A ge, BM I and plasma lipid profiles are presented in mean ± SD  
Females 
 Chinese Malays Indians 
Variables CAD- CAD+ P CAD- CAD+ P CAD- CAD+ P 
  n = 313 n = 124  n =42 n = 31  n =157 n = 27  
Age (years) 35±12 62±9 <0.0005 29±12 61±7.78 0.0005 38±13 61±8 <0.0005 
BMI (kg/m2) 22.14±3.82 23.91±3.34 0.447 23.27±6.08 28.03±3.95 0.260 24.73±4.77 25.22±4.90 0.261 
Smokers* (%) 3.19 16.81 <0.0005 4.76 10.34 0.327 1.91 7.69 0.148 
TC (mM) 5.54±1.20 4.61±1.24 <0.0005 5.09±1.04 4.68±1.20 0.121 5.26±1.08 4.04±1.11 <0.0005 
HDL-C (mM) 1.55±0.41 1.04±0.32 <0.0005** 1.39±0.33 0.99±0.31 <0.0005** 1.27±0.34 0.96±0.29 <0.0005**
LDL-C (mM) 3.61±1.20 3.57±0.99 0.543 3.35±0.97 3.64±0.91 0.552 3.60±1.10 2.99±0.64 0.082 
TG (mM) 1.36±0.79 1.75±0.80 <0.0005 1.04±0.64 1.82±1.02 <0.0005 1.46±1.11 1.68±0.73 0.314 
ApoA1 (mg/dl) 151.97±23.93 126.73±24.56 <0.0005 146.38±18.11 119.13±22.51 <0.0005 140.08±26.36 122.78±21.90 0.002 
ApoB (mg/dl) 92.43±26.66 98.71±28.65 0.031 97.12±20.56 98.42±26.25 0.811 108.89±27.45 90.67±25.02 0.002 
Lp(a) (mg/dl) 17.76±21.60 25.23±24.35 0.004 13.26±11.20 21.44±17.44 0.031 22.16±20.12 27.68±30.83 0.250 
 
*: Smokers and ex-smokers form one category while non smokers constitute another. **: Adjusted by smoking. 
4.2.2.3. Genotype and allele frequencies  
The genotype distributions for the three polymorphisms are shown in Table 4-3 and 
4-4.  All genotype frequencies did not deviate from the expected Hardy-Weinberg 
proportions. In terms of the association of the genotypes with CAD and dyslipidemia 
susceptibility, two genetic models, dominant and recessive, were used.  In the case 
of dominant model, no association was detected in the three ethnic groups.  Under 
the assumption of recessive model, the 734C>T and the 41A>G were found to be 
associated with CAD risk in the Chinese, with heterozygotes and mutant homozygotes 
being more prevalent in the CAD+ subjects, (P=0.0051, and P=0.0104, respectively) 
and the D/I in Indians (P=0.015). However, only the association of the 734C>T had 
statistical significance after multiple comparison correction (OR=1.49; 95% CI: 1.43 
– 1.55).   
 
The distribution of allele frequencies of the three polymorphisms in different ethnic 
groups was investigated before carrying out the test of their association with disease.   
The results showed that the allele frequencies of the 734C>T and D/I were 
significantly different among the three ethnic groups (Table 4-3).  The 734T and I 
alleles were the lowest in Indians, followed by Malays, and Chinese.  Unlike the 
734C>T and D/I, whose distributions were significantly different among the three 
ethnic groups, 41A>G showed different allele frequency only between the Chinese 
and Indians.  In terms of association with CAD susceptibility, the 734T frequency 
was significantly lower in the CAD+ patients than in the CAD- controls in the 
Chinese (0.26 in CAD- vs.  0.20 in CAD+, P = 0.003; OR = 0.72; 95% CI: 0.57 – 
0.90).  The statistical significance was still observed after Bonferroni correction.  In 
Indians, the I allele was associated with increased CAD risk (0.17 in CAD+ vs. 0.10 
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in CAD-, P = 0.01; OR= 1.89; 95% CI: 1.65-2.18).  However, this significance did 
not remain after Bonferroni correction.   
 
Considering the effect of confounders such as age, BMI and smoking, the binary 
logistic regression model was applied with these confounders as covariates.  It was 
observed that the association of the 734C>T polymorphism with CAD was still 
significant after adjusting for these confounding effects (P=0.039).  In fact, age and 
smoking were not significant confounding factors in the Chinese but BMI was.  In 
the Indians, smoking and age were the significant confounders.  However, the 
association of the D/I polymorphism with CAD remained significant in the presence 
of smoking and age in the model.  After Bonferroni correction, all these significant 
associations did not remain. 
 
There was no significant difference in genotype and allele frequencies of 734C>T and 
D/I between the normolipidemic and dyslipidemic subgroups in all three ethnic 
groups.  Comparing normolipidemic and dyslipidemic individuals in the three ethnic 
groups, significantly higher G allele frequency was observed in the normolipidemic 
Chinese (P=0.008).  The analysis under the assumption of recessive genetic model 
also showed that the AG+GG genotype was more prevalent in the normolipidemic 
subjects than the dyslipidemic subjects (P=0.0059).  However, these significant 
differences did not exist after multiple comparison correction. 
 
4.2.2.4. Linkage disequilibrium among these three polymorphisms  
The genomic distance between 41A>G and 734C>T is 12.5kb, with D/I being located 
between them.  The D/I is closer to 41A>G (2.2kb) than to 734C>T (10.3kb). Linkage 
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disequilibria of different degrees were found between these three polymorphisms in the 
various subgroups (Table 4-5).  The 734C>T was found to be in very strong LD with 
D/I in the CAD+ (∆> = 0.64, P<0.0005) in three ethnic groups and in the CAD- group 
(∆>0.90, P<0.0005).  Strong LD was also observed between 41A>G and 734C>T and 
between 41A> G and D/I. 
 
4.2.2.5. Multi-loci case-control analysis 
Other than the single-locus analysis, two forms of multi-loci association tests, using 
haplotypes and diplotypes, were also conducted to evaluate the combined effects of 
different polymorphic sites. Due to the nearly complete LD between D/I and 734C>T, 
the D/I was not included in the haplotype and diplotype analysis. Only subjects with 
complete genotype data at the two loci were examined in the two-locus association 
study. The final subjects consisted of 580 Chinese (158 CAD+ vs. 422 CAD-), 156 
Malays (45 CAD+ vs. 111 CAD-) and 202 Indians (51 CAD+ vs. 151 CAD-).  
 
The results of the 4 haplotypes for these two polymorphic sites are summarized in 
Table 4-6.  The differences in haplotype frequencies between the CAD+ and CAD- 
subjects and between the normolipidemic and dyslipidemic groups were evaluated by 
permutation test.  In all three ethnic groups, the GC haplotype was about two times 
higher among the CAD+ patients than among the CAD- controls.  However, 
statistically significant difference was attained only in the Chinese (Permutation 
P=0.032; OR = 1.85; 95%CI: 1.38-2.48) but not in Malays and Indians, which was  
most likely due to the smaller sample sizes in these two ethnic groups.  The 
comparison of the haplotype frequencies between the normolipidemic and the 
dyslipidemic groups showed that the GC haplotype was more frequent in the 
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normolipidemic subjects than in the dyslipidemic subjects (Permutation P=0.012; OR = 
0.32; 95%CI: 0.14-0.76) in the Chinese while the AC haplotype was higher in the 
dyslipidemic group as compared to the normolipidemic group (Permutation P = 0.023; 
OR = 1.44; 95%CI: 1.29-1.59).  The lower GC haplotype in the dyslipidemic subjects 
was not expected; however, the result is still reasonable, as dyslipidemia is only one of 
many risk factors for CAD. 
 
Diplotypes were determined by combining genotype information from the 41A>G and 
734C>T polymorphic sites.  All possible combinations of eight diplotypes were 
present in the Chinese group while the Malays and Indians had only seven diplotypes. 
There was no significant difference in diplotype frequencies between the CAD+ and 
CAD- subjects, as well as between the normolipidemic and dyslipidemic groups in all 
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Table 4-3. Genotype and allele frequencies (freq) of the ACAT2 polymorphisms in 
the three Singaporean ethnic groups.   
 
 Chinese Malays Indians 
 CAD- CAD+ CAD- CAD+ CAD- CAD+ 
CC 274 (56) 240 (65) 97 (66) 71(73) 162 (83) 87 (86) 
CT 182 (37) 110 (30) 45 (31) 23 (23) 29 (15) 14 (14) 
TT 37 (7) 19 (5) 4 (3) 4 (4) 4 (2) 0 (0) 
734C>T n (%) 
 
 T freq 0.26†‡ 0.20 0.18_ 0.16 0.09_  0.07 
T freq 0.003 0.563 0.386 
CC+CT vs. TT  0.165 0.563 0.305 
P 
 
 CC vs. CT+TT 0.005 0.325 0.493 
AA 367 (68) 175 (66) 100 (72) 48 (70) 231 (78) 56 (72) 
AG 164 (30) 84 (32) 34 (25) 18 (26) 61 (20) 20 (25) 
GG 9 (2) 4 (2) 4 (3) 3 (4) 5 (2) 2 (3) 41A>G n (%) 
 G freq 0.17† 0.17 0.15 0.17 0.12† 0.15 
G freq 0.960 0.604 0.342 
CC+CT vs. TT  0.878 0.308 0.609 P 
CC vs. CT+TT 0.010 0.663 0.267 
DD 313 (54) 198 (60) 128 (62) 64 (63) 182 (83) 91 (72) 
DI 223 (38) 105 (32) 72 (35) 34 (33) 34 (15) 30 (23) 
II 45 (8) 25 (8) 6 (3) 4 (4) 4 (2) 6 (5) 
D/I n (%) 
 
I freq 0.27†‡ 0.24 0.20_  0.21 0.10_  0.17 
I freq 0.156 0.773 0.011 
CC+CT vs. TT  0.945 0.638 0.119 P 
CC vs. CT+TT 0.058 0.918 0.015 
 
 
_, _,  :  Significant difference in allele frequencies between ethnic groups (P<0.01). 
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Table 4-4 Genotype and allele frequencies (freq) of 734C>T, D/I and 41A>G in the 
normolipidemic (Normo) and dyslipidemic (Dys) subjects. 
 Chinese Malays Indians 
 Normo Dys Normo Dys Normo Dys 
CC 170 (54) 107 (60) 53 (70) 45 (62) 93 (85) 70 (81) 
CT 117 (37) 65 (36) 20 (27) 25 (35) 14 (13) 15 (17) 
TT 29 (9) 8 (4) 2 (3) 2 (3) 2 (2) 2 (2) 
734C>T n (%) 
 
 T freq 0.28 0.23 0.18 0.20 0.08 0.11 
T freq 0.085 0.662 0.317 
CC+CT vs. TT  0.054 0.967 0.943 
P 
 
 CC vs. CT+TT 0.223 0.294 0.366 
AA 208 (64) 156 (75) 53 (74) 47 (71) 136 (81) 95 (74) 
AG 112 (32) 50 (24) 18 (25) 16 (24) 30 (18) 31(24) 
GG 7 (2) 2 (1) 1 (1) 3 (5) 2(1) 3 (2) 41A>G n (%) 
 G freq 0.19* 0.13* 0.14 0.17 0.10 0.14 
G freq 0.008 0.492 0.140 
CC+CT vs. TT  0.295 0.270 0.451 P 
CC vs. CT+TT 0.006 0.782 0.133 
DD 183 (53) 127 (56) 49 (64) 62 (62) 90 (84) 75 (82) 
DI 134 (38) 87 (38) 24 (32) 35 (35) 16 (15) 15 (16) 
II 31 (9) 14 (6) 3 (4) 3 (3) 1 (1) 2 (2) 
D/I n (%) 
 
I freq 0.28 0.25 0.20 0.20 0.08 0.10 
I freq 0.257 0.944 0.488 
CC+CT vs. TT  0.226 0.731 0.474 P 
CC vs. CT+TT 0.463 0.737 0.629 
* Significant difference in allele frequency (P<0.01) 
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Table 4-5. Linkage disequilibria between the 3 polymorphisms of ACAT2 gene 
 Chinese Malays Indians 
 CAD- CAD+ CAD- CAD+ CAD- CAD+ 
LD between 















∆ = 0.52 
P<0.0005 
∆ = 0.42 
P<0.0005 
∆ = 0.65 
P<0.0005 
∆ = 0.41 
P=0.004 
∆ = 0.62 
P<0.0005 
∆ = 0.68 
P<0.0005 
LD between D/I 
and 41A>G 
 ∆ = 0.52 
P<0.0005 
∆ = 0.37 
P<0.0005 
∆ = 0.75 
P<0.0005 
∆ = 0.58 
P<0.0005 
∆ = 0.59 
P<0.0005 
∆ = 0.53 
P<0.0005 
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Table 4-6 Haplotype frequencies for 41A>G and 734C>T in CAD+ and CAD- 
subjects as well as in normolipidemic and dyslipidemic various groups.   
 
Chinese 
Haplotype CAD- CAD+ Permutation P* Normo Dys Permutation P* 
AC 0.698 0.707 0.763 0.671 0.745 0.023 
AT 0.129 0.113 0.482 0.133 0.122 0.689 
GC 0.042 0.075 0.032 0.057 0.019 0.012 
GT 0.131 0.106 0.279 0.139 0.115 0.325 
Malays 
Haplotype CAD- CAD+ Permutation P* Normo Dys Permutation P* 
AC 0.791 0.751 0.483 0.796 0.785 0.869 
AT 0.047 0.071 0.421 0.058 0.037 0.350 
GC 0.047 0.093 0.126 0.067 0.0278 0.106 
GT 0.115 0.085 0.470 0.078 0.151 0.097 
Indians 
Haplotype CAD- CAD+ Permutation* Normo Dys Permutation P 
AC 0.853 0.843 0.877 0.862 0.839 0.613 
AT 0.031 1.92E-10 0.153 0.045 0.009 0.071 
GC 0.044 0.0784 0.164 0.045 0.043 0.781 
GT 0.072 0.078 0.842 0.041 0.110 0.103 
 
 
*Permutation test significance levels for individual haplotype frequency comparisons between 
the CAD+ and CAD- groups.
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4.2.2.6. Association of single-locus genotype with lipid traits in the CAD- subjects 
In terms of the association with plasma lipid profiles, three models, dominant, 
additive, and recessive, were applied when three different genotypes were present.  
For normolipidemic Malay and Indian females, no mutant heterozygote was observed. 
Therefore, only additive model was used in these two subgroups.  Except for the 
normolipidemic Malay and Indian females, there was no significant association to be 
found using any genetic model in other subjects. As such, only the data for 
normolipidemic female subjects is presented in details. 
 
4.2.2.6.1. c.734C>T 
There was no significant difference in lipid profiles between the CAD+ and CAD- 
subjects as well as between the normolipidemic and dyslipidemic subgroups in the 
Chinese. The correlation of genotypes with plasma lipid traits in female 
normolipidemic Malays and Indians is shown in table 4-7.  The normolipidemic 
female Malays with the CT genotype had significantly lower apoA1 level than those 
with the CC genotype (P=0.007).  In the normolipidemic female Indians, 
significantly decreased plasma apoA1 (P=0.027), increased apoB (P=0.007) and Lp(a) 
(P=0.011) levels were observed in the CT heterozygous than the CC individuals. 
These analysis were adjusted with age, BMI, and smoking.  No TT homozygote was 
found in the two female normolipidemic groups.  However, these statistical 
significances were not observed after multiple comparison correction in the two 
subgroups.  The CT carriers had a trend towards increased LDL-C compared with 
CC individuals, but this is not statistically significant.   
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4.2.2.6.2. D/I 
ANOVA with age, BMI and smoking as covariates showed that the effects of this 
polymorphism on apoA1 in female normolipidemic Malays and on Lp(a) in female 
Indians were very  similar to that of 734C>T (Table 4-8).  The phenomenon is not 
surprising as both polymorphisms are in strong linkage disequilibrium.  However, 
the statistically significance was only observed on Lp(a) level in Indian females 
(P=0.004), with DI heterozyotes being associated with increased Lp(a) level.  In 
addition, elevated LDL was found in DI heterozygotes comparing with the DD 
carriers in Malay females (P=0.013).  Actually, the trend was the same as that of 
734C>T on LDL in this Malay group.  However, all these significances did not 
remain after Bonferroni correction.  
 
4.2.2.6.3. c.41A>G 
In female normolipidemic Indians (Table 4-9), the heterozygous carriers of the 
41A>G had higher TC than AA homozygotes.  The rare GG homozygotes were not 
found in female Malays and female Indians.  
 
4.2.2.7. Association of diplotypes with lipid traits  
Diplotypes were determined by combining genotype information from the 41A>G 
and 734C>T sites. All possible combinations of eight diplotypes were present in 
Chinese group while Malays and Indians had only seven diplotypes.  There was no 
significant difference in diplotype frequencies between CAD+ and CAD-, as well as 
between normolipidemic and dyslipidemic groups in all three ethnic groups.  The 
association study of diplotypes and lipid traits was conducted only in CAD- subjects 
and only positive results were present here (Table 4-10).  There were only 4 
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diplotypes in normolipidemic Malay and Indian females and 1 diplotype (AA/CT) 
was omitted due to small sample size in the Malays.  In normolipidemic Malay 
females, only apoA1 level was found to be significantly different between AG/CT and 
AA/CC as well as AG/CC (P=0.0031 and P=0.0035 respectively).  In the Indian 
females, the AA/CT carriers had significantly higher level of apoB relative to the wild 
type AA/CC homozygotes (P=0.006).  After multiple comparison correction, the 
association did not exist any more. 
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Table 4-7. Genotypic lipid levels (M ean ± SD) of the 734C>T in the healthy normolipidemic Chinese, Malay and Indian females.                              
 Chinese Malays               Indians 
 CC CT TT  CC CT P  CC CT  








  n=49 












































































































































































Lp(a)** 8.50 9.97 12.18  12.30 18.92  14.15 30.57  
 
 
*: lnTG and lnLp(a): natural logarithmic transformed TG and Lp(a), respectively. 
**: TG and Lp(a) levels are presented in geometric means. 
Age, BMI and smoking were included as covariates in the ANOVA. 
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Table 4-8. Genotypic lipid levels (M ean ± SD) of the D/I in the healthy normolipidemic Chinese, M alay and Indian females.   
                                                                                    
 
 
Chinese     
 
Malays       
 
Indians  
 DD DI II P DD DI P  DD DI 
P 
 








  n=68 
 
n = 11  































































































lnTG* -0.055±0.36 0.0013±0.37 -0.0069±0.32 0.632 -0.136±0.34 -0.196±0.27 0.628 0.0808±0.36 0.0016±0.26 0.493 



























*: lnTG and lnLp(a): natural logarithmic transformed TG and Lp(a), respectively. 
**: TG and Lp(a) levels are presented in geometric means. 
Age, BMI and smoking were included as covariates in the ANOVA. 
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n = 19  































































































lnTG* -.0054±0.43 -.032±0.36 -.0114±0.30 0.955 -0.21±0.39 -0.24±0.35 0.789 0.016±0.38 0.06±0.52 0.382 
TG** 0.99 0.97 0.99  0.81 0.76  1.02 1.06  
lnLp(a)* 2.47±0.93 2.40±0.79 2.65±1.21 0.841 2.34±0.54 2.51±0.61 
 
0.634 2.63±0.71 2.46±0.84 0.387 




*: lnTG and lnLp(a): natural logarithmic transformed TG and Lp(a), respectively. 
**: TG and Lp(a) levels are presented in geometric means. 
Age, BMI and smoking were included as covariates in the ANOVA.
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Table 4-10. Diplotypic lipid levels in normolipidemic Malay and Indian females. 
                                                                                               
  Malays      
 
 Indians   
 AA/CC AG/CC AG/CT 
 
AA/CC AG/CC AA/CT AG/CT 
 n=13 n=4 n=4 
 
n=37 n=6 n=3 n=3 
TC (mM) 4.71±0.92 4.96±0.91 4.65±0.32 
 
4.56±0.81 4.70±0.50 4.98±0.85 4.53±0.52 
LDL-C (mM) 2.83±0.77 2.99±0.79 3.16±0.56 
 
2.84±0.87 2.86±0.64 3.33±1.09 3.05±0.45 
HDL-C (mM) 1.45±0.36 1.52±0.25 1.19±0.31 
 
1.30±0.37 1.38±0.38 1.26±0.21 1.02±0.045 
ApoA1(mg/dl) 150.08±15.39a 152.50±15.55b 125.50±16.34c 
 
133.00±23.53 130.60±7.27 125.67±9.45 108.33±21.60 
ApoB (mg/dl) 88.67±12.45 101.50±23.76 94.25±14.98 
 
92.30±18.92d 97.83±16.43 115.0±28.62e 99.33±3.51 
TG 0.87 0.99 0.71 
 
1.04 1.07 0.97 1.01 
InTG -0.13±0.44 -0.01±0.10 -0.34±0.38 
 
0.04±0.34 0.07±0.61 -0.04±0.40 0.01±0.15 
Lp(a) 12.68 11.13 16.44 
 
14.59 11.02 33.45 25.53 
InLp(a) 2.54±0.57 2.41±0.66 2.80±0.61 
 
2.68±0.68 2.40±1.08 3.51±1.20 3.24±0.68 
 
 
a significantly higher than c (P=0.031) 
b significantly higher than c (P=0.035) 
d significantly lower than e (P<0.006) 
Age, BMI and smoking were included as covariates in the ANOVA.
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4.2.3. Functional analysis of two nsSNPs of ACAT2 gene 
4.2.3.1. Expression of ACAT2 in AC-29 cell 
In contrast to pcDNA3.1 vector-transfected cells, ACAT2-transfected cells contained 
abundant lipid droplets, which were seen under inverted or differential interference 
contrast microscope or fluorescence microscope after Nile red staining (Figure 4-11). 
 
The mRNA expression was verified by reverse transcription PCR using ACAT2-specific 
primers and GAPDH-specific primers.  The amplification of ACAT2 was only detected 
in ACAT2 transfected cells, but not in parent AC-29 cells and in the cells transfected 
with vector alone (Figure 4-12 A).  With regards to the mRNA expression levels of 
wild type ACAT2 and the other three variants, reverse transcription real-time PCR 
showed that there was no significant difference in ACAT2 gene expression level 
between wildtype ACAT2 and mutant ACAT2s, when normalized by reference gene 
GAPDH (Gly14/WT: 1.32 ± 0.22, P=0.13; Ile254/WT: 0.94±0.14, P=0.57; 
Gly14Ile254/WT: 1.10±0.22, P=0.64).  The western blot results however showed that 
the ACAT2 protein was expressed about two-fold higher level in mutants with Gly14 
when compared to that of wildtype and the mutant with Ile254 (Figure 4-12 B).  
 
4.2.3.2. ACAT2 activity assay 
The measurement of ACAT enzyme activity was carried out in triplicate and their 
average was used for data analysis.  The ACAT2 activity assay showed that the rate of 
CE biosynthesis in intact cells transfected with the Gly14 mutants was higher than that 
in cells transfected with wildtype or  the Ile254 mutant only (Figure 4-13).  
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Figure 4-11. Cells viewed with inverted microscope (A and A’) and Nile red-staining 
with Texas red (B and B’) and differential infraction contrast (C and C’). 
ACAT2-transfected cells (A’, B’ and C’ was filled with numerous lipid droplets while 
no obvious lipid droplets were seen in control cells (vector-transfected cells, A, B and 







Figure 4-12. ACAT2 mRNA and protein expression in AC-29 cells. Lane 1: wildtype 
ACAT2; Lane 2: ACAT2-Gly14; Lane 3: ACAT2-Ile254; Lane 4: ACAT2-Gly14Ile254; 
Lane 5 and 6: negative controls (vector alone-transfected AC-29 cells and 
untransfected AC-29). Ratio: the expression level ratio of various mutant ACAT2 to 
wildtype ACAT2. (A) The amplified ACAT2 products were detected in 
ACAT2-transfected cells but not in control (cells transfected with vector alone and 
untransfected AC-29 cells). (B) Western blot analysis using anti-Xpress and anti- 
β-actin as primary antibody and quantitations of ACAT2 bands by densitometric 
analysis. The ACAT2 protein was detected in ACAT2-transfected cells. 
 
A B 
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Figure 4-13. ACAT2 enzyme activity analysis of wild type and mutant ACAT2s.  
(A) The relative rates of cholesteryl ester biosynthesis in intact cells expressing 
various ACAT2 indicated. (B) Normalized ACAT2 activity of various ACAT2 by 
different ACAT2 protein expression levels. 
 
 







1 2 3 4
Specifi   tivity (cpm/mg/min) 
   WT      Gly14       Ile254   Gly14Ile254   
B 






1 2 3 4 5 6
elative ACAT2 activity (cpm/mg/ in) 
     WT      Gly14     Ile254    Gly14Ile254     AC29    pcDNA3.1 
A 
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4.3. Discussion 
ACAT2 has been identified as an important enzyme in the development of 
hypercholesterolemia and as a therapeutic target for treatment of 
hypercholesterolemia and coronary artery atherosclerosis (Buhman et al., 2000; 
Chang et al., 2000; Rudel et al., 2005). It was hypothesized that the variations in 
ACAT2 gene may be implicated in hypercholesterolemia and CAD susceptibility as 
well as related phenotypes.  In order to test this hypothesis, the regulatory regions 
and the entire coding region of ACAT2 gene, were screened for sequence variations.  
This is the initial step for subsequent association study to investigate the effect of 
ACAT2 gene polymorphisms on hypercholesterolemia and CAD susceptibility. 
 
For the detection of ACAT2 gene polymorphisms, a highly sensitive and economic 
method, DHPLC, was used.  After screening about 300 cord blood samples, a total 
of fourteen polymorphisms were found.  Of these polymorphisms, two were 
single-base changes in the putative promoter region; five were sequence variants 
located in exonic regions: three were nsSNPs and two were silent mutations; and 
seven were sequence variants, comprising six single base substitutions and one 
48bp-insertion, within intronic regions.  Among these seven sequence variants, five 
SNPs, 41A>G, 734C>T, IVS9+37A>T, IVS9+51G>T, IVS1-8C>G, had been 
reported previously (Katsuren et al., 2001 and 2003; Haga et al., 2002), and other nine 
polymorphisms were novel and have been submitted to the NCBIs SNP database. 
 
DHPLC has been documented to be a highly sensitive method for the detection of 
point mutation and small insertions/deletions (Xiao and Oefner 2001; O’Donovan et 
al., 1998; Liu et al; 1997; Gross et al., 1999; Jones et al., 1999), which also has been 
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proven in the study.  In this study, all known polymorphisms within the coding 
region and all intronic-exonic boundaries had been detected.  However, within the 
5’UTR or putative promoter region, some SNPs, such as -74A>G, -1279G>A, 
-1283G>A, -1327A>C, and -1382A>C, had been reported in the NCBIs SNP database 
but were not found in current study.  It was postulated that these undetected 
polymorphisms may occur only in certain population or at quite low frequencies.  
For example, -1279G>A, -1283G>A, -1327A>C, and -1382A>C were found in 
Caucasians, and the -1279G>A occurs at a very low frequency (0.005 for rare A 
allele).  
 
In addition, it was proven that the use of primers with a GC clamp is able to improve 
the efficiency of mutation detection.  The mechanism behind is described as follows. 
At higher temperature, double-strand DNA dissociates into single-strand DNA, 
leading to peak broadening when passing through DHPLC column.  The addition of 
a GC-clamp at one end of the fragment should stabilize the DNA and raise the 
temperature at which the double-strand DNA is denatured into single-strand DNA to 
ensure a sharp peak even at higher temperature (Narayanaswami and Taylor, 2001).  
The use of GC-clamped primers greatly enhances the sensitivity of detection of 
mutant hetero- and homoduplex peaks in DHPLC profiles compared to 
non-GC-clamped primers. Thus, when screening sequence variants, the incorporation 
of appropriate GC-clamped primers provides a simple method of altering the melting 
behavior and increases the resolution of homo- and heteroduplex peaks.   
 
For a tri-allele polymorphism, c.1291G>T or A in exon 13, the two kinds of mutant 
heterozygotes (GT and GA) showed very similar DHPLC profiles, and direct 
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sequencing detected different base substitutions (G>T or A).  This polymorphism 
occurs at a very low frequency, as only one heterozygote of each was found among 
the 348 samples screened.  In order to exclude the possibility that this substitution 
was introduced during Taq DNA polymerase amplification, re-amplification by Pfu 
DNA polymerase with high fidelity was carried out.  The same heteroduplex profile 
can be generated from the amplicon obtained using the Pfu DNA polymerase and the 
base substitution was also confirmed by DNA sequencing.  Thus, this polymorphism 
is a naturally occurring genetic variant with a very low frequency in general 
population. 
 
Among the polymorphisms identified in this study, two polymorphisms were 
identified in the putative promoter region. However, previous study suggested that the 
fragment containing the two polymorphic sites was not important for promoter 
activity (Song et al., 2001). For the polymorphisms found in intronic regions, none of 
them was located within splicing sites or branch sites and thus it is unlikely to have 
biological influence.  So only those located in the coding region are considered for 
function analysis to evaluate their biological significance.   
 
The GRANTHAM D values of the Glu14Gly, Thr254Ile and Ala431Ser were close to 
100, while the D value of Ala431Thr was 58.  The BLOSUM scores of the former 
triad were negative and only the Ala431Thr has a positive value.  Recent studies on 
sequence variants in G-protein-coupled receptors using substitution matrix suggested 
that variations with GRANTHAM scores >100 or BLOSUM scores<-1 are 
increasingly associated with disease-causing mutations (Balasubramanian et al., 2005). 
However, these substitution matrix scores did not consider position-specific 
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information and whether these substitution matrixes are useful for predicting function 
is still controversial (Miller and Kumar, 2001; Ng and Henikoff, 2001; Leabman et al., 
2003). Interspecies sequence alignment and acyltransferase family members sequence 
comparison were carried out to define the evolutionary conserved sites.  The Glu14 
and Ala431 were conserved in Homo sapiens, Africa green monkey, Mus musculus, Rattus 
norvegicus, and Canis familiaris but not in all acyltransferase family.  The Thr254 
was not conserved both interspecies and in the acyltransferase family. PolyPhen 
demonstrated that the Glu14Gly was possibly damaging.  Combining all the 
predicted results, the Glu14Gly may have a functional role. 
 
Other than these prediction approaches, literature review on ACAT2 also gave us 
some information on the possible functional roles of these polymorphic sites.  For 
example, the 254th amino acid residue is very close to an important amino acid residue, 
serine, at the 245th residue. The mutation from serine to leucine mutation at the 245th 
residue led to loss of ACAT2 enzyme activity (Joyce et al., 2000; Lin et al., 2003).  
It was proposed that this 245th residue may be very important to ACAT2 protein 
expression or stability.  In addition, the amino acid residues at the amino-terminal 
region in ACAT family have been suggested to negatively mediate the enzyme 
activity (Guo et al., 2001).  Therefore, it is likely that the The254Ile and Glu14Gly 
polymorphisms may have some biological function.  
 
With the information on the potential biological significance of The254Ile and 
Glu14Gly polymorphisms, it is instructive to investigate their effect of these two 
polymorphisms on disease susceptibility in Singaporean population using a 
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case-control association study. The D/I polymorphism was also included in this study, 
as a long insertion is uncommon among sequence variations.  
 
The findings from this association study indicated that common genetic variants 
within the ACAT2 gene were associated with altered plasma lipid levels and CAD risk 
in Singaporean population.  The heterozygote 734C>T was associated with 
decreased apoA1 and/or increased apoB and Lp(a) in healthy female normolipidemic 
Malays and Indians.  The 41A>G heterozygotes had significantly higher TC level 
and a trend towards increased apoB in the Indian females. It was found that the 
734C>T was in almost complete LD with D/I polymorphism and in very strong LD 
with 41 A>G.  As such, very similar associations were observed for the 734C>T and 
D/I with plasma lipid levels.  However, all these associations with lipids were not 
observed after strict Bonferroni correction.   
 
The T allele of 734C>T was significantly lower in the Chinese CAD+ patients with 
multiple comparison correction.  In addition, the analysis using the recessive model 
also showed that the Chinese CAD+ patients had lower CT+TT genotypes compared 
with the CAD- controls.  These results suggest that the CT+TT genotypes and T 
allele may be protective against CAD in the Chinese, although no corresponding 
protective effect on plasma lipid levels was observed.   In the other two ethnic 
groups, Malays and Indians, the T allele frequency was also slightly higher in the 
CAD- subjects compared to the CAD+ patients but did not reach a significant level.  
No significant association was observed between the 734C>T polymorphism and 
dyslipidemia in any ethnic group.  This was consistent with that of the study done by 
Katsuren et al. (2001) in the Japanese.  The allele frequency of 734C>T in the 
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Chinese subjects in the study was also similar to those reported in the Japanese study.  
In the normolipidemic Indian and Malay females, the heterozygotes of 734C>T had 
decreased apoA1 and /or increased apoB and Lp(a) levels, but no significant 
difference was detected in the dyslipidemic subjects.  The effects of 734C>T on 
plasma lipid traits were probably explained by the function of ACAT2 in the synthesis 
and secretion of apoB-containing lipoproteins and in intestinal cholesterol absorption.  
As for the effect of ACAT2 on apoA1 level, it probably results from an increase in 
LCAT activity, which may complementarily increase if ACAT2 activity is lower in 
the T allele carriers.  Such compensatory increase in LCAT activity due to ACAT2 
activity deficiency was observed in ACAT2-/- ApoE-/- mice (Willner et al., 2003).   
 
Katsuren’s study in the Japanese (2001) showed that 734C>T heterozygotes in 
normolipidemic and dyslipidemic subjects had significantly higher apoC-III levels as 
compared to the other two homozygous genotypes (CC and TT).  There was no 
significant difference in apoA1 and apoB levels between different genotypes.  It 
should be noted that these association of the 734C>T polymorphism with lipids may 
be spurious, as the significance was not observed after strict multiple test correction.  
 
As for the 41A>G, there was no difference in allele frequencies of this nsSNP 
between the CAD+ and CAD- subjects in all three ethnic groups.  However, when 
the CAD- subjects were stratified into normolipidemic and dyslipidemic subgroups, 
the G allele frequency was significantly higher in normolipidemic subjects than in 
dyslipidemia subjects in Chinese but not in Malays and Indians.  It appears that the 
G allele was protective against dyslipidemia in the Chinese, but this effect was not 
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consistent across ethnic groups.  However, this effect was not detected after 
adjusting multiple tests. 
 
The 41A>G heterozygotes had higher TC and apoB in the normolipidemic female 
Indians compared to the AA homozygotes.  Together with the higher G allele 
frequency in the dyslipidemic Indians, it suggested that the G allele may be associated 
with an increase in ACAT2 activity, resulting in the corresponding increase in the 
intestinal cholesterol absorption and the secretion of apoB-containing lipoproteins.  
 
The impact of the D/I polymorphism on plasma lipid profiles was quite similar to that 
of the 734C>T.  In addition, significant effect of the D/I polymorphism on LDL 
level was observed among the normolipidemic Malay females, with DI genotype 
being associated with increased LDL level.  Increased LDL was also found in 
heterozygous carriers of the 734C>T, but the increase did not reach statistical 
significance.  The lack of statistical significance is most likely due to the smaller 
sample size of the heterozygotes of the 734C>T polymorphism in this group.  
Although the functions of introns are still controversial, it is not likely that the 
intronic D/I polymorphism exerts its effect through any change in the ACAT2 enzyme 
structure or serves any regulatory role.  As such, any D/I-related association may be 
due to its LD with a functional site.    
 
In order to assess the combined effects of multiple polymorphisms, the association 
testing using haplotyes and diplotye was carried out.  As the D/I site is in almost 
complete LD with 734C>T, it was deemed not sufficiently informative for inclusion 
in the haplotype and diplotype analysis. Therefore included only two loci, 41A>G and 
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734C>T, for haplotype and diplotype analysis were included.   In the haplotype 
case-control study, it was observed that in the Chinese, the GC haplotype was almost 
two times more frequent in the CAD+ patients than in the CAD- controls but three 
times more frequent in the normolipidemic group than those who are dyslipidemic.  
It was noted that the association of haplotype with CAD does not rule out the 
possibility of its association with lower atherogenic lipid levels since the latter is only 
one of the many risk factors of CAD.  It is clear that Malay individuals with 
diplotypes bearing the GC haplotype (AG/CC) have significantly higher protective 
plasma apoA1 levels while the Indian subjects with the AT-bearing diplotype (AA/CT) 
have the highest atherogenic apoB levels.  The probable small ‘protection’ conferred 
by the GC haplotype in terms of its association with favorable levels of lipids could 
be overridden by other more pronounced effects from genes that are in LD with other 
CAD candidate genes located both upstream and downstream of ACAT2 (12q13).  
These include the genes encoding the LDL receptor-related protein 6 (12p13.3-p11.2), 
apoB mRNA editing enzyme catalytic polypeptide 1  12p13.1, LDL, oxidized, 
receptor 1 (12p13-p12) and scavenger receptor class B, member 1 (12q24.31), though 
the latter might be far from ACAT2 gene.  In the vicinity of the ACAT2 gene are also 
those related to immune response, such as interleukins. They are known to play 
important roles in CAD, which is, in many ways, considered as an inflammatory 
disease.   
 
The association study of diplotypes and plasma lipid levels showed that, in female 
normolipidemic Malays, the AG/CT diplotype had the lowest level of apoA1 than the 
AA/CC and AG/CC diplotypes.  It is therefore apparent that the lower apoA1 is 
likely to be due to the T allele.  This is consistent with the single-locus analysis of 
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734C>T. In the female Indians, the AA/CT had a significantly higher level of apoB 
than the AA/CC.  Since the AA genotype was kept constant in the two diplotypes, 
the higher apoB is more likely to be attributed to the 734C>T site.   However, the 
effects of 734C>T on Lp(a), and 41A>G on TC were only observed in single-locus 
analysis but not with diplotypes.  This might be due to the reduced sample sizes of 
the diplotype analysis as only samples with both sites successfully genotyped were 
included.  
  
The lack of significant association between the polymorphisms and plasma lipid 
levels in the dyslipidemic subgroups may be due to the following.  Firstly, the 
contributions of a single gene or a few polymorphisms are expected to be very small.  
Therefore, their effects are very likely to be masked by a myriad of other 
environmental factors, such as diet, physical activity and lifestyle.  In statistical 
analysis, BMI, age and smoking were included as covariates in the ANOVA models 
to adjust for their confounding effects.  Secondly, there are many other genes 
involved in lipid metabolism. Genes such as those coding for apolipoproteins, LPL 
and LDL receptors confer great effects on lipid levels and CAD risks.  However, 
these were not taken into account in the statistical analysis although their influences 
on plasma lipid levels may mask that of 734C>T and 41A>G.  Thirdly, the T and G 
alleles may exert their influences only by interacting with other genes or 
environmental factors.  Fourthly, statistical analysis with the small sample sizes in 
Malays and Indians might not have sufficient power to reliably detect a true 
association.  Last but not least, it does not exclude the possibility of Type I error, as 
all these associations with lipids were not observed any more after Bonferroni 
correction for multiple comparisons. 
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The 734C>T polymorphism was shown to be associated with CAD risk in the Chinese 
Singaporean.   In addition, the 41A>G and 734C>T were found to be correlated 
with altered lipid profiles in female normolipidemic Malays and Indians, but the 
significance was not observed after Bonferroni correction. Thus, further experiments 
were carried out to verify whether these two nsSNPs were really functional variants 
and their underlying mechanism.  Meanwhile, the experimental study also verifies 
the validity of the computational predictions for these nsSNPs. 
 
The wild-type and three mutant ACAT2 proteins (Gly14, Ile254, and Gly14Ile254) as 
well as the empty vector were expressed in an AC-29 cell line,  in which ACAT 
activity was absent. The functional analysis was performed by measuring the 
expression levels of ACAT2 genes and their proteins, and their relative enzyme 
activities of various polymorphic forms. 
 
The preliminary results from in vitro experiments indicated that the relative catalytic 
activity of ACAT2-Gly14 was almost 2-fold higher compared to that of 
ACAT2-Glu14. There was no significant difference between ACAT2-Thr254 and 
ACAT2-Ile254.  The higher activity of ACAT2-Gly14 was obviously due to the 
higher protein expression of ACAT2 bearing Gly14.  No significant difference was 
detected after performing western blot to normalize the activities with their 
corresponding protein expression levels.  There was no significant difference in 
ACAT2 mRNA expression between wildtype and various variants, suggesting that a 
post-transcriptional mechanism may mainly account for the difference in ACAT2 
protein expression levels.  Thus, the current functional study suggested that the 
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Glu14Gly polymorphism was important to ACAT2 protein expression and/or protein 
stability while the Thr254Ile might be a non-functional polymorphism. 
 
The association study suggested that the Thr254Ile mutant was anti-atherogenic in 
Chinese (He et al., 2005).  In addition, the Glu14Gly affected the TC level in female 
normolipidemic Indians while the Thr254Ile altered apoA1 and/or apoB and Lp(a) 
concentrations. The possible reasons for the different effects in different subgroups 
were stated (He et al., 2005).  The effect of the Glu14Gly on plasma cholesterol 
concentration in female normolipidemic Indians was consistent with the higher 
expression level in the experimental study.  As for the Thr254Ile, its expected 
influence from this in vitro experimental study is opposite to that of epidemiological 
study.  This might be explained by the following reasons.  First, the functional 
effect of the Thr254Ile might be too small to be detected in the experimental system in 
AC-29 cells, but might become observable in a specific human tissue or upon 
exposure to relevant environmental factors.  Second, other factors such as the cell 
type and DNA constructs used for this study might affect experimental outcomes.  It 
is known that different cell types and DNA constructs might exert different regulatory 
influences that may affect the function of a genetic variant (Rebbeck et al., 2004).  
Finally, the inconsistency may be due to some inherent bias in epidemiological 
investigations, such as insufficient statistical power and multiple comparisons in the 
statistical analyses, which could produce false positive inferences (Rebbeck et al., 
2004).  The experimental study in AC-29 cell line also supported the computational 
prediction that the Glu14Gly was conserved and probably have biological implication 
while the Thr254Ile was not. 
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We also should be aware that these results are very preliminary, as all these 
experiments, including real-time RT PCR, western blot, and activity assay, were done 
with only one colony for each polymorphic form.  Therefore, before making a 
conclusion, all of these assays should be repeated with at least three colonies for each 
polymorphism type in  future work.  
 
In conclusion, a total of 14 ACAT2 gene polymorphisms were identified in this study. 
The population study showed that the three polymorphisms were associated with CAD 
susceptibility in an ethnic-specific manner, and the statistical significance was not 
observed any more except for 734C>T in the Chinese after multiple test correction.  
The 43A>G and 734C>T were correlated with altered plasma lipid profiles in female 
normolipidemic Malays and Indians, but the significance did not exist after Bonferroni 
correction.  For the functional characterization of the two nsSNPs, preliminary results 
suggested that the Glu14Gly might be important to ACAT2 protein expression and/or 
stability, implying that the Glu14Gly might clinically be related with CAD and 
hypercholesterolemia.  However, further study including at least three colonies for 
each polymorphic form is needed to confirm this finding. 
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5. ASSOCIATION STUDY OF THREE LIPOPROTEIN LIPASE 





LPL has a paradoxical role of being anti-atherogenic and pro-atherogenic, which is 
dependent on the tissues expressing LPL.  Plasma LPL confers decreased risk of 
atherosclerosis while arterial wall LPL is associated with increased risk (Clee et al., 
2000). 
 
Although there are many variants in the LPL gene, most of the functional LPL ones 
are rare and either or restricted to families with LPL deficiency or isolated in 
geographic regions (Brunzell, 1995; Santamarina-Fojo et al., 1991).  Three common 
genetic variants, the IVS6+1595C>T polymorphism in intron 6, the IVS8+484T>G 
polymorphism in intron 8, and the c.1342C>G in exon 9, are widely studied. Some 
results showed that these polymorphisms are associated with altered lipid profiles 
(Razzaghi et al., 2000; Morabia et al., 2003; Gerdes et al., 2005) and cardiovascular 
diseases susceptibility (Yang et al., 2004; Taylor et al., 2004).  However, 
inconsistent finding have been reported (Fidani et al., 2005; Spence et al., 2003; 
Brousseau et al., 2004).  These association studies were carried out mainly in 
Caucasian populations and a few studies have been done to examine the impact of 
these polymorphisms in the Asian population (Shimo-Nakanishi et al., 2001; Lee et 
al., 2004; McGladdery et al., 2001; Hall et al., 2000). To our knowledge, the 
combined effect of these three polymorphisms on CAD risk has not been investigated 
in any Asian population.   Thus in this study, the impact of the haplotypes formed 
by the three polymorphisms on CAD susceptibility in two Asian ethnic groups in 
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Singapore, namely the Indians and Chinese, was examined. The correlations of the 





5.2.1. Demographic characteristics of subjects 
The demographic characteristics of the CAD+ patients and the healthy (CAD-) 
controls are presented in Table 5-1.  The healthy controls were younger than the 
CAD+ patients and the smoking rate was significantly lower in the healthy group 
compared to the CAD+ group in both ethnic groups.  The Chinese CAD+ patients 
had higher BMI than the respective controls.  In terms of lipid parameters, 
anti-atherogenic lipid traits, such as HDL and apoA1, were significantly higher in 
healthy individuals than the CAD+ patients in both ethnic groups.  However, 
atherogenic TC and apoB were significantly lower in patients than controls in both 
ethnic groups. TGs were also significantly lower in the CAD+ patients compared with 
healthy controls in Indians.   All CAD+ patients were put on lipid lowering 
medications and advised to go on a restricted diet and adopt a healthier lifestyle. The 
lower levels of TC and apoB in the patients, along with lower TG values in Indian 
patients, were therefore mainly due to a regime of controlled diet and drug therapy.  
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Table 5-1.  Demographics of male Chinese and Indian subjects   
  Chinese   Indians  
Variables CAD- CAD+ P CAD- CAD+ P 
 n = 538 n = 899  n = 305 n = 302  
Age (years) 41±14 58±9 <0.0005 43±14 57±10 <0.0005 
BMI (kg/m2) 23.47±3.45 24.15±3.50 0.066† 24.51±3.93 24.68±3.24 0.576† 
Smokers* (%) 25.47 30.50 0.025 17.10 25.52 0.008 
TC (mg/dl) 224.26±50.63 202.70±55.21 <0.0005 228.50±46.05 198.88±50.86 <0.0005 
HDL-C (mg/dl) 48.72±12.68 33.96±11.67 <0.0005** 39.661±10.74 30.79±10.64 <0.0005)** 
LDL-C (mg/dl) 143.57±46.91 136.31±52.86 0.011 154.00±41.95 136.37±48.47 <0.0005 
TG (mg/dl) 175.16±173.30 165.59±95.75 0.568 189.56±97.07 132.64±89.37 0.003 
ApoA1 (mg/dl) 141.27±23.26 116.87±37.65 <0.0005 132.69±23.22 110.38±39.93 <0.0005 
ApoB (mg/dl) 111.98±31.35 104.91±31.80 <0.0005 129.23±31.49 106.15±30.66 <0.0005 
Lp(a) (mg/dl) 12.31±15.54 22.03±22.48 <0.0005 18.41±19.09 31.16±31.20 <0.0005 
*: Smokers form one category while non smokers and ex-smokers constitute another.  
Adjusted for the confounding effect of †age and**smoking. 
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5.2.2. Genotyping results of three LPL polymorphisms 














Figure 5-1. Genotyping of three polymorphisms. A: IVS8+484T>G. Lane 1,3,6, and 7: TT 
Lane 2 and 4: TG; Lane 5: GG. B: IVS6+1595C>T, Lane 1, 3, 6, and 7: CC; Lane 2 and 4: 
CT; Lane 5: TT. C: c.1342C>G. The PCR product contains two MnlI cutting sites, one of 
which is polymorphic site. Lane 2, 4, 5 and 7: CC; Lane 1 and 6: CG; Lane 3: GG. 
 
 
5.2.3. Distribution of three LPL polymorphisms 
All genotype frequencies were in accordance with HWE (P>0.05), with the exception 
of the IVS6+1595C>T polymorphism in the Indian controls (P=0.033). The test of 
HWE is very sensitive to rare homozygous genotype.  In this case, had there been 64 
instead of 66 individuals with the TT genotype, the distribution would have been 
1    2     3    4     5    6     7 
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within Hardy Weinberg expectation.  Therefore this departure is attributed to chance 
rather than an indication of a violation of Hardy-Weinberg assumptions.   This is 
also supported by the fact that the other two LPL and three ACAT2 gene 
polymorphisms in the same subjects are well within Hardy-Weinberg expectations. 
 
Table 5-2 and 5-3 show the distribution of genotype and allele frequencies of the 
IVS6+1595C>T, IVS8+484T>G and c.1342C>G polymorphisms between the CAD+ 
patients and controls as well as between dyslipidemic and normolipidemic subgroups 
in the Chinese and Indians, respectively.  No significant difference in genotype and 
allele frequencies of the IVS6+1595C>T polymorphism was observed between the 
healthy and CAD+ subjects in both ethnic groups after Bonferroni correction.  The 
major T allele of the IVS8+484T>G polymorphism was significantly higher in the 
CAD+ patients compared to the healthy controls in the Chinese (OR = 1.34, P = 
0.0063) and in Indians (OR = 1.47, P = 0.0014).  However, no significant difference 
in genotype frequencies was found in both ethnic groups under dominant and 
recessive models.  The C allele frequency of the c.1342C>G polymorphism was 
higher in the CAD+ patient in both ethnic groups but the statistically significant 
difference was only observed in the Chinese (OR = 1.72, P = 0.0034).  Furthermore, 
mutant homozygotes were significantly higher in the CAD+ patients compared with 
the healthy controls.  Different distributions of allele frequencies of the 
IVS8+484T>G and IVS6+1595C>T polymorphisms were found between Chinese and 
Indians controls; however, there was no significant difference in the allele frequencies 
of the c.1342C>G between the two ethnic groups. When stratifying the healthy 
controls into dyslipidemic and normolipidemic subgroups and comparing the 
distribution of allele frequencies and genotypes, no significant association of allele 
and genotype frequencies with dyslipidemia was found in the two ethnic groups. In 
dyslipidemic subjects, the T allele was present more frequently in Chinese compared 
to Indians. Significant LD with Δ ranging from 0.34 to 0.60 was observed in all 
loci-pairs for both ethnic groups (Table 5-4). 
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5.2.4. Hapolotype distribution  
The distribution of haplotypes in the CAD+ patients and control groups is present in 
Table 5-5. All eight of the expected haplotypes were observed.   The most 
predominant haplotype is the CTC haplotype which constitutes more than 50% of the 
population followed by the TTC and TGC haplotypes in both ethnic groups. The 
frequency of the most prevalent haplotype, CTC, is also significantly and consistently 
elevated in the CAD+ patients than the healthy controls in both Chinese and Indians 
(P=0.0096 and P=0.0011, respectively).   The OR of having CAD for individuals 
with the CTC ‘risk’ haplotype vs. those without is 1.4 (95% CI 1.1 to 1.8) for the 
Chinese and 2.0 (95% CI 1.3 to 3.0) for the Indians.    The TGG haplotype is 
‘protective’ with a significantly lower frequency in the Chinese CAD+ patients 
compared to that of healthy controls.  However, this association is not significant in 
the Indians.  Instead, another ‘protective’ TGC haplotype has a significantly higher 
frequency in the healthy controls.   
 
The haplotype distribution was also compared between dyslipidemic and 
normolipidemic subgroups in the two ethnic groups (Table 5-6).  Although there 
were 8 expected haplotypes present before stratifying healthy controls into 
dyslipidemic and normolipidemic subgroups, only 6 and 7 haplotypes were reported 
in the two subgroups in the Chinese and in the Indians, respectively. It may be 
because that haplotypes with low frequency are not reported by the software. No 
significant association was observed between haplotype distribution and dyslipidemia 
in both ethnic groups.  
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Table 5-2. Distribution of LPL polymorphisms in male CAD+ patients and controls 
 
 Chinese Indians 
 CAD- CAD+ CAD- CAD+ 
CC 183 351 93 103 
CT 236 412 121 142 
TT 67 106 66 41 
IVS6+1595C>T 
 
 T freq 0.38† 0.36 0.45† 0.39 
T freq 0.030 0.041 
CC vs. CT+TT 0.323 0.484 P 
 CC+CT vs. TT 0.401 0.005 
      
TT 252 421 133 132 
TG 155 208 100 69 
GG 33 27 30 15 IVS8+484T>G 
 G freq 0.25† 0.20 0.30† 0.23 
G freq 0.0063 0.0014 
TT vs. TG+GG 0.0214 0.0209 P 
 TT+TG vs. GG 0.0158 0.096 
      
CC 246 474 131 171 
CG 68 86 46 38 
GG 6 0 3 3 c.1342C>G  
 G freq 0.12* 0.08* 0.14 0.10 
 G freq 0.0034 0.0902 
P CC vs CG+GG 0.019 0.064 
 CC+CG vs. GG 0.0011 0.840 
 
 
† and ‡:  Significant difference in allele frequencies between ethnic groups (P<0.05) 
*: Significant difference in allele frequencies between cases and controls.  
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Table 5-3. Distribution of LPL polymorphisms in dyslipidemic and normolipidemic 
subjects 
 
         Chinese Indians 
Polymorphism  Dys Normo Dys Normo 
CC 84 102 45 48 
CT 117 116 66 55 
TT 30 37 36 30 
IVS6+1595C>T  
 
 T freq 0.39* 0.38 0.47* 0.43 
      
TT 120 134 71 62 
TG 76 77 52 48 
GG 13 20 17 13 IVS8+484T>G 
 G freq 0.25 0.26 0.31 0.30 
      
CC 132 114 67 64 
CG 35 33 25 21 
GG 3 3 0 3 
c.1342C>G 
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Table 5-4.  Linkage disequilibria correlation coefficient (∆) between two loci in 
male Chinese and Indians  
 












- 0.57 0.53 - 0.46 0.55 
IVS8+ 
484T>G 
0.52 - 0.34 0.49 - 0.38 
c.1342C>G 0.44 0.60 - 0.37 0.49 - 
 
In each race, values for CAD patients are above the diagonal and values for controls are 
below the diagonal.  
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IVS6+1595C>T IVS8+484T>G c.1342C>G Overall CAD-  CAD+ Permutation P* 
C T C 0.606 0.632 0.563 0.0096 
C T G 0.004 0.003 0.005 0.713 
C G C 0.028 0.016 0.048 0.001 
C G G 0.005 0.004 0.005 0.779 
T T C 0.165 0.169 0.158 0.566 
T T G 0.005 0.003 0.008 0.202 
T G S 0.107 0.106 0.109 0.855 
T G G 0.080 0.067 0.104 0.017 
Indians 
IVS6+1595C>T IVS8+484T>G c.1342C>G Overall CAD-  CAD+ Permutation P* 
C T C 0.511 0.576 0.451 0.0011 
C T G 0.010 0.005 0.013 0.312 
C G C 0.051 0.043 0.060 0.319 
C G G 0.004 0.008 0.000006 0.110 
T T S 0.193 0.181 0.205 0.425 
T T G 0.011 0.008 0.015 0.415 
T G S 0.113 0.087 0.136 0.042 
T G G 0.107 0.092 0.121 0.231 
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IVS6+1595C>T IVS8+484T>G c.1342C>G Overall Dys  Normo Permutation P* 
C T C 0.564 0.586 0.536 0.2496 
C T C 0.052 0.037 0.071 0.088 
C G G 0.005 0.005 0.005 0.955 
T T C 0.163 0.160 0.168 0.800 
T G C 0.102 0.106 0.096 0.692 
T G G 0.114 0.105 0.124 0.508 
Indians 
IVS6+1595C>T IVS8+483T>G c.1342C>G Overall Dys  Normo Permutation P* 
C T C 0.457 0.443 0.480 0.517 
C T G 0.018 0.007 0.022 0.264 
C G C 0.057 0.074 0.038 0.167 
T T C 0.201 0.229 0.162 0.137 
T G C 0.135 0.112 0.160 0.209 
T G G 0.132 0.135 0.128 0.861 




5.2.5. Association with plasma lipid levels  
ANOVA was carried out to examine the correlation of these LPL polymorphisms with 
lipid profiles using age, BMI and smoking as covariates.  These results are shown in 
Table 5-7 and Table 5-8.   In Chinese, a significant association was found between 
the IVS6+1595C>T polymorphism and plasma HDL level (P = 0.003), with the minor 
T allele being associated with elevated HDL, after Bonferroni correction.  The same 
trend of increased HDL level was also observed in c.1342C>G carriers but did not 
attain statistical significance, which is most probably due to the small sample size of 
mutant homozygotes for c.1342C>G.  
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When the healthy controls were classified into dyslipidemic and normolipidemic 
subgroups, the same effect of IVS6+1595C>T on HDL was still observed in 
normolipidemic subjects but not in dyslipidemic subjects in Chinese.  No significant 
effect was seen in the Indians.     
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Table 5-7. Genotypic lipid levels (M ean ± SD) of three polymorphisms in the healthy Chinese males  
  n TC(mg/dl) LDLC(mg/dl) HDLC(mg/dl) ApoA1(mg/dl) ApoB(mg/dl) lnTG* TG** lnLp(a)* Lp(a)** 
 CC 183 220.22±54.03 137.61±48.34 47.08±10.16† 139.47±24.89 110.97±33.18 5.00±0.62 195.89 2.15±0.92 8.58 
IVS6+1595C>T CT 236 231.65±49.36 144.02±46.29 48.41±10.86† 142.43±21.68 110.69±30.50 4.95±0.54 166.34 2.17±0.89 8.76 
 TT 67 224.67±47.38 142.22±43.00 51.58±11.74† 145.13±19.45 114.81±29.07 4.96±0.51 162.52 2.24±0.89 9.39 
            
 TT 252 221.42±52.74 140.41±49.25 48.42±12.54 140.02±22.42 112.44±32.21 4.99±0.53 173.91 2.18±0.89 8.85 
IVS6+483C>T TG 155 227.57±48.34 147.52±46.01 50.65±12.04 145.36±22.39 114.16±31.11 4.94±0.53 161.25 2.25±0.97 9.49 
 GG 33 218.20±52.46 
 
139.82±48.78 48.84±12.47 141.90±22.28 110.45±28.33 4.88±0.52 148.27 1.99±0.64 7.32 
            
 CC 246 230.04±52.95 155.16±49.92 46.62±10.57 139.42±21.49 117.82±31.59 4.97±0.52 169.01 2.15±1.01 8.58 
c.1342C>G  CG 68 226.70±42.56 147.70±42.37 47.41±11.15 146.05±19.53 110.65±30.27 4.98±0.54 169.88 2.03±1.01 7.61 
 GG 6 223.00±43.94 132.00±52.76 51.40±10.62 145.60±31.17 108.50±23.74 5.05±0.48 171.50 2.14±1.08 8.50 
*: lnTG and lnLp(a): natural logarithmic transformed TG and Lp(a), respectively.   
**: TG and Lp(a) levels are presented in geometric means.   
† Significant difference (P=0.003).   
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Table 5-8. Genotypic lipid levels (M ean ± SD) of three polymorphisms in the healthy normolipidemic Chinese males 
 
 
  n TC(mM) LDLC(mM) HDLC(mM) ApoA1(mg/dl) ApoB(mg/dl) lnTG* TG** lnLp(a)* Lp(a)** 










0.20±0.37 1.22 2.19±0.96 
 
8.93 
IVS6+1595C>T CT 116 4.94±0.76 3.31±0.78 1.30 0.28_ 141.50±20.20 92.62±21.02 0.16±0.39 1.17 2.11±0.81 8.24 
 TT 37 5.04±0.91 3.30±0.97 1.40 0.27_ 146.56±18.97 98.82±24.16 0.19±0.37 1.21 1.93±0.77 6.89 
            
 TT 132 4.88±0.77 3.24±0.82 1.28±0.26 139.88±20.37 95.46±22.51 0.21±0.35 1.23 2.18±0.86 8.85 
IVS8+484T>G TG 77 5.03±0.79 3.35±0.80 1.30±0.27 142.32±22.25 97.14±22.79 0.17±0.41 1.19 2.11±0.97 8.25 
 GG 20 4.98±0.96 3.33±1.08 1.31±0.22 141.55±15.50 100.15±23.02 0.16±0.44 1.17 1.95±0.72 7.03 
            
 CC 114 5.07±0.75 3.58±0.71 1.24±0.29 138.57±21.07 99.41±22.94 0.20±0.38 1.22 1.94±0.98 6.96 
c.1342C>G CG 33 5.01±0.69 3.37±0.65 1.28±0.38 147.47±19.68 93.60±20.16 0.20±0.37 1.22 1.82±1.06 6.17 




*: lnTG and lnLp(a): natural logarithmic transformed TG and Lp(a), respectively. 
**: TG and Lp(a) levels are presented in geometric means. 





We have characterized the distribution and association of three LPL polymorphisms with 
the respective plasma lipid profiles, CAD susceptibility, and the severity of CAD in male 
Chinese and Asian Indians living in Singapore.   The major outcome of this study is the 
finding of different distribution of allele and haplotype frequencies of these three 
polymorphisms between the CAD+ patients and controls, suggesting that these 
polymorphisms may confer some effects on CAD risks in both ethnic groups.  No 
significant difference was found in allele and haplotype frequency distribution between 
normolipidemic and dyslipidemic subgroups.  Regarding the effect on lipid profiles by 
individual polymorphisms, it was found that, in the Chinese, the IVS6+1595C>T 
polymorphism carriers had significantly higher HDL-cholesterol, and this increase in 
HDL-cholesterol level was also observed in the c.1342C>G polymorphism carriers but 
not reaching statistically significant level. No association was found between the 
IVS8+484T>C polymorphism and lipid levels.   In addition, these three polymorphisms 
were found to be in strong LD with each other. 
Our results showed that the three polymorphisms are very common in the Chinese and 
Indians living in Singapore.   Among them, the IVS6+1595C>T polymorphism is the 
most prevalent, followed by the IVS8+484T>G and c.1342C>G.   The C allele 
frequency of the c.1342C>G polymorphism (0.12) in the Chinese is in agreement with a 
previous study in Singapore (Lee et al., 2004). However, its higher frequency in the 
Indians relative to the reported frequency can be explained as follow. It was not stated 
whether all of their subjects were healthy. If CAD+ subjects had been included, then the 
difference would be reasonable, as here generally the CAD+ subjects had lower allele 
frequency than healthy controls (Table 5-2). 
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The case-control association analysis based on the distribution of allele frequencies 
indicated that the rare G allele of IVS8+484T>G was associated with decreased CAD risk 
in both ethnic groups, while the rare T allele of IVS6+1595C>T and the rare G allele of 
c.1342C>G was associated with lower CAD risk in Chinese and Indian, respectively.   
As such, these polymorphisms may have anti-atherogenic effects or may be in LD with 
another functional site.   
 
The c.1342C>G polymorphism results in a truncated LPL protein.   It had been 
demonstrated that the c.1342C>G polymorphism can increase LPL enzymatic activity 
and non-enzymatic activity, which then enhance TG-rich lipoproteins conversion and 
LDL removal (Nierman et al., 2005). These might contribute to the decreased risk of 
cardiovascular diseases. In contrast, the IVS6+1595C>T and IVS8+484T>G 
polymorphisms are sequence variants in non-coding region.   Thus, it has been 
proposed that the effect of the IVS8+484T>G and IVS6+1595C>T polymorphisms on 
CAD risk was due to their LD with the functional variant, c.1342C>G.  However, the 
effect of c.1342C>G could not explain all the IVS8+484T>G- and 
IVS6+1595C>T-related association.   For example, in single-locus analysis, both 
common alleles of these two polymorphisms were correlated with higher CAD risk while 
no association was seen between the c.1342C>G and CAD risk in Indians.  In haplotype 
analysis, the effect of IVS8+484T>G was more apparent, which was independent of 
c.1342C>G.   
 
In order to examine the combined influence of these three polymorphisms, the haplotype 
was constructed and the haplotype frequencies were compared between cases and 
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controls. It was suggested that the most common CTC haplotype was consistently 
atherogenic in Chinese and Indians, while the TGG and CGC haplotypes were associated 
with lowered CAD risk in the Chinese and the TGC haplotype was protective from CAD 
in the Indians.   The opposite effects of the CTC and CGC haplotypes on CAD 
susceptibility in the Chinese suggests that the anti-atherogenic effect of G allele of the 
IVS8+484T>G polymorphism is independent of the c.1342C>G polymorphism.   In 
addition, in the Indians, the CTC haplotype was pro-atherogenic while the TGC 
haplotype was anti-atherogenic, although the same C allele was present in the c.1342C>G 
polymorphic site.   Furthermore, it is known that the IVS6+1595C>T polymorphism is 
located in intron 6 and no functional element has been identified thus far in this intron.  
On the other hand, though the IVS8+484T>G polymorphism is within intronic region, a 
regulatory element encompassing the IVS8+484T>G site was reported to be important 
for LPL transcriptional activity (Enerback et al., 1992).   Taken together, the 
IVS8+484T>G polymorphism may be a functional site by itself, which is consistent with 
the Razzaghi et al.’s studies (2000). 
 
We also found that the T allele of IVS6+1595C>T increased plasma HDL-cholesterol in 
Chinese and this effect was probably due to its LD with a functional site, such as 
c.1342C>G.   A similar increasing trend in HDL level was also found in homozygous 
GG carriers of the c.1342C>G, but it is not statistically significant. The lack of statistical 
significance may be due to too few individuals with the GG genotype, as the higher HDL 
level in G allele carriers was reported in a previous study with large sample size in 
Singapore (Lee et al. 2000).   In addition, although this study showed a significant 
effect of T allele of IVS6+1595C>T on lipid profiles in the Chinese, this polymorphism 
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was not associated with CAD risk. One possible reason is that its impact on HDL level is 
not sufficiently strong to cause any significant difference in CAD susceptibility.  
 
We did not observe any significant differences in allele and haplotype frequencies 
between normolipidemic and dyslipidemic subgroups. As such, these polymorphisms 
may influence atherosclerosis susceptibility through other mechanisms rather than 
through altering lipid profiles.  Due to the dual role of LPL in atherosclerosis, an 
independent association of these polymorphisms with CAD risk is not unexpected despite 
the lack of significant association with circulating lipid levels.   Furthermore, many 
genetic and environmental factors have been suggested to modulate the effects of LPL 
polymorphisms on CAD risk and lipid profiles, such as smoking, practical activities, age, 
race, sex, and oestrogen (Lee et al., 2004; Senti et al., 2001; Holmer et al., 2000; 
Hallman et al., 2001).  Thus, it is also possible that the interaction between LPL and 
these factors might have masked the small influence of LPL on lipid traits. 
 
In conclusion, it was shown that the most prevalent CTC haplotype of the three LPL 
polymorphisms, IVS6+1595C>T, IVS8+484T>G and c.1342C>G, was consistently 
associated with increased CAD susceptibility in male Chinese and Indians living in 
Singapore. The finding is that the rare alleles of the three individual polymorphisms 
decreased CAD risk in male Chinese and/or Indians and the protection against CAD is 
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